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1. Introduction
1
 
1.1 Iminosugars  
Molecules, that mimic natural or synthetic carbohydrates, in which, the endocyclic oxygen 
atom has been replaced by a nitrogen atom, are called as iminosugars or azasugars. 
 
Figure 1.1 
The iminosugar motif is present in several classes of monocyclic and bicyclic compounds, 
leading to a large and structurally diverse class of molecules. Iminosugars have the potential to 
block or modify glycosidase enzymes, which are involved in a wide range of biological 
processes and they have therefore attracted a great deal of interest since they were first 
discovered. This interest has focused on the isolation of new iminosugars, the study of their 
biological activity and, indeed, their synthesis. 
 
1.2 Structure of iminosugars 
The first iminosugar, nojirimycin (1, NJ) [Figure 1.3], was discovered in 1966
2a
 and numerous 
iminosugars have since been isolated from plants and microorganisms.
2b
 Naturally occurring 
sugar mimics with a nitrogen in the ring are classified into six structural classes: These 
molecules may have a pyrroline (a), pyrrolidine (b), piperidine (c), pyrrolizidine (d), 
indolizidine (e) or nor-tropane (f)  skeleton and these can therefore be grouped as monocyclic 
or bicyclic structures as shown in [Figure 1.2].  
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Figure 1.2 General Iminosugars core structures 
1.2.1 Monocyclic structures  
There are three classes of monocyclic iminosugars, pyrroline, piperidines and pyrrolidines 
with general structures shown in [Figure 1.3], Nojirimycin (or 5-amino-5- deoxy-D-
glucopyranose) (NJ, 1) [Figure 1.3] is the main representative of the piperidine class of 
monocyclic iminosugars. It is a polyhydroxylated piperidine corresponding to glucose in the 
pyranose form and was first described as an antibiotic produced in bacterial cultures of 
Streptomyces roseochromogenes R-468 and Streptomyces nojiriensis SF-426.
3
 As a 
hemiacetal, NJ is an inherently unstable structure and therefore its corresponding 1- deoxy 
analogue, 1-deoxynojirimycin (DNJ; 2) [Figure1.3], was synthesised by reduction with NaBH4 
by Paulsen and coworkers.
3b,4
 DNJ was later isolated from the roots of mulberry leaves and 
was called moranoline.
5
 DNJ is also produced by many strains of the Bacillus and 
Streptomyces genera. DNJ is related to another natural product, 1- deoxymannojirimycin 
(DMJ, 3) [figure 1.3], where the hydroxyl group at C-2 has the opposite stereochemistry, 
mimicking the pyranose form of D-mannose. DMJ was found to be produced by Streptomyces 
lavendulae SF-425 and has recently been extracted from Adenophora triphylla.
5
 A number of 
other piperidine iminosugars have since been isolated from a range of plants and bacterial 
cultures and these are shown in [Figure 1.3].
2
 Iminosugars with a hydroxyl group at C-1, 
nojirimycin B (manno-NJ, 4) and galactostatin (galacto-NJ, 5), were also isolated from 
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species of Streptomyces. Fagomine, 1,2- dideoxynojirimycin (6) has been isolated from the 
seeds of Japanese buckwheat (Fagopyrum esculentum)
6
 as well as the Moreton Bay Chestnut 
and Castanospermum australe.
7
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Figure 1.3 Naturally occurring piperidines 
Polyhydroxylated pyrrolines and pyrrolidines resemble sugars in the furanose form and can be 
potent inhibitors of the corresponding glycosidases specific for carbohydrates with a matching 
pattern of hydroxyl substitution and stereochemistry. Some of the naturally occurring 
pyrrolines and pyrrolidines are shown in [Figure 1.4] 
 In 1976, 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine (DMDP, 7), a naturally occurring 
analogue of β-D-fructofuranose was found in the leaves of the legume, Derris elliptica.8, 9 This 
compound is a very common metabolite as it has since been isolated from various other plants 
and microorganisms.
10
 A second example of a pyrrolidine analogue is 1,4-dideoxy-1,4-imino-
D-arabinitol (D-AB1, 8), which resembles 7 but has only one hydroxymethyl group. D-AB1 
was initially isolated from the fruits of Angylocalyx boutiqueanus but, like DMDP, has since 
been isolated from different species of plants.
11, 12
 The 6-deoxy derivative of DMDP (6-deoxy-
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DMDP, 2,5,-imino-1,2,3-trideoxy-Dmannitol, 9) was isolated from the seeds of Anglocalyx 
pynaertii.
 13
 and polyhydroxypyrroline nectrisine (10) was isolated from a broth culture of the 
fungus Nectria ludica.
2
 
 
Figure 1.4 Naturally occurring pyrrolines and pyrrolidines iminosugars 
1.2.2 Bicyclic structures 
There are three classes of natural bicyclic iminosugars: indolizidines, pyrrolizidines and 
nortropanes, which have the general structures as shown in [Figure 1.2]. The first bicyclic 
iminosugar, an indolizidine, was isolated from a legume called Swainsona canescens in 1979 
and was named swainsonine (11) [Figure 1.5].
14
 It has since been isolated from locoweeds 
(Astragalus and Oxytropis species) which cause the disorder ‘locoism’ in animals. Another 
similar alkaloid, castanospermine (12) [Figure 1.5], was later isolated from the seeds of the 
tree Castanospermum australe.
15
  
 
Figure 1.5 Naturally occurring indolizidines iminosugars 
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It was found to share the same core indolizidine structure as 11 but differs in the substitution 
pattern of the hydroxyl groups. The seeds of Castanospermum australe were also found to 
produce 7-deoxy-6-epi-castanospermine (13).
15 
Lentiginosine 14, isolated from the leaves of Astragalus Lentiginous, a plant found in western 
part of North America, was more recently discovered and characterized for the first time in 
1990 by Pastuszak et al.
43
 
                                 
Figure 1.6 The plant of Astragalus Lentiginous 
(+)-Lentiginosine (14) is the least hydroxylated naturally occurring indolizidine derivative 
possessing a glycosidase inhibitor activity: it shows highly selective inhibitory activity against 
amyloglucosidase (see section 1.6 below).  Owing to the growing interest in hydroxylated 
indolizidines as different glycosidase inhibitors, there has been a plethora of publications 
concerning the synthesis of hydroxylated indolizidines including lentiginosine.    
The first polyhydroxylated pyrrolizidines, alexine (15) and australine (or 7aepi-alexine, 16) 
[Figure 1.7] were isolated in 1988 from the legumes, Alexa leipetala and Castanospermum 
australe.
16
 These structures differ from the long known necine bases, pyrrolizidine alkaloids, 
with a hydroxymethyl side chain at the C-1 position. 
____________________________________________________________________Chapter 1 
 
6 
 
 
Figure 1.7 Naturally occurring pyrrolizidines iminosugars 
Polyhydroxylated nortropanes were the final class of naturally occurring bicyclic iminosugars 
to be discovered when calystegines were found to be secondary metabolites in plants and were 
implicated in the maintenance of plant-bacterium relationships.
17
 A shown in [Figure 1.8], 
 
 
Figure 1.8 Naturally occurring nortropanes iminosugars 
Calystegines have a nortropane ring system, two to four hydroxyl functions of varying 
stereochemistry and position and a tertiary alcohol group at the bridgehead carbon C-1 of the 
bicyclic ring. The first calystegines, A3 (17), B1 (18) and B2 (19), were extracted from root 
cultures of C. sepium.
17
 
1.3 Biological activity of iminosugars 1,18 
Iminosugars present a wide structural diversity in the basic skeleton (five-membered ring, six-
membered ring, simple or fused ring), in the number of hydroxy functions and in the relative 
and absolute configuration of the stereocenters. Of course, this structural diversity modulates 
the kind and the potency of the activity of each one of them. Anyway, the most important 
feature that many molecules belonging to this class of compounds present is the ability to 
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inhibit the glycosidases in a reversible and competitive manner. These families of ubiquitous 
enzymes are involved in a lot of key biological processes such as degradation of 
polysaccharides and glycoconjugates (glycoproteins, glycolipids, proteoglycans) in nearly all 
life forms
18
 and overall in the biosynthesis, transformation and degradation of one of the most 
important class of biological molecules, the membrane glycoproteins. Glycosylation is a form 
of co-translational and post-translational modification in which glycosidases build a specific 
sugar antenna on the protein which is forming. The number and the typology of the involved 
monosaccharides and the kind of the linkage establish an accurate biological message.  
 Glycoproteins are complexes in which a sugar portion is covalently linked to an asparagine 
residue (N-glycans), a serine or threonine residue (O-glycans) of a protein. These molecules 
are involved in a lot of crucial biological processes such as cell-cell adhesion and exogen 
molecules recognition, but also in a lot of pathologic methabolic pathways like viral and 
bacterial infection and tumor metastasis [Figure 1.9]. 
 
 
 
 
 
  
 
Figure 1.9 Glycoconjugates and molecular recognition mechanisms 
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The oligosaccharide chains of these molecules play an important role in the correct 
functioning of these proteins by stabilizing them and ensuring that they have the correct 
conformation. They may also be involved in the targeting mechanism of certain proteins. 
The first example involved the first isolated iminosugar NJ (1) which was reported to inhibit 
both α-glucosidases and β-glucosidases.3 The reduced form of NJ, DNJ , exhibited activity 
against glycosidases I and II, whereas DMJ and its bicyclic counterpart Swainsonine (11) were 
reported to inhibit lysosomal α- mannosidases.2, 9 Castanospermine (12) has been shown to be 
a powerful inhibitor of the α- and β-glucosidases in the mammalian gut.15 Australine was 
found to be a good inhibitor of the α-glucosidases, amylglucosidase and subsequently the 
glycoprotein enzyme glucosidase I.
19
 
Unsurprisingly, the inhibition of glycosidase and glycosyltransferase enzymes can affect the 
digestion and metabolism of polysaccharides as well as the maturation, transportation and 
secretion of glycoconjugates. Glycocongugates expressed at the cell surface – often possessing 
complex, branched extracellular carbohydrate structures are involved in several fundamental 
biological functions such as cell-cell recognition, cell adhesion and signalling. The role of 
these biomacromolecules in cell differentiation, immune response, oncogenesis, tumor 
metastasis and viral infections has prompted considerable interest in iminosugars as a class of 
compounds for therapeutic intervention, with the emphasis on their potential applications in 
the treatment of diabetes, cancer and viral disease.  
1.3.1 Inhibition of digestive glycosidases  
Digestive glycosidases, located in the small intestine, are enzymes that hydrolyze dietary 
carbohydrates to monosaccharides, which are then absorbed through the intestine wall. It was 
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thought that treatment of non insulin dependent diabetes (type II diabetes) could be achieved 
by means of blocking these enzymes, thus regulating the absorption of carbohydrates through 
the intestine wall. The original discovery of DNJ (2) resulted from investigations prompted by 
the knowledge that extracts of mulberry were able to suppress the rise in blood glucose that 
follows eating, suggesting that this activity could be beneficial for diabetes treatment.
9
 DNJ 
(2) was subsequently found to have a good inhibitory effect on mammalian α- glucosidase in 
vitro and was thus considered to be a promising agent for treatment of diabetes.
18, 20
 
Unfortunately, the compound lacked efficacy in vivo for this clinical indication but these 
studies stimulated the synthesis and evaluation of many derivatives of DNJ and N-alkylated 
analogues, such Miglitol (22), were subsequently found to be potent inhibitors of the 
glycogenolysis induced by glucagen in studies with hepatocytes.
21
 Miglitol (GLYSETTM) is 
now used in the treatment of type II diabetes and is available in the USA and Canada. 
 In type II diabetes, an increase in hepatic glucose production and blood glucose levels is 
observed. Inhibiting hepatic glycogen phosphorylase could prevent this from occurring. 
Isofagomine (20) [Figure 1.10] was recently found to be a good inhibitor of liver 
glycogenphosphorylase, blocking glycogen degradation in hepatocytes.
22
 The specificity of 
iminosugars is well illustrated by the fact that some N-alkylated derivatives of isofagomine 
(20) are active inhibitors at micromolar concentrations, whereas Fagomine (21) and DNJ (2) 
lack activity [Figure 1.10].
23 
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Figure 1.10 
1.3.2 Inhibition of lysosomal storage diseases  
Disorders in the biosynthesis or catabolism of glycolipids in the cell have an impact on so 
called lysosomal storage diseases like type I Gaucher disease or Fabry disease.
24
 In normal 
cells there is a balance between the degradation of glycosphingolipids (GSLs) in the lysosome 
and their biosynthesis in the endoplasmic reticulum (ER)/Golgi system. The rates of influx of 
GSLs and efflux of metabolites are in equilibrium. In a lysosomal storage cell, enzyme 
activity in the lysosome is so low that GSLs accumulate. However, although the catalytic 
activity of enzymes is reduced, it is not totally eliminated. Thus, drugs that could regulate the 
biosynthesis of GSLs to a concentration that fits well in the residual enzymatic activity could 
prevent storage. Studies have thus been carried out with N-alkylated DNJs, which are 
inhibitors of ceramide specific glycosyltransferases,
 25
 and N-butyl DNJ (23) [Figure 1.11], 
marketed as Zavesca
®, is now used in the treatment of type1 Gaucher’s disease. 
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Figure 1.11 N-butyl DNJ 
The discovery that swainsonine (11) can induce a reversible phenocopy of the genetic 
lysosomal storage disease, mannosidosis, in animals has led to the use of chemically induced 
deficiencies of lysosomal hydrolyses as models for studying the pathogenesis of lysosomal 
storage disease.
26, 27
 Mannosidosis is characterised by the accumulation in cells, and excretion 
in urine, of mannose rich oligosaccharides resulting from a deficiency of lysosomal α-
mannosidase. Treatment with swainsonine (11) is particularly effective in mimicking 
lysosomal storage disease because of the compound’s potent inhibitory activity against 
lysosomal α-mannosidase and its lysosomotropic behaviour. It is a weak base with a pKa of 
7.4, which ensures that it is taken up rapidly into cells by permeation and, once inside the 
lysosomes, becomes protonated and becomes concentrated. Swainsonine (11) has since been 
granted orfan drug status for the treatment of gaucher disease. 
1.3.3 Processing glycosidase 
The α-D-glucosidases and α-D-mannosidases involved in the post-translational processing of 
asparagine-linked glycans of glycoproteins can be selectively inhibited by various 
iminosugars.
28
 Using these inhibitors, the consequences of altering the glycosylation of a 
particular glycoprotein or the glycotype of cells can be studied in a defined way. Indeed, 
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castanospermine (12), DMJ (3) and swainsonine (11), become the standard commercially 
available reagents used in biochemical studies for inhibition of α-glucosidases I, α-
mannosidases I and α- mannosidases II. These compounds are not completely specific, 
however, and they do not inhibit processing unless they are present in relatively high 
concentrations, which in itself increases lack of specificity. Consequently, there is current 
interest in the discovery of more specific glycosidase inhibitors and this has prompted 
structure activity relationship studies. For example, N-methyl-DNJ (24) [Figure 1.12] has been 
found to be a poorer inhibitor of α-glucosidases I than DNJ (2) and conversely for α-
glucosidases II. Castanospermine also exhibited a similar inhibition of α-glucosidases I to N-
methyl- DNJ (24) suggesting that substitution of the piperidine nitrogen favours inhibition of 
α-glucosidases I. 
 
Figure 1.12 N-Methyl DNJ 
DMJ (3) was found to inhibit α-mannosidase I, which is particularly susceptible to iminosugar 
pyranose analogues. Although swainsonine (11) has been shown to be a potent inhibitor of α-
mannosidase II, it does not inhibit other processing α-mannosidases in human cell cultures.9 
The specificity of synthetic iminosugars for the various processing glycosidases has not yet 
been exhaustively evaluated, but the available information suggests that many are more 
specific in vitro than their parent compounds. The effect of the common glycoprotein 
processing inhibitors on the biosynthesis, intracelluar transport and function of most well 
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characterised glycoproteins has been thoroughly evaluated however. Indeed, their effects on 
many cellular processes have been evaluated, but perhaps the two areas of most excitement 
and interest relate to anti-cancer and antiviral applications. 
1.3.4 Anti-cancer activity and anti-viral activity 
In the case of the development of the tumor metastasis, the role of the glycoproteins is 
absolutely crucial.
29
 Cell migration is an essential process of the mechanism of metastasis. The 
extra cellular matrix (ECM) represents the molecular scaffold for cell migration. Therefore, 
adhesion of the cells to the ECM is critical. Engagement of integrin receptors with ECM 
ligands gives rise to the formation of complex multiproteins which link the ECM to the 
cytoplasmic actin skeleton. Both ECM proteins and the adhesion receptors are glycoproteins, 
and it is well accepted that N-glycans modulate their conformation and activity, thereby 
affecting cell-ECM interactions. Likely targets for glycosylation are the integrins, whose 
ability to form functional dimers depends upon the presence of N-linked oligosaccharides. Cell 
migratory behaviour may depend on the level of expression of adhesion proteins, and their N-
glycosylation that affect receptor-ligand binding. In regard to the involvement of 
glycoproteins in viral infections, in human immunodeficiency virus (HIV) and in hepatitis B 
virus (HBV), N-linked oligosaccharides play a crucial role in the folding of viral glycoproteins 
by mediating interactions with the lectin-like chaperone proteins calnexin and calreticulin with 
nascent glycoproteins.
30
 These interactions can be prevented by inhibitors of the α-
glucosidases and this causes some proteins to be misfolded and retained within the 
endoplasmic reticulum, interfering with the viral life cycle. 
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1.3.5 Anti-insecticide activity 
 Nojirimycin and pyrrolidine-based iminosugar derivatives are evaluated as potential 
inhibitors of porcine and insect trehalases with selectivity towards the insect glycosidase. 
Trealose, hydrolyzed into glucose (vital for insect flight) by the enzyme α-trehalase (EC 
3.2.1.28), an inverting glycosidase. Trehalose is not found in mammalian cells, but humans 
possess the enzyme trehalase, probably to handle ingested trehalase. Trehalase inhibitors have 
great potential as novel insecticides and fungicides. Selectivity toward insects’ trehalases are a 
main issue to be addressed.
34
 
 
Figure 1.13 Some example of Trehalase inhibitors 
 
1.4 Mechanism of action of glycosidases 
As we already said, glycosidases enzymes that catalyze the cleavage of glycosidic bonds in 
oligosaccharides or glycoconjugates. It is possible to make a classification on the basis of the 
number, the position or the configuration of the hydroxy groups in the substrate. Glycosidases 
catalyze the cleavage of glycosidic bonds involving terminal glucose connected at the site of 
cleavage through an -linkage at the anomeric center are classified as α-glucosidases. In the 
same way, if the configuration of the anomeric carbon is β, we can talk about β-glucosidases. 
The great potency and specificity of the iminosugars as glycosidase inhibitors is due to their 
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capacity to mimic the transition state of the pyranosidic or furanosidic units of the natural 
glycosidase substrates.
31
 Since competitive inhibition is observed with a lot of inhibitors, 
probably both conformational and electrostatic influences are important in the active site 
binding. During glycosidic bond cleavage reaction can occurs with one or two stereo chemical 
outcomes, inversion or retention of configuration through double or single nucleophilic 
substitution. Both of this enzymatic mechanisms involve key oxonium ion intermediate 
generated in the transition state preferably in its half-chair conformation b than in the chair 
conformation a [Figure 1.14]. 
 
Figure 1.14 
The partial cleavage of the glycosidic bond enhances the positive charge generated on the 
oxygen or anomeric carbon of the natural substrate. The substitution of one of the two atoms 
by protonated nitrogen will mimic, in the transition state, the charge in these centers.
32
 
 
Figure 1.15 
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Nojirimycin and 1-Deoxinojirimycin  are potent glucosidase inhibitors, in fact they are able to 
mimic, when protonated (I and II), the charge development of the transition state resembling 
glucosyl oxycarbenium ion b, but they have a chair conformation instead of the expected half-
chair conformation of b [Figure 1.16]. 
 
Figure 1.16 
It is not possible that the transition state has a chair conformation when there is a charge on 
the ring oxygen. Therefore, I and II cannot be expected to be perfect transition state 
analogues. In substance, the significant factors to obtain the inhibition of glycosidases are the 
charge and the shape of the transition state, defined by the hybridization and the conformation 
of the pyranose ring in the natural substrate and piperidine ring in the inhibitors. It is 
fundamental that inhibitors are protonated to interact, through hydrogen bonds, with catalytic 
sites.  
The shape, pattern of hydroxyl substitution and stereochemistry for iminosugars selectivity, 
albeit important, is not always easily predictable.
35
 It was initially thought that inhibitors of 
glucosidases and mannosidases should have structures closely resembling glucose and 
mannose respectively. For example DNJ (2) has a structure similar to that of glucose and DMJ 
(3) has a structure similar to mannose, and indeed these compounds are known to inhibit α-
glucosidase and α-mannosidase respectively, demonstrating that the differing stereochemical 
arrangement of the hydroxyl groups plays a key role in controlling inhibitory selectivity. This 
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argument often holds for glucosidase inhibitors, which typically do have structures with 
hydroxyl substitution patterns similar to glucose.
36
 However, close mimicry between the 
structure of an inhibitory iminosugar and the enzyme’s substrate is not always seen. As an 
example, (+)-Lentiginosine (14), has only two hydroxy groups positioned on the five-
membered ring.  Beside the presence of the basic nitrogen atom, other two features are 
essential for the bio-activity: the trans configuration of the two hydroxy groups and the S,S 
absolute configuration of the carbons bearing these groups (see section 1.7.1).  In another 
example, 6-epicastanospermine (25) has a structure closely resembling the D-mannosyl cation 
(26), but was found to inhibit α- glucosidases and not the expected α-mannosidase.37 With the 
exception of DMJ (3); α-D-mannosidase inhibitors in reality generally do not have structures 
that closely resemble mannose. For example, swainsonine (11) exhibits potent inhibition of α-
mannosidases although its structural resemblance to α-D mannose is not obvious. Winkler and 
Holan were able to offer an explanation for these inconsistencies based on the results of 
molecular orbital calculations and structure-activity relationship studies with α-D-mannose 
analogues and mannosidase inhibitors.
38
 These calculations and studies showed that there are 
two optimized half chair geometries of the mannosyl cation, a “flap up” form (C1) and the 
“flap down” form (C2), the former being the lower in energy [Figure 1.17]. This study showed 
that the best inhibitors resembled the “flap up” half chair geometry of the mannosyl cation. 
This model was also able to rationalize why 6-epi-castanospermine (25), which superficially 
resembles mannose, is actually a poor mannosidase inhibitor; it has the incorrect ring 
conformation for good superimposition onto the mannosyl cation in the “flap up” half chair 
conformation.
39 
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Figure 1.17 Structural configurations of D-mannosyl cations 
Nevertheless, in many cases, further exploration is required to establish a proper 
understanding of structure activity relationships for carbohydrate processing enzymes. Thus, 
for example, the basis for selective mannosidase-inhibitory activity of protonated DNJ (II) 
remains unclear since this compound does not appear to closely mimic the structure of the 
“flap up” mannosyl cation (26). A possible explanation might be that binding in the 
mannosidase catalytic pocket is in this case dominated by ionic interactions between the 
protonated DNJ structure and the catalytic acidic residues lining the pocket.
40
 
Polyhydroxylated pyrrolidine, piperidine and indolizidine alkaloids are able to inhibit the 
hydrolytic reaction.
41
 The spatial distribution of the hydroxy groups of these compounds 
allows the formation of a series of hydrogen bonds inside the catalytic enzymatic cavity that 
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ease the recognition of the alkaloid as natural substrate. However, the presence of the nitrogen 
atom in the ring instead of oxygen determines the fundamental difference on which is based 
the inhibition mechanism of this class of compounds. At a physiological pH the nitrogen atom 
is protonated, therefore the alkaloid works like the hydrolysis intermediate of the natural 
sugar, stabilizing itself in the enzymatic cavity. This kind of structure cannot be hydrolyzed 
because there is no more electronic availability on the heteroatom. In consequence, enzymatic 
activity is stopped. 
Given the promising enzyme inhibitory activity of iminosugars in general, considerable effort 
has been made over the last three decades to develop efficient synthetic routes to these 
compounds. This work has been prompted both by the need to provide material for biological 
assessment and clarification of structure activity relationships and also in the hope that 
synthesis of new structures might provide compounds wth improved activity and selectivity. 
1.5 Lentiginosine and its unnatural enantiomer 
Iminosugars such as (+)-lentiginosine (14), (–)-swainsonine (11) and (+)-castanospermine (12) 
are polyhydroxylated alkaloids with an indolizidine structure [Figure 1.18]. 
 
Figure 1.18 
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Iminosugar has potential for the treatment of viral infection,
 45
 cancers
46
 and diabetes.
47
 
Celgosivir,
48
 a 6-butanoil derivative of castanospermine is already on the market as a drug 
against Gaucher’s disease. 
 
(+)-Lentiginosine [(1S,2S,8aS)-octahydro-1,2-indolizinediol] (14) shown selective inhibitory 
activity against amyloglucosidase, higher than that of castanospermine.
49
 Indeed, enzymatic 
tests carried out on natural (+)-lentiginosine 14 showed that it has inhibitory activity against 
Aspergillus niger amyloglucosidases with an half maximal inhibitory concentration (IC50) 
equal to 5 μg/mL (amyloglucosidase from Aspergillus niger), synthetic (+)-Lentiginosine 14 
molecule showed that it has inhibitory activity against Aspergillus niger and Rhizopus mold 
amyloglucosidases (EC 3.2.1.3) with an half maximal inhibitory concentration (IC50) equal to 
0.43 μg/mL (amyloglucosidase from Aspergillus niger) and to 0.48 μg/mL (amyloglucosidase 
from Rhizopus mold). Furthermore, with amyloglucosidase from Aspergillus niger synthetic 
(+)-lentiginosine showed inhibition (Ki = 2 μM) five times stronger than that reported for 
natural (+)-lentiginosine. Therefore, (+)-lentiginosine is the most potent and selective inhibitor 
of amyloglucosidases among azasugars with indolizidine structure. 
Amyloglucosidase is not the only target of this very interesting molecule. A recent research 
performed by the group of Prof. Nunziatina de Tommasi of the Pharmaceutical Sciences 
Department of the University of Salerno,  showed that (+)-lentiginosine has an inhibitory 
activity against the human Heat Shock Protein 90 (Hsp 90).
49c, 65
 This protein has an important 
role in the cell proliferation, differentiation and apoptosis. For this reason, there is a growing 
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interest towards this molecule as a target for potential anticancer drugs.
50
 In deseases such as 
chronic pancreatic tumors
51
 or breast cancer
52
 is observed an enhanced Hsp 90 expression. 
The unnatural enantiomer of (+)-lentiginosine (14) is (–)-lentiginosine (27) [Figure 1.19].53 
 
Figure 1.19 
This compound has an activity profile very different with respect to (+)-lentiginosine. Its 
inhibition activity against amyloglucosidase from Aspergillus niger is much lower than that of 
(+)-lentiginosine (IC50 =17 µg/ml) and is not able to inhibit Hsp 90 protein. Despite that, this 
molecule showed capacity to induce apoptosis.
54
 Experiments performed on healthy donors 
and tumoral cell cultures, showed that (–)-lentiginosine (27), when present in concentration in 
the order of 200 µM, possesses a proapoptotic activity but, at the same time, has a cytotoxicity 
clearly lower in respect to that of a chemotherapic agent such as SN38 (7-ethyl-10-
hydroxycamptothecin) [Table1, Figure 1.20]. 
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Table 1 
Cell lines Compounds MAIC50± SD (μM) 
a
 
MOLT3 
(human acute lymphoblastic 
T cells) 
(–)-lentiginosine 213.33 ± 96.62 
(+)-lentiginosine >1000 
SN38 14 ± 2 
SHSY5Y 
(neuroblastoma cells) 
(–)-lentiginosine 95.5 ± 19.09 
(–)-lentiginosine >1000 
SN38 <0.1 
HT29 
(humancolorectal 
adenocarcinoma cells) 
(–)-lentiginosine 577 ± 101.3 
(+)-lentiginosine >1000 
SN38 <1 
PBMCs 
(healthy peripheral blood 
mononuclear cells ) 
(–)-lentiginosine 384.52 ± 49.02 
(–)-lentiginosine >1000 
SN38 <1 
a) MAIC50 Value = Metabolic activity cytotoxic inhibitory concentration 50% 
Figure 1.20 Effect of compound 14, 27 and SN38 on cell viability in tumour cell line. 
For the experimental tests four cell lines were used. In the table, the levels of cytotoxicity of (–
)-lentiginosine, (+)-lentiginosine and SN38 are compared. The cytotoxicity is expressed as the 
necessary concentration to inhibit 50% of mitochondrial enzymatic activity (MAIC50). As high 
as is MAIC50 value, minor will be the toxicity of the compound. 
In [Figure 1.21] is showed a comparison of the proapoptotic activity of SN38, (–)-
lentiginosine (27) and (+)-lentiginosine (14) on the four cell lines. The activity is expressed as 
% of hypodiploid nuclei. 
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The study of the activity of (–)-lentiginosine has shown that cell death induced by the 
molecule has the typical characteristic of apoptosis, because of the incremented expression 
and activity of caspases (cysteine-aspartic proteases), enzyme that plays an essential role in 
apoptosis (but also in necrosis and inflammation). Unfortunately, the sequence of events in the 
caspase cascade induced by (–)-lentiginosine is not yet defined. Further investigation is 
needed to clarify the relationship between apoptotic, toxic effects of (–)-lentiginosine and 
events. 
 
Figure 1.21 
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Apoptosis induced by D-(–)-lentiginosine in MOLT-3, HT-29 and SH-SY5Y tumour cell line. 
The results showed that D-(–)-lentiginosine increased caspase 9 expression at 18 h in all the 
cell lines from 1.5–3.1 folds. Cytochrome-C in the cytoplasm was found to be increased from 
2.3–2.6 folds in treated cells with respect to control cells. These effects were accompanied by 
a remarkable collapse of the mitochondrial membrane potential and by the down regulation of 
anti-apoptotic genes, as well as the up regulation of pro-apoptotic genes of the Bcl-2 family. 
Thus, the study establishes that the enantiomer of a natural iminosugar is endowed with a 
possible anti-tumorigenic effect that might be ascribed not only to its capacity to inhibit 
glycosidases, but also to other unknown mechanisms. These data encourage further 
investigation on similar compounds to make them an interesting platform for the generation of 
new anticancer drugs. 
Cancer cell death by apoptosis occurs through two types of mechanism a) Extrinsic or b) 
Intrinsic. 
 
 
 
D-(–)-lentiginosine induced apoptosis involves the intrinsic pathway. [Figure 1.22] The 
expression of caspase 9 (a) was assessed by western blot analysis after 3 and 18 h of treatment 
[Figure 1.22]. 
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Figure 1.22 Effect of Cytochrome-C release, measured on the treatment of MOLT-3, SH-SY5Y and HT-29 
cells with D(–) lentiginosine at 100 µM for 3 and 18 h. 
 
Cytochrome-C production was assayed by enzyme-linked immunosorbent assay (ELISA) and 
the results are shown in [Figure 1.23]. The results are the cumulative mean values of three 
independent experiments. After 3 h of treatment, a noticeable, but not significant, increase in 
Cytochrome-C occurred in all the three cell lines. After 18 h of treatment the release of 
Cytochrome-C was highly significantly increased by 2.3 folds in MOLT-3 and HT-29 cells 
and by 2.6 folds in SH-SY5Y cells, respectively, in comparison with respective control cells. 
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Figure 1.23 The data are represented as mean values±S.D. of three independent experiments. Asterisks (**P 
<0.001) indicate highly significant differences between treated and control cells.  
 
1.6 Aim of the thesis 
Owing to the very interesting and broad biological profile of (+)-lentiginosine and of its 
enantiomer (–)-lentiginosine, the principal goal of this thesis was to design a straightforward 
synthetic method to obtain derivatives of lentiginosine starting from the convenient 
intermediates of its synthesis carried out in Prof. A. Brandi’s group. The derivatives planned 
were intended to conjugate the lentiginosine structure with aromatic and heteroaromatic 
structures, hydrophilic and hydrophobic functionalities.  
A series of derivatives of the lentiginosine have been synthesized with the aim to define and 
optimize very simple, efficient and versatile synthetic methods. In the case of (+)-
lentiginosine, of which is exactly known the target, the synthesis of new derivatives is directed 
to find molecules which can have more potency in the inhibition of amyloglucosidase. In the 
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case of (–)-lentiginosine, the obtaining of new derivatives was finalized, besides the finding of 
new more potent proapoptotic agents, to the study of its mechanism of action, in particular to 
find its exact target. 
1.6.1 The mechanism of interaction between (+)-lentiginosine and glucoamylase 
The choice of the derivatives to synthesize has been made on the basis of computational 
studies performed by the group of Prof. Paola Gratteri of the Pharmaceutical Sciences 
Department of the University of Florence. 
At this point it is appropriate to illustrate the interaction mechanism of our lead compound, 
(+)-lentiginosine. Glucoamylase is a glucosidase which catalyzes the hydrolysis of β-D-
glucose from the non- reducing ends of starch (and other related oligo- and polysaccharides).
55
 
This enzyme cleaves the α-1,4-glucosidic bond preferentially and, at a slower rate, the α-1,6- 
glucosidic bond.
53
 Glucoamylase is inhibited by sugar analogues having a structure which 
resembles that of the enzyme’s natural substrate, amylose in this case.  
In [Figure 1.24]
56
 are compared the natural glucoamylase substrate amylose, (+)-lentiginosine 
(14) and 1-deoxynojirimycin (DNJ), maybe the most investigated iminosugar.
57
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Figure 1.24
 
As we already said, one of the most important features of iminosugars is that they have a 
nitrogen atom instead of the oxygen atom present in the sugar structure. In contrast of DNJ 
and of natural substrate amylose, (+)-lentiginosine (14) has only two hydroxy groups and 
these functional groups are not positioned on the six-membered ring, like in the case of the 
other two compounds, but on the five-membered ring. Accordingly, the analogy of (+)-
lentiginosine with the natural substrate is not immediate. But, if we observe [Figure 1.24], it is 
immediately clear that, beside the presence of the basic nitrogen atom, other two features are 
essential for the activity: the trans configuration of the two hydroxy groups and the S,S 
absolute configuration of the carbons bearing these groups. Indeed, compounds that do not 
possess a hydroxy function at C-2 or that have a cis-dihydroxypyrrolidine unit are inactive.
55, 
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58 
Furthermore, (–)-lentiginosine, which has an R,R absolute configuration on the C-1 and C-2 
carbons, is 35 times less active than (+)-lentiginosine.
53 
The computational docking studies were performed using the Glucoamylase II (α-1,4-D-
glucan glucohydrolase, EC 3.2.1.3, inverting glycosidase) from Aspergillus awamori (PDB: 
DOG1; structure determined by X-ray as complex with 1-deoxynojirimycin).
59
 Before 
performing the computational studies, an evaluation of the protonation state was carried out 
(pH 7± 0.2). 
In [Figure 1.25] is shown the catalytic site of the enzyme. 
 
Figure 1.25 
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In [Figure 1.26] is illustrated the interaction model between the enzyme and (+)-lentiginosine. 
 
Figure 1.26 
As we can see [Figure1.26], the two hydroxy groups establish two fundamental hydrogen 
bonds with two amino acid residues of the cavity, the D55 aspartate and the R54 arginine. The 
nitrogen atom forms a hydrogen bond with the water molecule W501, which has a catalytic 
role. This type of interaction suggested that a substitution on the moiety of the molecule not 
crucially involved in the interaction with the enzyme, that is the six-membered ring, should 
not interfere with the favourable interaction, but on the contrary could represent a tool to 
obtain derivatives, possibly more active than the lead compound, through the connection of 
groups that could improve the interaction with the target. Therefore, considered the possibility 
534
501
D55
W417
R54
W178
E179
A39
W52
Y311
W120
Y48
Y116
E400
L177
K108
Y50
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of synthesising a new indolizidine functionalized on the six-membered ring that, apart being at 
the same time a new derivative by itself, could be a tool for the easy and stable introduction of 
new functionalities on the lentiginosine structure. 
Computational docking studies with glucoamylase suggested that an aromatic ring fused to 
the six-member ring (+)-lentiginosine could be favorably accommodated in the enzyme cavity 
and increase the affinity of the ligand towards the enzyme.  [Figure 1.27] 
 
Figure 1.27 
1.6.2 Synthetic Targets  
Computational docking studies have been performed by Prof. Paola Gratteri, university of 
Florence, on the basis of these studies following synthetic targets were designed and 
synthesized from L- and D- tartaric acids [Figure 1.28]. 
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Figure 1.28 
The computational docking studies of our synthetic targets B are illustrated in [Figure 1.29]. 
 
Figure 1.29 
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The π-π stacking interaction between the benzofused system and a phenylalanine residue 
positioned at the access of the enzymatic pocket promises to stabilize the interaction of the 
compound with the enzyme. 
1.6.3 Importance of aromatic ring
60
 
 Benzene ring (or a phenyl group) is a neutral moiety its presence in molecule does not 
affect its pKa. 
 In spite of its low H:C ratio, these rings confer exceptional chemical stability compared 
with simple unsaturated congeners (e.g. the cycloalkene or the open chain hexatriene). 
 The high thermodynamic and chemical stability of the system is attributed to the 
delocalization of p-orbitals containing 6π electrons (resonance stabilization of a 
conjugated cyclic triene). 
 Effect on the Polar surface area (PSA).  
 Effect on the clogP  
a) +ve value of clogP indicate the substituent makes phenyl ring more lipophilic and 
increases the logP of the molecule. 
b) –ve value of clogP indicates the substituent makes the molecule more polar by 
decreasing its lipophilicity.  
 Functional group modification has effect on the biological activity and Metabolism. 
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1.6.4 Medicinal chemistry aspects of aromatic ring
61, 62
 
 Aromatic ring preferred for replacements of linear and branched alkyl/ cyclo alkyl groups. 
 Aromatic ring gives rigidity to the molecule and potentially increases the non-covalent 
interaction. 
 Involvement in π-π stacking, O-H/π and cation- π interactions. 
 Drug design perspective: aromatic rings and their functionalized counterparts can be 
considered as versatile pharmacophores that increase these individual non-bonding and 
electrostatic interactions between the ligand and macro-molecules. Hence, incorporation of 
these rings into a molecule can improve the binding affinity and therefore the potency of 
the drug increased.  
 The presence of an aromatic ring in a molecule provides a platform for functionalizations 
of a compound. It serves as a core that helps to orient other groups in a structure in the 
right direction and therefore enhance the interaction with functionalities in the receptor.  
  An introduction of phenyl group into a molecule addresses important physicochemical 
property such as lipophilicity and therefore influences the absorption, distribution and 
clearance (excretion and metabolism) properties of a compound. 
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Revisited synthesis of 3,4-bis-tert-butoxypyrroline N-oxide and                                     
[(–)-7S-OH-Lentiginosine]:  synthesis and proapoptotic activity 
2.1 Introduction 
Among the natural Indolizidine iminosugars, (+)-lentiginosine
63
 is one of the more recently 
discovered, but has already attracted large interest because of the potent glycosidase inhibition 
activity despite of its simple dihydroxylated structure, and also because of the debate that 
arose about its absolute configuration
64 
[Figure 2.1]. 
 
Figure 2.1 
Our long-lasting interest on (+)-lentiginosine 14 has reinforced recently with the discovery of 
a potent alternative bioactivity of this compound as potent inhibitor of the HSP90 protein.
65 
Moreover, very recently it was found that the enantiomeric (–)-lentiginosine 27 is a potent 
proapoptotic agent against different strains of cancer cells, but with very low cytotoxicity.
66
 In 
search of new candidates which display the same bioactivity, we decided to examine another 
indolizidine, the (–)-(1R,2R,7S,8aR)-1,2,7-trihydroxyindolizidine [(–)-7S-OH-lentiginosine, 
29] as a proapoptotic agent. The enantiomer of 29 is a non-natural compound, in its protected 
form, is an advanced intermediate in two syntheses of lentiginosine,
67
 and has been employed 
____________________________________________________________________Chapter 2 
 
36 
 
to produce lentiginosine conjugates.
68
 The important biological profile of these compounds in 
both enantiomeric forms suggested, at first, the improvement of the synthesis of 29 to render it 
more available for biological tests and other applications. We report here a revisited synthesis 
of (–)-7S-OH-lentiginosine 29, which benefits of a novel efficient and practical approach to 
the key intermediate 3,4-bis-tert-butoxypyrroline N-oxide 28, and of a convergent and cascade 
version of the previous synthesis of the indolizidine skeleton. The effects of 29 on cell 
viability and apoptosis of cell lines of different origin are, then, described.  
In this chapter, is described the synthesis of 7S-OH-lentiginosine (29) starting from D-tartaric 
acid through a seven step strategy based on diastereoselective 1,3 dipolar cycloaddition of  
3,4-bis-tert-butoxypyrroline N-oxide 28 (Scheme 2.1). Analogously, the enantiomer (7R-OH-
lentiginosine) has been obtained from L-tartaric acid following same sequence.
67,69 
 
Scheme 2.1 
2.2 Nitrone 
Nitrones are N-oxides of an imine and a functional group in organic chemistry. The general 
structure is R1R2C=NR3
+
O
-
, where R3 is different from H. Nitrones are very reactive species: 
they exhibit a broad reactivity profile and are recognized as versatile synthetic intermediates 
due to their ability to undergo numerous useful reactions [Figure 2.2].
70-75 
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Figure 2.2 
2.2.1  1, 3 dipolar cycloaddition mechanism 
The nitrone-alkene 1,3-dipolar cycloaddition is useful method for obtaining isoxazolidine ring 
systems, with highly selective regio- and stereocontrol in a single [Figure 2.3].
76 
 
 
Figure 2.3 
It is possible to generate up to 3 new stereocenters using this 1,3-dipolar cycloaddition, and 
the isoxazolidine N-O bond can be reductively cleaved to afford synthetically versatile amino 
alcohols. The nitrone 1,3-dipolar cycloaddition is best described as a concerted reaction 
between 2π and 4π electron addends.77 As with the Diels-Alder reaction, the thermally allowed 
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1,3-dipolar cycloaddition is a suprafacial [π2s+π4s] process. Regio- and stereocontrol in 
nitrone 1,3-dipolar cycloadditions have been reviewed in detail in the literature
76, 78 
and the 
scope of the following discussion will therefore be limited to 1,3- dipolar cycloadditions of 
cyclic nitrones with alkenes. 
In 1,3-dipolar cycloadditions different substituents on the dipole do not vary the cycloaddition 
rate. Moreover, there is no solvent effect, i.e. the solvent polarity has a little effect on 
cycloaddition rate. Stereochemistry of 1,3-dipolar cycloaddition reactions is always 
stereospecific with respect to dipolarophile, supporting the concerted pericyclic reaction 
mechanism. Cycloadditions experience a large negative entropy of activation, therefore 
transition states are highly ordered. 
 
2.2.2 1,3 dipolar cycloaddition: regiochemistry and stereochemistry                                
 There can be two regiochemical outcomes for the cycloaddition of a cyclic nitrone with a 
substituted alkene. In principle, a C-4 or C-5 substituted isoxazolidine can be obtained [Figure 
2.4]. However, it has been shown that steric and electronic factors conspire to control the 
regioselectivity of the reaction which substantially favour a 5-substituted isoxazolidine 
product from alkenes bearing both electron donating and electron withdrawing substituent’s.79 
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Figure 2.4 Regiochemical outcomes of 1,3-dipolar cycloaddition 
As regards the electronic control of nitrone cycloaddition, regiochemistry is typically 
rationalized by analysis of frontier molecular orbital interactions, where maximum orbital 
overlap contributing to the transition state involves interaction of the most energetically 
proximal HOMO-LUMO pair combination [Figure 2.5], and determines the reaction outcome. 
For nitrone-alkene cycloadditions, both sets of interactions favour a 5-substituted 
isoxazolidine product except in the case of alkenes carrying the most electron demanding of 
substituents (such as nitroethylene).
80
 Reactions of monosubstituted alkenes with 5- membered 
ring nitrones, such as 1-pyrroline-N-oxide, behave accordingly and 5-substituted isoxazolidine 
are predominantly formed. 
81
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Figure 2.5 Frontier molecular orbital interactions in 1,3-dipolar cycloadditions 
The 1,3-dipolar cycloaddition of a cyclic nitrone with a mono-substituted alkene can proceed 
with formation of two new stereogenic centers at C-3 and C-5 (Isoxazolidine numberings), 
which can potentially yield four different diastereoisomers, when 5-substituted isoxazolidines 
are formed.
82
 As cyclic nitrones do not have the capacity to exhibit E/Z isomerism, the 
stereocontrol in cycloadditions of these nitrones is typically higher than for their acyclic 
counterparts. It is the dipolarophile orientation (endo or exo) and direction of approach (anti or 
syn) towards the 1,3-dipole that determines the product stereochemistry. The endo/exo 
selectivity of cycloaddition reactions can be influenced by the interactions of secondary π 
orbitals [Figure 2.6].
83
 In Diels-Alder reaction, the endo isomer is usually dominant with 
dienophiles carrying functionality that allows formation of favourable secondary orbital 
interactions in the transition state. In 1,3-dipolar cycloadditions of nitrones, the interaction of 
the N-nitrone pz orbital with a vicinal pz orbital is small.
84
 Therefore, unlike Diels-Alder 
reactions, the endo/exo selectivity in nitrone cycloadditions is largely controlled by steric 
factors, and hindrance between the nitrone and alkene substituents disfavours the endo 
transition state. The 1,3-dipolar cycloaddition of cyclic nitrones generally occurs via an exo 
transition state therefore. 
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Figure 2.6 Orbital interactions of exo and endo approach 
The stereochemical outcome of the cycloaddition is further complicated for cyclic nitrones 
bearing an existing stereogenic feature in the form of a substituent at one of the ring sp
3
 
carbons. In this case, cycloaddition with a mono-substituted alkene may proceed to give a 5-
substituted isoxazolidine product through four possible transition state combinations [Figure 
2.7] and anti/syn selectivity, determined by the face from which the alkene preferentially 
attacks the cyclic nitrone, also has to be considered. This selectivity is usually determined by 
steric factors, with the dipolarophile attacking from the least sterically demanding anti face of 
the cyclic nitrone. The most favourable transition state for a 1,3-dipolar cycloaddition of this 
type is therefore generally exo-anti, and this has been observed by many groups.
85,86,87
 Minor 
products resulting from the endo-anti and exo-syn are often seen, whereas the highly sterically 
demanding endo-syn product is rarely observed. 
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Figure 2.7 Possible approaches of dipolarophile in 1,3-dipolar cycloaddition. 
 
2.2.3 Cyclic Nitrone (3,4-bis-tert-butoxypyrroline N-oxide)  
Cyclic nitrone (3, 4-bis-tert-butoxypyrroline N-oxide) 28 has been synthesized in the group of 
Prof. A. Brandi in both the enantiomeric forms starting from the easily available chiral pool 
compounds L- and D-tartaric acids. [Figure 2.8]
68a, 89,100 
 
Figure 2.8 
2.3 Result and discussion  
2.3.1 Synthesis of 3, 4-bis-tert-butoxypyrroline N-oxide (28) 
In literature, there are some reports to synthesis of different cyclic or acyclic nitrones with 
different methods. Synthesis of 3-4-bis-methoxymethylpyrroline N-oxide was earlier reported 
by Prof. Petrini, University of Camerino, Italy starting from L-tartaric acid.
90b
 Synthesis of 3-
4-bis-O -protected pyrroline N-oxide (28) with several protecting groups have been used later 
on to mask the two trans-related hydroxyl moieties (Me, Bn, t-But, MOM, TBDPS, TBDMS, 
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and Bz) of easily available chiral pool compounds L- and D-tartaric acids. The appropriate 
protecting group was chosen on the basis of the desired final product and the nature of the 
reaction necessary to obtain it. Among them the most used is the tert-butyl group
91
 because of 
its high stability under many different reaction conditions, it’s easy and traceless hydrolysis, 
and its bulkiness that can induce superior diastereofacial control compared to other smaller 
protecting groups. Two general and complementary approaches use to synthesize nitrone 28 
are commonly employed (Scheme 2.2).
90, 92
  
In one approach, a tartaric ester is firstly protected then reduced to the diprotected tetrol 31. 
The activation of the primary hydroxyl group via mesylation or tosylation 32 followed by 
cyclization with hydroxylamine afford the N-hydroxypyrrolidine 33 that can be oxidized to 28 
by reagents such as HgO,
91
 NaOCl
93
 and MnO2
94
 (Scheme 2.2).
 
                                                        
In this approach, the overall yield 25-35% over 5 steps. 
 
Scheme 2.2
91-93
 
Tert-Butylation of tartaric ester is achieved with isobutene catalyzed by acid. The reaction can 
be carried out by bubbling isobutene through an acidic tartaric ester solution or by condensing 
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the gas at low temperature in a high pressure vessel, then running the reaction at room 
temperature for 2 days. Under these conditions, the di-tert-butyl ether of dimethyl tartrate 30 
(R’=Me) was obtained in 39% yield in addition to the monoester 34 (R’=Me) in 23% yield.95 
This reaction, however, is not easily reproducible, the tricky step being neutralization of the 
reaction mixture, because in absence of a large amount of isobutene even a trace of acid can 
quickly shift the equilibrium from 30 towards the monoprotected diol 34 (Scheme 2.3).  
 
Scheme 2.3 
Recently, Occhiato et al,
96
 reported tert-butylation of primary and secondary alcohols by using 
tert-butyl acetate in the presence of catalytic HClO4 at room temperature.
 
 Under these very 
practical conditions, dimethyl tartaric acid afforded the di- and mono-tert-butyl ether in 43% 
and 41% yields respectively, after 44 h. The major drawback was the need of a very high 
diluted solution (0.0025M) to form equimolar amount of the di- and monoether, otherwise, the 
monoether derivative was the principal product. Under the reported conditions, cyclic alcohols 
react with tert-butyl acetate better than the acyclic ones; tested this procedure on a cyclic 
derivative of tartaric acid such as imide 35. (Scheme 2.4) 
Benzylimide 35 was prepared by treating tartaric acid with benzylamine to get 
benzylammonium salt of tartaric acid as recently reported by Rosenberg.
97
 Benzylammonium 
salt of tartaric acid was refluxed in xylene, with removal of water to obtain benzylimide 35. 
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Scheme 2.4 
A reaction performed on imide 35 in a 0.1 M solution of t-BuOAc in the presence of a 
catalytic amount of HClO4 (0.1 eq) after 18 h afforded the ethers 36 and 37 in 3:1 ratio with 
91% overall yield (Scheme 2.3). This excellent result of protection step convenience us to the 
feasibility of another approach towards synthesize 3-4-bis-tert-butoxypyrroline N-oxide (28). 
Unfortunately, reduction of imide 36 with LiAlH4 in refluxing THF afforded the 
corresponding benzyl pyrrolidine 40 (R = t-Bu) in very low yield (17%), along with 1-benzyl-
3,4-di-tert-butoxy-1H-pyrrole 41(Scheme 2.5). 
 
Scheme 2.5 
The aromatization of other succinimide derivatives with LiAlH4 was already reported, and 
could be avoided using milder reducing reagents such as borane.
99
 However it was decided to 
first produce the N-benzylpyrrolidine 39 (scheme 2.6) then to carry out the protection. 
Benzylimide 35 was treated with NaBH4 and I2 at 0
 
°C under anhydrous condition, heated at 
the reflux temperature for 6 h afforded 38. The borazine 38 was isolated and characterized. 
This compound does not have symmetry elements and the diastereotopic carbinolic protons 3-
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H and 4-H resonate at different frequencies. To remove borane borazine 38 was treated with 
HCl to get 39 as a white solid. The protection of dihydroxy etherification of the dihydroxy 
pyrrolidine 39
68, 96 
with t-BuOAc/HClO4 resulted to be even more efficient affording a 5.6:1 
mixture of di- and mono protected pyrrolidine 40 and 42, respectively. Analogously to the 
previous case, the reaction could be run on gram scale (2.8 g of 39) using a 0.1 M 
concentration with the exception of the use of an excess of HClO4 (1.5 equiv), because of the 
presence of the basic nitrogen atom. Both the reagent/solvent t-BuOAc and the side product 42 
could be recovered and reused. It should be stressed here that obtainment of 40 by the 
isobutene method was never possible in our hands. (Scheme 2.6) 
 
Scheme 2.6 
Unprecedented hydrogenolysis of the benzyl group in 40 was quite tricky. In the presence of a 
catalytic amount of Pd/C or Pd(OH)2/C and H2 (1 Atm) in MeOH, debenzylation was slow 
and surprisingly a significant amount of 4-tert-butoxypyrrolidin-3-ol that is monodeprotection, 
was formed. Luckily, in the presence of AcOH (10 eq), debenzylation was complete after 2.5 
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h and ether hydrolysis was suppressed (Scheme 2.7). After neutralization, 43 was obtained in 
87% yield. 
 
Scheme 2.7 
The oxidation of the secondary amine 43, has been accomplished with different reagents such 
as H2O2 or urea hydroperoxide catalyzed by SeO2, Na2WO4, Na2MoO4 or MTO, alkyl 
hydroperoxide in the presence of a (trialkanolaminato)titanium(I) complex, or Oxone
®
.
68,98
 
The key oxidation of C2 symmetrical pyrrolidine 43 was performed using oxone.
68, 98
 
 
The 
reaction was performed in a solvent system constituted by Na2EDTA aqueous solution, 
CH3CN and THF in 1:1:0.25 ration in presence of NaHCO3 at 0 °C afforded 3,4-bis-tert-
butoxypyrroline N-oxide (28) in 93% yield. Crude nitrone 28 was obtained sufficiently pure to 
be used in the next step without further purification. Starting from L-tartaric acid the 
enantiomeric nitrone ent-(+)-28 was prepared following the same procedure (Scheme 2.8). 
In this approach, the overall yield is 46%
  
over 5 steps.
100 
 
Scheme 2.8 
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2.3.2 Synthesis of (-)-(1R-2R-7S-8aR)-1, 2, 7-trihydroxyindolizidine 
 [(-)-7S-OH-lentiginosine] 
In this chapter, we are going to discuss the synthesis (–)-7S-OH-lentiginosine (29) carried out 
by the old approach as well as new approach. In literature, Prof. A. Brandi reported synthesis 
of 7S-OH-lentiginosine in 2000.
67c
 We compared both approach towards synthesis of (–)-7S-
OH-lentiginosine (29) transformed. 
 
 2.3.2.1 Old approach towards Synthesis of (-)-(1R-2R-7S-8aR)-1,2,7 
trihydroxyindolizidine 
In the old approach, synthesis of (–)-7S-OH-lentiginosine via 1,3-DC reaction of 3,4-bis-tert-
butoxypyrroline N-oxide (28) with butenol 44 (5 eq) in benzene at 60
 
°C for two days afforded 
a mixture of diastereomeric cycloadducts 45a, 45b and 45c in 10:2:1 ratio with complete 
regioselectivity (Scheme 2.9).
67c
 The major exo-[4-OtBu] anti adduct 45a was obtained in 
74% yield after chromatography.  
 
Scheme 2.9 
The similar results could be obtained in shorter time at higher temperature. In particular at 100 
°C in the presence of 5 equiv of butenol, nitrone was consumed in 1.5 hours. Adduct 45a was 
isolated in 75% yield after chromatography on silica gel, and the ratio between the two main 
cycloadducts was ca. 5:1 as in the previous case. 
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Scheme 2.9 Possible approaches of dipolarophile in 1,3-dipolar cycloaddition 
Possible approaches of 1,3-DC of dipolarophile with nitrone are described above (Scheme 
2.10). The exo-anti approach is highly favored, because of the hindering effect of the ring and 
its substituents in an endo approach. endo-syn product is rarely observed.     
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Scheme 2.10 
 
The cycloadduct 45a was converted into indolizidine through activation of primary hydroxy 
group by mesylation and subsequent spontaneous cyclization to salt 46a, that was reduced, 
without isolation, with H2 in the presence of catalytic amount of Pd/C to obtain protected 7-
OH-lentiginosine 47 [Table 2.1] . Final deprotection of 47 affords (–)-7S-OH-lentiginosine 
(29). 
 
Table 2.1 
Reagent and condition of 1,3-DC/Cyclization/N-O bond reduction sequence 
 Step a Step b Step c Yield of 47 
    1 44 (5 eq), C6H6, 60 °C, 2 days TsCl, TEA, dry DCM H2, Pd/C,     
MeOH, 1 day 
64% 
    2 1  44 (5 eq), toluene, 100 °C, 1.5 h     MsCl, TEA, dry DCM H2, Pd/C, 
 MeOH, 15 h 
64% 
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2.3.2.2 New approach towards the Synthesis of (–)-(1R-2R-7S-8aR)- 1,2,7 
trihydroxyindolizidine.
100
  
In our new revised approach, another possible change to make the process more convergent 
was to use a dipolarophile with the hydroxyl functionality activated in advance towards the 
nucleophilic substitution, such as 3-butenyl tosylate 48, and running a one pot three step 
reaction in a sealed Sovirel flask. The two-step domino process consisting of 1,3-
DC/nucleophilic substitution was carried out, in the presence of an excess amount of 
dipolarophile 48 (4 equiv) at room temperature for three days, because of the thermal 
instability of salt 46b. After 3 days, activated Zn, AcOH and Et2O was added to the white 
slurry of the salt 46b and the mixture kept at room temperature under stirring for one more 
day. Neutralization and purification by flash chromatography on silica gel afforded three 
diastereomeric indolizidines 47a and 47b in ca. 5:1:0.2 ratios (60%, 12% and 2% yield 
respectively) and the excess of dipolarophile 48 that was recovered in 95% yield in the very 
early chromatographic fractions (Scheme 2.11).
100 
 
Scheme 2.11 
Table 2.2 
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Reagent and condition of 1,3-DC/Cyclization/N-O bond reduction sequence 
 Step a Step b Step c Yield of 47a-c 
    1 48 (4 eq), RT, 3 days  
     Zn, AcOH, Et2O    60%, 12% 2% 
 
Reductive cleavage of the isoxazolidine N-O bond with H2 over Pd/C afforded analogous 
results, except for the hydrogenation of the double bond of the excess dipolarophile that could 
not be recovered.  
This one pot procedure has some advantages over the previous one. In particular, it is more 
convergent, is run at rt, the excess of dipolarophile can be easily recovered and reused, does 
not require anhydrous conditions and special handling, and the overall yield of 47 is similar to 
the previous ones (60% vs. 64%). The only drawback of this variation is the overall long 
reaction time (4 days). The same process was carried out starting from ent-28 to obtain the 
enantiomeric ent-29. 
 
Scheme 2.12 
Eventually, deprotection of indolizidine 47 by treatment with TFA afforded pure triol 29 in 
87% yields. (Scheme 2.12) In conclusion, the overall new process allowed a more 
straightforward access to (–)-7S-OH-lentiginosine 29 which is very promising in the light of 
its interesting biological activity. 
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2.4 Biological activity
100 
The effect of 29 on both cell viability and apoptosis of tumour cell lines of different origins 
was investigated by the group of Dr. Beatrice Macchi at the University of Tor Vergata, Rome. 
The cytotoxic effect of 29 was assayed towards MOLT-3, SH-SY5Y, HT-29, MCF- 7, and M-
14 cell lines [Table 2.3]. HT-29 cells were slightly more sensitive. Conversely, the well-
known cytotoxic chemotherapeutic agent SN38, used as a positive control, was highly toxic 
towards all the tested cell lines [Table 2.3]. 
Cell lines Compounds MAIC50±SD(µM) 
MOLT3 
(human acute lymphoblastic T cells) 
(-)-lentiginosine 213.33 ± 96.62 
(+)-lentiginosine >1000 
(-)-7S-OH lentiginosine 485±16.62 
SN38 14±2 
SHSY5Y 
(neuroblastoma cells) 
(-)-lentiginosine 95.5 ± 19.09 
(+)-lentiginosine >1000 
(-)-7S-OH lentiginosine 396±9.09 
SN38 <0.1 
HT29 
(human colorectal adenocarcinoma cells) 
(-)-lentiginosine 577 ± 101.3 
(+)-lentiginosine >1000 
(-)-7S-OH lentiginosine 285±35.3 
SN38 <1 
PBMCs 
(peripheral blood mononuclear cells ) 
(-)-lentiginosine 384.52 ± 49 
(+)-lentiginosine >1000 
SN38 <1 
[a] MAIC50 value=metabolic activity cytotoxic inhibitory concentration 50%, SD=standard deviation. 
Table 2.3. Effects of compounds 29 and SN38 on viability, as assessed by the MTS assay in   
tumour cell lines. 
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It was important to verify, whether the effect of the tested compound on cell viability could be 
ascribed to the induction of cell death by apoptosis. To this aim, cell lines were treated for 24 
hours with 29 at concentrations ranging from 1 to 10
3
 µM. The results of apoptosis expressed 
as a percentage of hypodiploid nuclei (hypodiploid nuclei are nuclei that contain less number 
of chromosomes than normal cell nuclei) are shown in [Figure 2.9], the values being the 
mean±SD of three independent experiments. The results underline a dose effect response in 
the presence of a concentration of 29 from 1 to 10
3
 µM in all the tested cell lines. However, 
the assayed cell lines exhibited different susceptibility to compound-induced apoptosis. The 
MOLT-3, MCF-7, and M-14 cells were highly susceptible to apoptosis induced by 29, with 
differences in comparison with control cells that were significant at a concentration as low as 
10 µM. Conversely, SH-SY5Y and HT-29 cells treated with 29 showed apoptosis levels that 
were significantly different from control cells at a concentration of 10
2
 µM or higher. The 
reference positive control SN38 was effective in inducing apoptosis in all the cell lines 
assayed at a concentration of 10 µM, as expected. 
 
                                            
Figure 2.9 A) Effects of the compound (–)-7S-OH-lentiginosine 29 on apoptosis in cell lines 
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To further characterize apoptosis induced by 29, effects of compound 29 on both upstream and 
downstream caspases was investigated. To this purpose, MOLT-3, SH-SY5Y, HT-29, MCF-7, 
and M-14 cells were treated with 29 at 10
2
 µM that is, at the minimum compound 
concentration equally able to induce apoptosis in all the cell lines. The expression of both pro 
and cleaved caspase 3 and caspase 8 after 6 and 24 hours of culture was investigated by 
immunoblotting. The results, reported in [Figure 2.10], show that Pro-caspase 3 was 
constitutively expressed both in untreated and in treated cells except in MCF-7 and in M-14, 
where it was expressed only after treatment with compound 29. Densitometry analysis values 
indicate that pro-caspase 3 expression was increased, following 6 hours of treatment, by 2- 
and 4-fold only in MCF-7 and in M-14 cells, respectively. Conversely, the cleaved form of 
17/24 KDa was highly expressed with respect to the untreated control as early as after 6 hours 
and this expression was increased after 24 hours by 1.2- to 2-fold in SHSY5Y,  HT-29, 
MOLT-3, and M-14 cells. Moreover, pro-caspase 8 expression was constitutive in MOLT-3, 
SH-SY5Y, MCF-7, and M- 14 cells. At 6 hours following treatment with 29, the expression of 
pro-caspase 8 increased from 1.5- to 3-fold in the entire cell lines except for HT-29 cells, in 
which a 7-fold increase was observed. 
These results highlight that 29, which is an enantiomer of a synthetic glycosidase inhibitor, is 
endowed with a well detectable, caspase-related pro-apoptotic activity on a broad range of 
tumour cell lines of lymphoid as well as epithelial origin. The present study further extends 
previous data indicating that (–)-lentiginosine (27), which is the synthetic enantiomer of a 
natural product, was able to induce apoptosis in different tumour cells in vitro.
66 
Although triol 
29 [(–)-7S-OH-lentiginosine] differs only for the presence of the OH group at C7 with respect 
to 27, its biological activity presented two distinct aspects. It was able to induce appreciable 
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apoptosis in MOLT-3 cells starting from half the concentration with respect to (–)-
lentiginosine (27). 
 
 
Figure 2.10 Caspase 3 and caspase 8 expression in cells line after incubation of 100 µM of 29 
 
Apoptosis induced by 29 was well detectable starting from 24 hours after treatment, 
meanwhile (–)-lentiginosine induced apoptosis as early as 18 hours after treatment. The reason 
underlying this slightly different biological behaviour is not clear. However, we can notice 
that the delayed time of 29 in inducing apoptosis with respect to (–)-lentiginosine, fits with the 
fact that caspase 3 and caspase 8 expression peaked at 24 hours after treatment. In addition, 
maximal cytotoxic activity, as detected by the MTS assay, also occurred 24 hours after 
treatment. The comparison of results of the MTS assay with those of apoptosis suggests that 
most of the cytotoxic activity exerted by 29 towards the different tumour cell lines was 
attributable to apoptosis, except for HT- 29 cells that were quite resistant to apoptosis while 
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more sensitive than the other cell lines to metabolic activity inhibition. Observe that 
compound 29 is 50–100 times less potent as a pro-apoptotic agent than etoposide. However, 
the concentration of 29 necessary to cause a cytotoxic effect (MAIC50 value ) is 40 to 400 
times higher than that of etoposide, accordingly, indolizidine 29 is less cytotoxic than 
etoposide analogously to the parent (–)-lentiginosine (27).66 
 
2.4 Conclusion      
The synthesis of the enantiopure 1,2,7-trihydroxyindolizidine 29 was revisited leading to a 
sensible overall improvement particularly in the preparation of nitrone 28. In the previous 
approach, the overall yield of nitrone synthesis reached 25-30%, but the reaction, particularly 
the protection step, was not easily reproducible. In the new approach 46% overall yield of the 
nitrone was achieved over 5 steps and all reaction are reproducible. The revisited synthesis of 
1,2,7-trihydroxyindolizidine 29 was also more convenient because all the reactions were 
carried out at room temperature, do not require anhydrous conditions, and is more atom 
economical, because the excess of dipolarophile is  recovered, even if overall yield of 29 is 
similar (60 v 64%). It has been proved that (–)-7S-OH-lentiginosine 29 is a proapoptotic agent 
versus different tumor cell lines, and it has similar potency to that of the parent compound 27. 
The results lead us to a more insightful investigation to assess the potential antitumor effect of 
the enantiomer of lentiginosine and its derivatives. Taken together these data demonstrate how 
these compounds, with a structure resembling that of sugar mimetic glycosidase inhibitors, 
endowed with previously unknown pro-apoptotic activity, could constitute a new distinct class 
of pro-apoptotic agents. Actually, recent data have shown how iminosugars, in general, can be 
endowed both with cytotoxic and glycosidase inhibition activity on human cancer cell lines of 
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different origin.
101b
 These studies suggest that a more deep investigation should be aimed to 
assess whether inhibition of glycosidase might directly be involved in induction of apoptosis 
by these compounds. 
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Stereoselective synthesis of a highly hydroxy functionalized 
benzo[e]indolizidine via Cu (I) catalyzed Ullmann reaction 
3.1 Introduction 
Lentiginosine [(1S,2S,8aS)-octahydroindolizine-1,2-diol] (14), one of the least substituted 
indolizidine iminosugars, has shown an interesting activity in addition to the glycosidase 
inhibition. In particular, it was shown to be a potent inhibitor of HSP90.
101
 Moreover, its 
enantiomer [(1R, 2R, 8aR)-octahydroindolizine-1,2-diol] (27)
4,102 
and the corresponding 7-OH 
derivative [(1R,2R,7S,8aR)-octahydroindolizine-1,2,7-triol](29)
100 
 have a low cytotoxicity 
effect, but can induce apoptosis in cancer cell strains. 
The search for new, more selective and potent candidates of this important class of compounds 
suggested the modification of the indolizidine skeleton through its conjugation with relevant 
substructures, like functionalized chains, or amino acid structures. The six membered ring of 
lentiginosine was the target of these functionalizations.
68
 Proceeding on this idea, the synthesis 
of benzosubstituted lentiginosines was taken in account, supported by computational studies 
that suggested a better interaction of a benzolentiginosine with the enzymatic cavity. It was, 
then decided to fuse a benzene ring at six-membered ring of lentiginosine, at the [e]-bond 
position. The importance of benzene rings in  medicinal chemistry is  mentioned in the 
literature.
61, 62
 All the more, natural aryl substituted polyhydroxylated pyrrolidines, like 
codonopsine or radicamine,
103
 show interesting biological activities. 
In this chapter, we discussed the synthesis of benzosubstituted lentiginosines [Figure 3.1] 
starting from L- tartaric acid. The strategy is based on the diastereoselective 1,3-dipolar 
cycloaddition of 3,4-bis-tert-butoxypyrroline N-oxide (28) with halogen substituted styrenes 
described in (Scheme 3.1). 
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Figure 3.1 
One particular advantage of this approach was anticipated to be the control of the regio- and 
stereochemistry of the 1,3-dipolar cycloaddition (1,3-DC), and possibility of carrying out a 
metal catalyzed ring closing amination in the final step (Scheme 3.1). 
 
 
Scheme 3.1 
3.2 Result and discussion  
3.2.1 Synthesis of benzo[e]indolizidine from nitrone (28), which derived from tartaric 
acid 
3.2.1.1 Synthesis of isoxazolidine 
The cycloaddition of nitrones 28 and 51 with two functionalized styrenes, 2,6-dichlorostyrene 
(49) and 2-bromostyrene (50) was carried out (Scheme 3.2).
123 
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Scheme 3.2 
Reagents Reaction time adduct Yield exo-anti exo-syn endo-anti 
51 + 49 1h 45’ 52 94% 6.8 6.4 1 
51 + 50    2 h  53 92% 18.4 11.6 1 
28 + 50    5 h 54 99% 12 3.5 1 
 
Table 1 Cycloaddition between halogenated styrene and nitrones. 
The 1,3-DC of nitrone 51 with dichlorostyrene 49 in toluene as solvent was performed in the 
MW oven at the temperature 75 °C for 2 h. A higher temperature for the reaction should be 
avoided to prevent the polymerization of styrene and the degradation of the starting materials. 
The 1,3-DC of 51 with 49  was less diastereoselective than the corresponding reaction with 
bromostyrene 50 (ca 1:1 vs 1.6:1 exo-anti/exo-syn ratio). The presence of two o-Cl atoms 
could hamper the coplanarity between the vinylic group and the benzene ring, reducing the 
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stereofacial preference induced by the C-4 TBDMSO substituent.  Likely, the mono-
substituted bromostyrene 50 can better accommodate the substituted phenyl ring in an anti 
approach. The highest stereoselectivity was obtained with the dipolarophile 50 and di-tert-
butoxy nitrone 28 that afforded the adduct exo-(3-OR)-anti 54a in 73% yield (calculated). 
Diastereomeric adducts exo-syn and endo-anti were not easily separable by chromatography 
on silica gel, and were separated at later steps. In all the cases, the exo-(3-OR)-anti 
diastereoisomer (52a-54a) (Scheme 3.3), deriving from the exo attack of the alkene on the 
opposite face of the C-3 substituent of the nitrone, was the major adduct. The second and third 
isomers were, respectively, the exo-(3-OR)-syn and the endo-(3-OR)-anti isomers (52b-54b 
and 52c-54c). 
 
Scheme 3.3 Possible diastereisomers can derive from cycloaddition of 49, 50 with nitrone. 
The cycloaddition reaction between 28 / 51 and styrenes 49 / 50 could give four 
diastereoisomer; the exo-anti diastereoisomer should be the most favoured, whereas the endo-
syn diastereoisomer should be the less favoured [Figure 3.2]. 
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Figure 3.2 
The stereochemistry of cycloadducts 52-54 was assigned by NMR analyses and then 
confirmed by the analysis of the corresponding derivatives. In particular, a NOE interaction 
was present between 2-H and 4-H in 54a and between 2-H and 5-H in 54b in agreement with 
an exo-preferred approach [Figure 3.3]. The trans relationship between the 3a-H and 4-H 
protons in the 3-(Ot-Bu)-anti adducts 54a and 54c was indicated by the small 
2
J3a-H/4-H 
coupling value (4.1 and 3.5 Hz, respectively). 
 
 
Figure 3.3 Diagnostic NOE interactions in adducts 54a and 54b 
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3.2.1.2 Opening of isoxazolidine ring 
The selective reduction of the isoxazolidine N-O bond was carried out with Zn and acetic acid 
and afforded the corresponding pyrrolidines in good yields (Scheme 3.4). 
 
 
Scheme 3.4 Only major distereoisomers are reported  
NOE experiments on pyrrolidines derived from adduct 57a and 57b confirmed the assigned 
configuration. In particular, a NOE interaction between 2-H and 4-H was observed only in 57a 
and the interaction between the vicinal 2-H and 3-H proton was smaller in pyrrolidines 57a 
than in the corresponding isomers 57b in accord with the assigned relative configuration 
[Figure 3.3]. 
 
 
Figure 3.4 Diagnostic NOE interactions in adducts 57a and 57b 
3.2.1.3 Closure of benzoindolizidine ring  
The halogen atom present on the aromatic ring is crucial for the last step of the synthesis that 
is a nucleophilic aromatic substitution promoted by an appropriate catalyst. In literature 
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several examples of cyclizations of model compounds are reported (Scheme 3.6).  Buchwald 
et al 
104c
 synthesized 1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinoline (60) in 55% yield by 
intramolecular Pd catalyzed nucleophilic aromatic substitution of the 2-Br-
phenethylpyrrolidine (58) (Scheme 3.6). Fort et al,
105c
 have carried out the same cyclization of 
the chloro derivative 59 in the presence of a Ni catalyst in 81% yield (Scheme 3.6).  
 
Scheme 3.6 
Although our substrates 55-57 are highly functionalized, but the skeleton is quite similar with 
these model reactions, we decided, then, to apply the same reaction conditions used by 
Buchwald and Fort with our substrate in order to achieve our next goal. 
3.2.1.3.1 Buchwald-Hartwig Amination reaction 
The formation of aniline starting from aromatic halides and primary or secondary amines is a 
reaction strategically very important for the synthesis of amino-aromatic nucleus, which is 
basically important for compounds of pharmaceutical interest. The first reaction of amination 
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of aryl starting from aromatic halides has been addressed by the group of Migita in 1983, 
which used a stoichiometric amount of tetrakis-triphenylphosphine palladium [Pd (PPh3) 4] for 
the reaction between various bromobenzene and (N, N - diethylamino) tributylstannane.
 104
  
Buchwald
104
 and Hartwig
105
 developed the first general procedure of aryl amination catalyzed 
by palladium tetrakis-triphenylphosphine [Pd(PPh3)4]. This reaction allows the insertion of 
amines, alcohols, acetyl esters and methyl ketones in aromatic structures, on which a halogen 
atom (except fluorine) or a trifluoroacetate group (OTf) is present. The catalytic reaction 
conditions require the use of a metal in an oxidation state (0), a ligand of the metal, a base and 
a suitably high boiling solvent. The ligand choice is crucial as it can determine a very 
significant change in the yield of the reaction (from 0 to 90%). In [Figure 3.5] is illustrated the 
amination mechanism,
 106
 useful to understand the importance of the role of the ligand. 
 
Figure 3.5 
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The active catalyst is a palladium complex in an oxidation state (0). This complex is very 
oxygen labile, therefore it is necessary a deoxygenation of the reaction medium. The first step 
of the mechanism is the formation of the complex I, derived from an oxidative addition of the 
aromatic halide to the palladium activated complex. The ligand hindrance plays a key role in 
the formation of the activated catalyst complex.
107
 The oxidative addition is the rate 
determining step (rds) of the reaction. Then, two possible reaction steps can occur depending 
on which among the base or the amine reacts at first (a and b pathways, respectively). In any 
case, the deprotonation of the amine is very important for the formation of the complex IV.  
Through a reductive elimination, complex IV is split in the aniline and in the regenerated 
catalyst. During this step, an electron donating effect of the ligand can promote the elimination 
of the product and decrease the rate of the competitive β-elimination reaction on the amines 
which have removable protons in this position.
108 
Usually, the arylbromides and -iodides undergo the Buchwal–Hartwig reaction at lower 
temperatures, in shorter reaction time and affording better yields than the corresponding 
arylchlorides, which often do not react at all.  To obtain benzocondensated derivatives of the 
lentiginosine 61-63, initially a Buchwald–Hartwig reaction was attempted [Figure 3.6]. 
 
 
Figure 3.6 
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In the cyclization reaction of 55a and 56a were employed complexes of both palladium and 
nickel as catalysts, in fact nickel complexes have been shown to be more efficient in the 
amination of arylchlorides.
109,110
 A series of tests, to find the best reaction conditions, were 
also performed using pyrrolidine with the model compound 1-(2-chlorophenyl)ethanol 
(racemic). In order to facilitate the oxidative addition of the substrate to the metal, 2-
bromostyrene 50 was also used. Furthermore, the bromoderivative 56a was a suitable 
substrate for an Ullmann-type reaction catalysed by Cu(I), accordingly, also this option was 
explored. 
3.2.1.3.2 Copper mediated cyclization by Ullmann reaction  
The Ullmann reaction leads to formation of biphenyls starting from aromatic iodides (or 
bromides) with the employment of stoichiometric amounts of metallic copper at high 
temperatures (>200 °C).
111 
The active catalytic species is Cu(I). The nature of the 
organometallic intermediates that are formed in the catalytic cycle and the copper oxidation 
state in these intermediates are not well defined yet. Two different kinds of mechanisms are 
hypothesized, with (A, B) or without (C, D) variation of the copper oxidation state [Figure 
3.7]. 
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Figure 3.7 
The oxidative addition [Figure 3.7, A], a key step in the Pd-catalysed reaction, maybe can not 
occur because: i) the contemporary presence of Cu(III) and X
-
 in the same reaction ambient is 
unknown in the literature (because of the reduction potential of the two ions); ii) Ullmann-type 
reactions smoothly occur with ortho substituted aromatic systems, unlike Pd-catalysed 
reactions; iii) aromatic triflates do not react under the Ullmann type conditions, but react very 
easily in Pd-catalysed reactions. However, it is not possible to exclude anyone of the proposed 
mechanisms. 
3.2.1.3.3 Intramolecular amination reactions 
The cyclization reactions carried out on substrate 55a were numerous: only a summary is 
reported in Table 2. The ligands used were: 2,2’-bipyridyl (I), (2-biphenyl)di-tert-
butylphosphine (II), L-proline (III) and tetramethylethylenediamine (IV) (Scheme 3.7, Table 
2). 
____________________________________________________________________Chapter 3 
 
70 
 
 
 
      
Scheme 3.7                                                                                 
 Ar-
X 
Scale 
(mg) 
M source 
(mol. equiv. 
%) 
L
[a]
 M:L Base 
(mol. 
equiv.) 
Solv. T 
(°C) 
T 
(h) 
Yield 
(%) 
1 55a 30 
Ni(OAc)2 (5) bpy 1 : 3 
tBuOH 
(0.1)/NaH 
(1.2) 
THF 90 5 0 
2 55a 66 
Pd(OAc)2 (10) bptbp 1 : 2 tBuOK (1.2) toluene 110 21 0 
3 55a 30 
- - - tBuOK (2.5) toluene 130 5 0 
4 55a 27 PdCl2TEMED 
(10) 
bptbp 1 : 2 tBuOK (1.2) THF 90 5 0 
5 55a 218 CuI (10) Pro 1 : 2 K2CO3 (2.0)   DMF 100 48 5 
 
Table 2 Intramolecular N-arylation by Buchwald-Hartwig reaction conditions 
 
 All the reactions under Buchwald-Hartwig conditions failed to give any cyclization product. 
Bisphenylphosphine II 
112-114
 used in the experiments 2 and 4 with Pd (0) did not activate the 
metallic center. The Ni-catalyzed reaction did not give any transformation of the substrate. A 
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possible reason for the absence of reactivity of the substrate could be the presence of the free 
hydroxy group that could give rise to a strong hydrogen bond with the nitrogen atom lowering 
its nucleophilicity and, on the other hand, moving it away from the aromatic ring, hampering 
an intramolecular attack. Anyway, protection of hydroxy group did not bring any benefit to 
the product formation. It was also considered to oxidize the hydroxy group. Unfortunately the 
presence of the amino group limited the reagent choice for a direct oxidation.
115-117
 The use of 
manganese oxide (IV) also failed,
118
 in accord with a reduced reactivity of benzylic OH group. 
Because of the role of tBuOH in combination with sodium hydride, we supposed that 
alcoholic functions can be deprotonated and the formed alkoxide interferes with the vicinal 
metal coordinated with the benzene ring quenching its catalytic effect. The presence of an 
intramolecular hydrogen bond in apolar solvents was proved by the persistence of the broad 
band in the 3100-3550 cm
-1
 region of the IR spectra of diluted solutions of 55a (30–5 mM in 
CDCl3). Attempts to convert the free OH group in silyl ether with TBDMSCl and TMSCl in 
DMF, or TMSOTf in DCM failed or gave very small yields of the desired compound. To 
verify this hypothesis, the cyclization under Ullmann reaction condition was examined, 
because the highly polar solvents used in Cu(I) catalyzed C-N coupling should effectively 
reduce the strength of the internal hydrogen bond in substrates 55-57, and shield the reactivity 
of the hydroxy group. 
Finally, only under Ullmann conditions, using Cu(I) 10 mol% as catalyst, proline as ligand 
and potassium carbonate as base, the formation of the cyclization product 61 was observed 
even if in very small amount (5% yield) [Table 2. Entry 5]. Somewhat better results were 
obtained by switching to the bromoderivative 56a. In [Table 3] are described the cyclization 
reactions performed on 56a. 
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Scheme 3.8 
 
CuI/Cu/L-Pro (mol %) Base Solvent T t yield 
10/100/20 K3PO4 Dry DMF 100 °C 48 h 37% 
30/30/60 DBU t-BuOH 100 °C (MW) 10 h 30% 
30/30/60 K3PO4 t-BuOH/H2O/THF 100 °C (MW) 5 h 46% 
 
Table 3 Intramolecular N-arylation by Ullmann reaction conditions 
Cyclization of pyrrolidine 56a in the presence of copper salts was tested using various 
combinations of catalyst sources, with or without proline, an organic or inorganic base, under 
anhydrous or aqueous conditions. It was found that CuI in the presence of metallic Cu was 
more efficient as catalyst than CuI alone or the CuSO4/Cu couple and that the use of proline as 
copper ligand increased the yield. The catalytic effect of copper was proved by analyzing the 
thermal cyclization of 56a (DMF, DBU or K3PO4, 120 °C, 2 h) that afforded only traces of 
62a along with a mixture of decomposition products. DBU and K3PO4 were more efficient 
than K2CO3 in DMF, but in protic solvents a higher yield was obtained when K3PO4 was used 
as base. Unfortunately, the desired compound 62a could be isolated in only 30-46% yields at 
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best (Scheme 3.8, table 3). A significant amount of decomposition products was always 
detected in the crude reaction mixtures even when conversion was not complete. Generally, 
with longer reaction times or a higher temperature, decomposition increased with detrimental 
effect on the overall yield in accord with a relative instability of 62a under the reaction 
conditions. 
1
H NMR spectra of the crude mixtures showed a large excess of high field signals 
suggesting that the TBDMS protecting group could be part of the problem. In fact, it has been 
reported that the TBDMS group can be removed in the presence of copper salts.
120 
Then, the copper-mediated cyclization of the di-tert-butyl derivative 57a was studied using 
the best reaction conditions found, i.e. CuI/Cu/L-Pro as catalyst mixture, K3PO4 as base and a 
1:1 mixture of tBuOH/H2O as solvent (Scheme 3.9, Table 4). 
 
 
Scheme 3.9 
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No CuI/Cu (%) T ( °C) t (h) RSM (%)
b
 Yield (%)
c
 
1 30/30 100 (MW)
 a
 3.5 61 36 (90) 
2 30/30 120 1.5 32 48 (71) 
3 50/50 90 (MW)
 a
 10 n.d. 75 
4 50/50 90 10 n.d. 65 
5 80/80 90 (MW)
 a
 13 15 62 (73) 
6 80/80 110 2 n.d. 21 
7 80/80 100 (MW)
 a
  3.5 30 31 (44) 
8 50/50 95 10 28 58 (81) 
9 50/50 90 12 n.d. 74 
10 50/50 90 12 7
(d)
 77 (82)
d
 
 
[a] MW: Microwave heating. [b] RSM: recovered starting material (57a) after chromatography;                                                                   
n.d: not determined [c] Isolated yield after chromatography; values in parentheses refer to yields based on 
conversion. [d] The reaction was made on ent-57a    
 
Table 4 Intramolecular N-arylation by Ullmann reaction conditions 
The replacement of the protecting group led to a significant reduction of decomposition 
products. Preliminary tests on 57a revealed that a higher yield based on converted starting 
material could be achieved when the reaction is run at lower temperature and for longer time 
(Table 4 entries 1-2 and 5-7). Half mol equiv of the CuI/Cu couple was found to be the best 
compromise between conversion percentage, overall yield and a reasonable reaction time (10-
12 h) when the reaction was carried out at 90 °C. Due to the long reaction time, conventional 
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heating was preferred over microwave irradiation that was only slightly more efficient (Table 
4, entries 3, 4 and 9). Finally, the best reaction conditions (Table 4, entries 9 and 10) were 
applied to both the enantiomeric pyrrolidines 57a and ent-57a. The corresponding tricyclic 
products 63a and ent-63a were obtained in 74 and 77% yield, respectively, demonstrating no 
major effect of the use of the chiral L-proline as catalyst ligand with different enantiomers. 
Under the same conditions, the dichloro derivative 55a proved to be less reactive affording 
only traces of the corresponding benzoindolizidine after 48 h at 100 °C. The known reduced 
reactivity of chloro aromatic compounds in comparison with the corresponding bromo 
derivatives and the steric hindrance of the densely functionalized phenethyl pyrrolidines 55 
compared to 56 and 57, seem to justify the lack of reactivity. 
NOE experiments on tricyclic compound 63a confirmed the assigned configuration. In 
particular, hydrogen 3a-H showed NOE interactions with both 2-H and 5-H [Figure 3.8]. 
 
Figure 3.8 Diagnostic NOE interactions in adducts 63a. 
3.2.1.4 Deprotection of benzo[e]indolizidine   
The last step of the synthesis, the deprotection of the protecting groups on the hydroxy 
functions in position 2 and 3 of tricyclic product 63a, was carried out with TFA at 0 °C- rt.  
However, the reaction did not afford any product 64 but only decomposition products. 
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Probably the presence of the OH group on benzylic position renders the compound unstable 
(Scheme 3.10). 
 
Scheme 3.10 
In order to avoid this drawback, deprotection of 57a was carried out in the same conditions 
before cyclization in order to get 65. The tri-hydroxy derivative 65, without purification was, 
then, subjected for intramolecular aryl amination under the best reaction conditions, which 
gave compound 64 in 40% overall yield over the two steps (Scheme 3.11). 
 
 
Scheme 3.11 
 
3.2.1.5 Synthesis of benzo[e]indolizidine (64)  
Having in hand the indolizidine 63 it was needed to remove the hydroxyl functionality to 
obtained benzolentiginosine. The removal of OH group was achieved by first transformation 
in the corresponding acetate followed by reduction with H2 on Pd. The acetylation of 63 was 
carried with acetic anhydride in pyridine at 0 °C to obtain 66.121 The protected tricyclic 
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product 66 was then treated with Pd/C under H2 to get diprotected benzo[e]lentiginosine 67 in 
83% yield (Scheme 3.12). 
 
 
Scheme 3.9 
Deprotection of diol 67 with TFA at 0 °C gave benzo[e]lentiginosine 68 in 91% yield. The 
synthesis of benzo[e]indolizidines 64 and 68 was, then, complete in satisfactory with good 
yield in both enantiomeric forms, to explore their biological activity. 
 
3.2.2 Synthesis of benzo[e]indolizidine from nitrone (74), which derived from malic acid 
We decided to test the optimized Ullmann reaction condition on an analogous system bearing 
only an alkoxy group on the pyrrolidine ring. Therefore, we decided to synthesize another 
benzo[e]indolizidine starting from nitrone 74, which can be easily derived from malic acid.  
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3.2.2.1 Synthesis of (S)-4-tert-butoxy-3,4-dihydro-2H-pyrrole 1-oxide (74).
127
 
The optically pure chiral five membered 4-tert-butoxy pyrrolidine N-oxide (74) was prepared 
through a convenient six step procedure starting from L-malic acid (Scheme 3.10). In 
particular, the diethyl ester of malic acid 69 was treated with tert-butyl acetate in the presence 
of a catalytic amount of HClO4 to protect the free hydroxyl group,
96
 then the diester 70 was 
reduced to the corresponding diol 71, which was in turn mesylated 72. Cyclization with 
hydroxylamine afforded the N-hydroxypyrrolidine 73 through a double-nucleophilic 
displacement of the (bis)mesylate. The final step consists of a regioselective MnO2 oxidation 
of hydroxylamine 73 that can afford two regioisomeric nitrones. The two nitrones 74 and 75 
were obtained in 9:l ratio by treatment of 73 with MnO2 in dichloromethane at room 
temperature. The assignment of the structure to the two nitrones was easily made on the basis 
of the coupling pattern of the HC=N proton in the 
1
H NMR spectra ( 6.79 ppm, quartet, J = 
1.8 Hz for 74, and  6.83, multiplet for 75). 
 
Scheme 3.10 
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3.2.2.2 Synthesis of (3S)-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinolin-3-ol (83 and 84). 
The 1,3-DC of (S)-4-tert-butoxy-3,4-dihydro-2H-pyrrole 1-oxide (74) with 2-bromostyrene 50 
in toluene at 85 
o
C for 3 h afforded two major diastereomeric adducts 76, 77 along with two 
other diastereoisomers (78, and 79) and a regioisomer 80 in traces amounts (50:14:4:2:1 ratio) 
as colourless liquids in 88% overall yield (Scheme 3.11). The observation of the regioisomer 
80, albeit in very minute amount, is remarkable for this kind of 1,3-DC that is commonly 
highly regioselective. It must be due to some influence of the Br electron withdrawing 
substituent on the styrene dipolarophile. It is well known that electron withdrawing 
substituents on alkene dipolarophiles favour the 4-regioisomers. Adducts 76 and 78 could not 
be separated by chromatography on silica gel and were obtained 67% yield (ca: 12:1 mixture), 
whereas the adduct exo-syn (77) , endo-syn (79) and a regioisomer 80 could be separated by 
chromatography on silica gel. 
 
 
Scheme 3.11 Diastereomeric adducts derived from 1,3-DC of nitrone 74 with 50 
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The structure and stereochemistry of the adducts were assigned by NMR analysis.  
In particular,  
 
 
 
Figure 3.9 Selected NOEs for the determination of relative configuration in pyrrolo[1,2-
b]isoxazolidines 76, 77, and 79. 
The cycloaddition reaction between 74 and 50 could give four diastereoisomeric 2-substituted 
pyrrolo[1,2-b]isoxazolidines. This selectivity is usually determined by steric factors, and 
analogously to the previous cases, the exo-(3-OR)-anti diastereoisomer (76) (Scheme 3.11), 
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deriving from the exo attack of the alkene on the opposite face of the C-3 substituent of the 
nitrone, was the major adduct. The second is the exo-(3-OR)-syn isomer (77) and third endo-
(3-OR)-anti isomer (78), whereas the endo-syn diastereoisomer (79) should be the less 
favoured.  
Reduction of the major diastereoisomers 76 (12:1 mixture with 78) and 77 with Zn in acetic 
acid/ H2O gave the 2-(bromophenethyl) pyrrolidines 81 and 82 as white solids in 82% and 84 
% yield, respectively (Scheme 3.12). 
 
 
Scheme 3.12 
2-Bromophenyl-tert-butoxypyrrolidines 81 and 82 were subjected to intramolecular amination 
reaction by using the Ullmann reaction condition as previously, and the protected 
benzo[e]indolizidines 83 and 84 were obtained as colourless oil in 71% and 68% yield 
respectively, after chromatography on silica gel (Scheme 3.13). 
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Scheme 3.13 
The structure and stereochemistry tricyclic protected benzo[e]indolizidines 83 and 84 was 
assigned by NMR analysis. In particular NOE experiments on benzo[e]indolizidine 83 shown 
interaction with both 4-H and 5-H protons, whereas NOE interactions was present between 3-
Ha with 3-H and 5-H protons in benzo[e]indolizidine 84 [Figure 3.10]. 
 
Figure 3.10 Diagnostic NOE interactions in 83 and 84. 
The synthesis of protected benzo[e]indolizidines 83and 84 was, then, complete in satisfactory 
good yield.  
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3.3 Biological activity 
The synthesized compound were tested on glycosidase inhibition activity and compared with 
(+)lentiginosine 1. The result are given in below [Table 5]. 
 
 
 
  
 (+) 1 
 
     64 
 
     68 
 
ent-68 
   α–glucosidase EC 
      3.2.1.20 yeast 
    0       0       0       29  
   β–glucosidase EC 
      3.2.1.21 Almonds 
    0       0       35       15  
   β–mannosidase  EC 
      3.2.1.25 Snail 
    0       17       20       0  
 
Table 5 Inhibition (in %) toward glycosidases at 1 mM concentration of benzo-lentiginosines. 
 
Benzo[e]lentiginosine 64 and 68 are completely inactive towards amyloglucosidase. 
Benzo[e]lentiginosine 64 shows some degree of activity only towards β-mannosidase, whereas 
68 show a limited activity towards β glycosidase and β-mannosidase. Interestingly the 
enantiomer of 68 shows the similar low activity, however towards α–glucosidase and β- 
glycosidase. The parent (+)-Lentiginosine is inactive towards all these glycosidases.  
The glycosidase inhibition activity was not good as expected. One possible explanation is the 
fact that the nitrogen atom is not as basic as in lentiginosine, because of the conjugation of the 
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nitrogen lone pair with the aromatic ring, and is less prone to protonation to form the 
intermediate 85 that mimics the transition state for glycoside bond hydrolysis [Figure 3.11]. 
 
 
Figure 3.11 
 
3.4 Conclusion 
1,3-DC of enantiopure 3,4-dialkoxy-pyrroline N-oxide with 2-bromostyrene, followed by 
reduction of the isoxazolidine N-O bond and copper-catalyzed intramolecular N- arylation 
provides a convenient method for the synthesis of highly functionalized benzo[e]indolizidines. 
The bromo-phenyl pyrrolidines undergo cyclization under Ullmann reaction conditions 
(copper catalyst, protic solvents) whereas Pd and Ni catalysts, which operate in apolar 
solvents, failed to give the same reaction. The required reaction conditions involving a high 
temperature (90 °C), stoichiometric copper, and a base are well tolerated by t-butyl ether 
groups whereas TBDMS ethers suffer a partial decomposition. Our optimized Ullmann 
reaction condition could be nicely applied to the nitrone derived from malic acid affording the 
corresponding benzo[e]indolizidines or hexahydropyrrolo[1,2-a]quinolines 83 and 84 with the 
same efficiency of tartaric acid derivatives. The method provides access to benzocondensed 
derivatives of iminosugars which demonstrated only low glycosidase inhibitor activity 
towards α-glycosidase, β- glycosidase and β-mannosidase. 
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Development of new synthetic methodology towards synthesis of substituted 
tetrahydroquinolines 
4.1 Introduction 
Heterocyclic ring systems are among the most important organic compounds and they have 
always had a significant role in organic synthesis, because of their being abundant in nature. 
Heterocyclic rings are present in compounds involved in many biological processes like 
vitamins, coenzymes, hormones, porphyrins, DNA, RNA.  
Heterocyclic compounds, especially aza-heterocycles, constitute the most important class of 
compounds in the pharmaceutical and agrochemical industries, with heterocycles comprising 
around 60% of all drug substances. Many commercial pharmaceuticals are also derived from 
aza-heterocyclic scaffolds as pyridines, indoles, quinolines, azepines, and pyrimidines. 
Therefore, as key building blocks in pharmaceutical research, heterocycles have continued to 
be important subjects in medicinal chemistry from the beginning. It is not surprising if this 
class of compounds has received special attention by chemists that always have shown interest 
in finding new synthetic methods to introduce enormous variety of structural features in order 
to increase the potential of these molecules. The transformation of heterocycles to other more 
complex molecules is nowadays an established process in organic synthesis.             
The quinoline heterocyclic scaffold in general and the tetrahydroquinoline ring system in 
particular, are very common structural motives and are found in numerous biologically active 
natural products and pharmacologically relevant therapeutic agents. Because of the 
significance of these scaffolds in drug discovery and medicinal chemistry, the development of 
new methodologies for the synthesis of tetrahydroquinolines derivatives continues to be a very 
active field of research.
122
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In the previous chapter, we described an optimized intramolecular amination reaction under 
Ullmann’s reaction conditions that give access to the tetrahydroquinoline core structure.123 
Accordingly, we considered to extend our work and develop a new general methodology 
towards the synthesis of substituted tetrahydroquinolines. The proposed approach is a three-
step sequence consisting of a nitrone 1,3-dipolar cycloaddition (1,3-DC), reduction of 
isoxazolidine ring, and ring closure by intramolecular copper mediated Ullmann reaction, 
which is the key step of our synthetic methodology (Scheme 4.1).  
 
 
Scheme 4.1 General approach towards tetrahydroquinolines.  
To determine the scope of this approach, we studied some examples starting from different 
acyclic nitrones. Either electron rich and electron poor acyclic nitrones were used in order to 
study the electronic effect on the 1,3-DC. Moreover, the effect of the presence of an 
ethoxycarbonyl group on the styrene double bond was considered. 
 
4.2 Result and discussion 
4.2.1 Synthesis of (2S*,4R*)-1-benzyl-2-phenyl-1,2,3,4-tetrahydroquinolin-4-ol (91) 
1,3-DC of phenyl benzyl nitrone 86
124
 and bromostyrene 50 in xylene at 150 °C for 6 h 
afforded a mixture of diastereomeric cycloadducts 87 and 88 in 3.1:1 ratios (Scheme 4.2). The 
two adducts were inseparable by column chromatography. 
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Scheme 4.2 
 
The relative configuration of cycloadducts 87 and 88 was assigned by NMR analyses. In 
particular, a NOE interaction was present between 5-H and 3-H, only in the cis-isomer 87 
[Figure 4.1]. 
 
Figure 4.1 Diagnostic NOE interactions in adducts 87 and 88 
 
Therefore, nitrone 86 and dipolarophile 50 interact preferentially through an exo transition 
state (TS) considering the reacting nitrone in its Z-configuration [Figure 4.2]. 
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Figure 4.2 
 
The mixture of isoxazolidine 87 and 88 (3.1:1 ratio) was reduced with Zn in acetic acid/H2O 
(1:1) to get amino alcohols 89 and 90 (ca. 2:1 ratio) in 92% overall yield (Scheme 4.3). Amino 
alcohols 89 and 90 could be only partially separated by column chromatography.  
 
 
Scheme 4.3 
 
NOE experiments on 89, which derived from adduct 87, showed the presence of a strong 
interaction between the following couple of hydrogens: 1-H/3-H (3.3%), 1-H/2-Ha (2.5%), 3-
H/2-Ha (2.7%) and 3-H/CH2Ph (3.2%) [Figure 4.3]. These data suggest that in CDCl3, amino 
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alcohol 89 is mainly in a cyclic conformation that is stabilized by an intramolecular hydrogen 
bond [Figure 4.3, structure II]. 
 
Figure 4.3 Diagnostic NOE interactions in major isomer 89 
 
The mixture of secondary amines 89 and 90 (ca 1:1 ratio) was subjected to intramolecular 
cyclization under Ullmann’s reaction condition and afforded a mixture of phenyl substituted 
quinolines 91a and 91b in ca 4:1 ratio. After chromatographic separation an enriched fraction 
of quinoline 91a (isomeric ratio 10:1) was obtained in 44% overall yield along with recovery 
of starting material 89 (30%) (Scheme 4.4). The relative configuration of the major quinoline 
could not be established by NMR analysis, but in analogy with the other studied examples (see 
below) it could be assigned as trans. Moreover, the partial conversion of amino alcohol 88 
(70%) was in accord with a lower reactivity of this isomer. Accordingly, the yield of the 
Ullmann reaction was 80% for 90 that afforded the trans-quinoline 91a, whereas amino 
alcohol 89 was converted into the less stable cis-quinoline 91b in 11% yield (70% 
conversion).  
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Scheme 4.4 
 
4.2.2 (2S*,4R*)- and (2S*,4S*)-2-(4-methoxyphenyl)-1-methyl-1,2,3,4-
tetrahydroquinolin-4-ol (97and 98) 
The nitrone N-(4-methoxybenzylidene) methanamine oxide (92) containing an electron 
donating group on the C-Ar group was synthesized following the literature procedure and then 
reacted with bromostyrene 50 overnight in toluene at 110 °C by standard heating (oil bath). 
Under these reaction conditions, the two diastereoisomeric adducts 93 and 94 were formed in 
1:1 ratio and quantitative overall yield (Scheme 4.5). The diastereoselectivity of the 
cycloaddition was lower compared to nitrone 86 (ds 50% vs 71%). The same reaction carried 
out at lower and higher temperature (90 °C and 150 °C) afforded the products in lower yield 
and different ratio. In particular, the formation of the cis-adduct 93 was slightly favored at 90 
°C whereas the trans-isomer 94 was favored at 150 °C (Scheme 4.5). 
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Scheme 4.5 
The differences in stereoselectivity are very low and suggest that the cis-adduct 92 could be 
the kinetically favored isomer whereas trans-adduct 93 was thermodynamically more stable 
isomer. Anyway, the lower recovery of the cis-adduct 92 at 150 °C could be also explained by 
a lower thermal stability of cis isomer, that could undergo decomposition more easily than its 
trans isomer 93. 
The stereochemistry of cycloadducts 93 and 94 was assigned by NMR analysis. In particular, 
a NOE interaction between protons 5-H and 3-H (0.8%) was present only in the cis-adduct 93 
[Figure 4.4]. 
 
Figure 4.4 Diagnostic NOE interactions in isomer 93 
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Cycloadducts 93 and 94 were separated by chromatography on silica gel and then reduced 
with Zn in acetic acid/H2O (9:1) at 85 °C for 3 h to afford 95 and 96 with 94% and 91% yields 
respectively (Scheme 4.6). 
 
 
Scheme 4.6 
Analogously to aminoalcohol 89, the NOESY-1D spectra of 95 recorded in CDCl3 show a 
significant NOE interaction between protons 1-H and 3-H (3.0%) in accord with the presence 
of a cyclic structure stabilized by an intramolecular H-bond [Figure 4.5]. 
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Figure 4.5 
 
Under the usual Ullmann reaction condition, amines 95 and 96 undergo intramolecular 
cyclization to give 97 and 98 in 38% and 71% yield, respectively (Scheme 4.7). 
 
 
 
Scheme 4.7 
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The relative configuration of stereogenic centers in 97 and 98 was confirmed by NMR 
analysis. In particular, a NOE interaction between protons 4-H and 2-H (0.8%) was present 
only in the cis-adduct 97. Moreover, the trans-relationship between 4-H and 2-H in 97 was 
indirectly validated by their NOE interactions with 3-H protons [Figure 4.6]. 
 
 
 
 
Figure 4.6 
The Ullmann reaction on 95 and 96 show that the relative configuration of substituents on C-1 
and C-3 largely affect the capability of cyclization of this type of substrate. In fact, 95 is 
stabilized in a chair conformation by hydrogen bonding. Compound 96 lacks this stabilization 
and likely requires lower activation energy to reach TS of the reaction. Moreover, the lower 
efficiency in the formation of the trans-disubstituted tetrahydroquinolines 97 in comparison 
with the cis-isomer 98 can be ascribed to its lower stability caused by the presence of one of 
the two substituents in a pseudo-axial orientation on the piperidine ring. As shown in [Figure 
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4.7], isomer 97 experiences a 1,3-diaxial interaction between 2-H and 4-OH that hampers its 
formation, whereas in 98 there is not such steric interaction because both the substituents can 
occupy pseudo-equatorial positions. The stereochemistry effect on the cyclization reaction is 
even more critical when a third substituent is present (see below).   
97 
98 
 
Figure 4.7 The three Dimensional structures of diastereomers 97 and 98 
 
4.2.3 Synthesis of (2S*,4R*)-2-(4-aminophenyl)-1-methyl-1,2,3,4-tetrahydroquinolin-4-ol 
(104) 
In this example, we studied the effect on the cycloaddition of an electron withdrawing group 
on the C-aryl group of the nitrone. The N-(4-nitrobenzylidene)methanamine oxide (99) was 
synthesized following the procedure reported in the literature.  
The reaction of nitrone 99 with bromostyrene 50 in chlorobenzene at 150 °C for 3 h gave the 
adducts 100 and 101 in 2.4:1 ratio, respectively. The two adducts were inseparable by column 
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chromatography. A pure sample of the major compound 100 was obtained after repeated 
purification and used for the characterization (Scheme 4.8).  
 
 
Scheme 4.8 
 
The stereochemistry of cycloadducts 100 and 101 was assigned by NMR analysis. In 
particular, a NOE interaction was present between hydrogens 5-H and 3-H (0.8%) in accord 
with a cis-relationship in cycloadduct 100 [Figure 4.8].  
 
 
Figure 4.8 
Accordingly, the stereoselectivity of the 1,3-DC of nitrone 99 with 50 was higher than nitrone 
92 and similar to nitrone 86.  
Treatment of the mixture of isoxazolidines 100 and 101 (2.4:1 ratio) with Zn in acetic 
acid/H2O (1:1) caused the reductive opening of the isoxazolidine ring and the concomitant 
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reduction of the nitro group affording amino alcohol 102 and 103 (2.2:1 ratio) in 62% yield. 
The Mixture of amino alcohol 102and 103 could be only partially separated by column 
chromatography (Scheme 4.9). 
 
Scheme 4.9 
 
Cyclization of mixture of amino alcohol 102 and 103 (1:1 ratio) under the usual Ullmann 
reaction conditions afforded the mixture of trans-cis disubstituted tetrahydroquinoline 104a 
and 104b (7:1 ratio) in 50% yield (Scheme 4.10). 
 
 
Scheme 4.10 
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4.2.4 Synthesis of (2S*,3R*,4R*)-ethyl 4-hydroxy-2-(4-methoxyphenyl)-1-methyl-1,2,3,4-
tetrahydroquinoline-3-carboxylate (110) 
The application of the method to the synthesis of more substituted tetrahydroquinoline 
derivatives was then studied. The trans-disubstituted alkene (E)-ethyl 3-(2-bromophenyl) 
acrylate (105) was synthesized following a literature procedure
125 
and then used as
 
dipolarophile in the cycloaddition with nitrone 92. The 1,3-DC was carried out without solvent 
at 90 
o
C for 48 h and afforded the two diastereomeric adducts 106 and 107 with complete 
regioselectivity. Cycloadducts 106 and 107 were obtained in 2.1:1 ratio and 82% overall yield 
and could be separated by column chromatography on silica gel (Scheme 4.11). 
 
Scheme 4.11  
The relative configuration of cycloadducts 106 and 107 was assigned by NMR analysis. In 
particular, a NOE interaction between hydrogen 5-H and 3-H (0.7%) was present only in the 
major isomer 106 attesting the cis-relationship between these two atoms [Figure 4.9]. A 
significant NOE interaction between 4-H and the 4-MeOC6H4 group (2.5%) of the same 
isomer 106 was also in accord with the reported structure.  
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Figure 4.9 
Therefore the 1,3-DC of 92 with 105 occurred preferentially through the exo(4-
MeOC6H4),endo(CO2Et)-TS [Figure 4.10]. 
 
Figure 4.10 
Reduction of separated cycloadducts 106 and 107 with Zn in acetic acid: H2O (9:1) afforded 
the corresponding amino alcohols 108 and 109 in 99% and 84% yield respectively (Scheme 
4.12).   
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Scheme 4.12  
Analogously to the previous cases, NOESY 1D spectrum of a CDCl3 solution of 108 is in 
accord with a cyclic conformation stabilized by an intramolecular H-bond [Figure 4.11]. 
 
Figure 4.11 
Under the usual reaction conditions, amino alcohol 108 underwent intramolecular cyclization 
affording the trisubstituted tetrahydroquinoline 110 in low yield (20%) (Scheme 4.13). 
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Scheme 4.13 
The stereochemistry of the final product 110 was confirmed by NMR analysis. In particular, 
the value of NOE interactions between 3-H and 2-H and 4-H were in accord, respectively, 
with a trans and a cis relationship [Figure 4.12]. 
 
 
Figure 4.12 
Under the usual condition, diastereoisomer 109 failed to give the corresponding 
tetrahydroquinoline derivative 111 but was converted into a complex mixture of 
decomposition products including 2-bromobenzaldehyde and (E)-ethyl 3-(4-
methoxyphenyl)acrylate. These side products likely formed through retro-aldol and retro-
Michael type reactions (Scheme 4.14). 
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Scheme 4.14 
As in the case of tetrahydroquinoline 97, the low yield of 110 can be rationalized by steric 
factors that hamper the ring closure. In the case of compound 111, the presence of three 
substituents on the same face of the ring system prevents completely the intramolecular 
cyclization favoring the fragmentation processes [Figure 4.13] 
 
Figure 4.13 The three Dimensional structures of diastereoisomer 111 
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4.2.5 Synthesis of (2R*, 3S*,4S*)-ethyl 4-hydroxy-1-methyl-2-phenyl-1,2,3,4-tetrahydro-
1,8-naphthyridine-3-carboxylate (117).  
Finally we studied the application of the reported 3-step sequence to the synthesis of a 
naphthyridine derivative. Naphthyridines are interesting molecules that can be used as ligands 
for biological and pharmacological applications.
125b
 Treatment of a mixture of nitrone 91 and 
(E)-ethyl 3-(2-chloropyridin-3-yl) acrylate (112)
125
 at 90 °C for 48 h under solvent free 
conditions afforded diastereomeric cycloadduct 113 and 114 in 7.7:1 ratio and 94% overall 
yield (Scheme 4.15). Analogously to the 1,3-DC of 92 with 105 [see Figure 4.10], the favored 
approach between 92 and 112 occurs through an exo(Ar)endo(CO2Et)-TS, but in this case the 
diastereoselectivity was higher (ds 89% vs 68%) and the major adduct, the trans-trans-
trisubstituted isoxazolidine 113, was obtained after chromatographic separation in 94% yield.  
 
 
Scheme 4.15 
The relative configuration of 113 and 114 was assigned by analysis of their NOESY-1D 
spectra. In particular, in both the isomers the hydrogen 5-H and 4-H are trans-oriented (NOE 
1.1%). Moreover, hydrogen 5-H has a NOE interaction with 3-H (0.7%) in 113 and with the 4-
OMe-C6H4 (0.6%) in 114 [Figure 4.14].  
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Figure 4.14 
The usual reduction conditions (Zn in acetic acid/H2O) could not be used to open the 
isoxazolidine ring in 113 because under these conditions the pyridine-chlorine bond was also 
cleaved (Scheme 4.16). An analogous result was obtained by hydrogenation in the presence of 
Pd/C and acetic acid in MeOH.   
We tried, then, to reduce the cycloadduct in milder reaction conditions. A chemoselective 
reduction of the N-O bond could be finally achieved following a methodology developed in 
the Chemistry Department by Prof. A. Brandi’s research group i.e. using Mo(CO)6
126 
as 
reducing agent in acetonitrile/water at the reflux temperature. Under this milder reaction 
conditions amino alcohol 116 was obtained in high yield (81%) (Scheme 4.16). 
 
 
Scheme 4.16 
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Analogously to the previous cases, NOESY 1D spectrum of a CDCl3 solution of 93 is in 
accord with a cyclic conformation stabilized by an intramolecular H-bond [Figure 4.15]. 
 
Figure 4.15 
Finally, 116 was cyclized under the usual Ullmann reaction conditions to get highly 
functionalized naphthyridine 117 in 33% yield (Scheme 4.17). The cyclization yield was only 
modest, but higher than the corresponding trisubstituted tetraidroquinoline 110 (see Scheme 
4.17). This last example prove that the three step approach can be applied also to prepare 
naphthyridine derivatives and that in this case the presence of the electron poor aromatic ring 
allow also the use of chlorine as leaving group in the copper catalyzed cyclization. 
 
Scheme 4.17 
The stereochemistry of the final product 117 was confirmed by NMR analysis. In particular, 
the value of NOE interactions between 3-H and 2-H and 4-H were in accord, respectively, 
with a trans and a cis relationship [Figure 4.16]. 
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Figure 4.16 
By using our three step reaction approach towards synthesis of tetrahydroquinoline, were 
synthezed the following molecules by using nitrones [Figure 4.17]. 
 
 
 
Figure 4.17 
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4.3 Conclusion 
The new synthetic methodology described demonstrated useful for the synthesis of complex 
heterocyclic compound for natural product synthesis or for biological application. Our three 
step reaction sequence is useful to contruct substituted tetrahydroquinolines which are used in 
material chemistry, natural chemistry and medicinal chemistry.We applied our developed 
methodology to acyclic C-Aryl nitrones that led to synthesis of highly functionalized 
tetrahydroquinolines and a naphtiridine. 
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Stereoselective synthesis of benzo[f]indolizidine and benzo[g]indolizidine 
 
5.1 Stereoselective synthesis of benzo[f]lentiginosine via Pd catalyzed intramolecular   
carbonylation of secondary amine. 
5.1.1Introduction                                                                                                                                                                                     
Heterocyclic compounds, especially aza-heterocycles, are ubiquitous in natural products, 
pharmaceuticals and represent the most important class of key structural units in large number 
of bioactive molecules. The amaryllidaceae alkaloids, such as Lycorane and crinane, The 
Protoberberines alkaloids are the large group of naturally occurring alkaloids contains same 
basic core structure like benzo[f]indolizidine 120 [Figure 5.1].
128
   
 
 
Figure 5.1 
 
Indolizidine alkaloids, lentiginosine and its stereoisomers are widespread in plants and 
microorganisms. Their intriguing structure combined with their potent ability to inhibit 
glycosidase as well as anticancer activity, anti-HIV and immunoregulatory activity. Aim of 
our thesis is to synthesis the modified derivative of lentiginosine to improved biological 
activity of lentiginosine. In chapter 3, it was discussed synthesis of benzo[e]indolizidines 64 
and 68, and their biological activity.  Benzo[e]indolizidine 64, 68 are not more biologically 
active, likely because nitrogen atom is in conjugation with aromatic ring and lone pair of 
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nitrogen is not available for protonation to form the tetrahedral mimic of transition state 
enzyme hydrolysis. We decided, then to synthesize benzo[f]indolizidine 120 to check 
biological activity as well as hypothesis based on computational docking studies with 
amyloglucosidase [Figure 5.2]. 
 
Figure 5.2 
Our approach towards the enantiomer of benzo[f]lentiginosines 120 starts from the 
enantiopure pyrrolidine-N-oxides 28 derived from L- and D-tartaric acid. Benzo[f]lentiginosine 
120 was obtained by alkylation of pyrrolidine N-oxides 28 with a suitable Grignard reagent 
followed by hydroxylamine reduction, ring-forming carbonylation, amide reduction and OH-
deprotection (Scheme 5.1). 
 
Scheme 5.1 
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5.1.2 Result and discussion 
5.1.2.1 Synthesis of benzo[f]lentiginosine from 3,4-bis-tert-butoxypyrroline N-oxide (28) 
via carbonylation of secondary amine. 
Alkylation of pyrrolidine-N-oxides 28 which is derived from D-tartaric acid was carried out 
with benzylmagnesium chloride 122 at 0 °C in THF to afford mixture of hydroxylamines 123 
and 124 in 10:1 ratio, respectively, not separable by column chromatography (Scheme 5.2). 
 
Scheme 5.2 
Subsequent reduction of the mixture of hydroxylamines 123 and 124 with Zn in acetic 
acid/water (1:1) at room temperature for 2 h gave pyrrolidines 125 and 126 with 93% yield. 
Pyrrolidine 125 and 126 were partially separated by column chromatography (Scheme 5.3). 
 
 
Scheme 5.3 
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Several reports can be found in the literature for the next goal: the cyclization of a secondary 
amine with aromatic ring with one carbon insertion (Scheme 5.4). In literature reports, 
paraformaldehyde was used as the source of carbon homologation, in a Pictet-Spengler type 
cyclization. All reactions were carried out in different reaction conditions in order to obtain 
cyclized product. Some model reaction are given below (Scheme 5.4).
129, 130
 
 
Scheme 5.4 
 
We applied same the reaction condition with our substrate, but unfortunately we were not able 
to obtain our desired product (Scheme 5.5, Table 1). 
 
 
Scheme 5.5 
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Table 1 
No             Catalyst Temp (T 
o
C) Time (Hours) Product 
1 HCHO, HCOOH 90 7 - 
2 HCHO, Sc(OTf)3, CH3CN:H2O  rt 24 ND 
3 HCHO, CF3COOH, Dry DCM rt 24 ND 
 
One likely reason for the failure in the obtainment of 127 is the nature of the aromatic ring. In 
fact the aromatic ring in 125 is not activated towards an electrophilic intramolecular 
cyclization of the intermediate methyleniminium cation. The activation of aromatic ring needs 
some activating group, for ex. OR groups, like the examples of Scheme 5.4. As we wanted the 
unsubstituted aromatic ring, we had to find another possible way to close the ring.  
In the literature were found some reports on carbonylative cyclization of amines.
131 
Carbonylation of primary amines has been done by many groups, but the carbonylation of 
secondary amines is reported in very few reports, especially for cyclic amines.
132
 The 
carbonylation of amines by Pd(OAc)2 catalysis under CO atmosphere was studied by Orito et 
al.
132
 We then applied the condition reported for carbonylation of 125. The catalyzed 
carbonylation was carried out under CO/O2 atmosphere in the presence of Pd(II) catalyst in 
combination with a Cu(II) salt and gave as product the amine carbonylation product followed 
by cyclization on the aromatic ring (Scheme 5.6, Table 2). 
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Scheme 5.6 
Table 2 
 M Source (Mol eq) Base 
(eq) 
Solvent T (
o
C) t (h) Yield 
(%) 
1 PdCl2 (0.05) /CuSO4(1.5)  Dioxane:H2O  100 4 0 
2 PdCl2 (0.1) /Cu(OAc)2 (3)  Toluene 110 6 0 
3 PdCl2 (0.1) / CuCl2 (3)  Toluene 110 5 0 
4 Pd(OAc)2(0.1)/Cu(TFA)2(1),  Dioxane 100  0 
5 Pd(OAc)2(0.2) /Cu(OAc)2(3), t-BuOK 
(2.5) 
DMF 140 6 0 
6 Pd(MeCN)2Cl2(0.3)/Cu(OAc)2(3), t-BuOK 
(2.5) 
Toluene 110 6 21 
7 Pd(MeCN)2Cl2(0.2)/Cu(OAc)2(3), t-BuOK 
      (2) 
Dioxane 110 15 52 
8 Pd(OAc)2(0.05) /Cu(OAc)2(0.5),  Toluene 110 4 43 
9 Pd(OAc)2(0.1) /Cu(OAc)2(3), DBU (2) Toluene 110 4 31 
10 Pd(OAc)2(0.2) /Cu(OAc)2(3), t-BuOK 
(2.5) 
Dioxane 110 7 56 
11 Pd(OAc)2(0.5) /Cu(OAc)2(4), t-BuOK 
(3) 
Dioxane 110 24 72 
 
Table 2 Intramolecular Pd catalyzed carbonylation reaction of secondary amine. 
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The carbonylation reaction was carried out by using PdCl2 in combination with CuSO4, 
Cu(OAc)2 and CuCl2, but the catalyst was not even partially soluble in reaction solvent, and 
decomposition of catalyst occurred[Table 2, entries 1-3];  The starting material was just 
recovered.  Increasing the catalyst loading didn’t cause any change in the reaction. The use of 
Pd(OAc)2with Cu(TFA)2 [Table 2, entry 4], gave the same solubility problems and 
decomposition of the catalyst.  We tried to make some more variation with Pd catalyst in 
combination with Cu(OAc)2, because Cu(OAc)2  showed better solubility than other Cu salts. 
Different Pd catalyst were used [Table 2, entry 2, 6 and 8] with varied molar amounts, but 
Pd(OAc)2 /Cu(OAc)2 [Table 2, entry 8]  gave the most satisfactory results than other 
combination of Pd catalyst with Cu(OAc)2. Knowing the best combination of catalyst for this 
reaction, then variations were made of the solvent, temperature and reaction time. All this 
reactions needed high temperature, so an high boiling solvent with good solubility of the 
catalyst is necessary. We carried out one trial in DMF at 140 °C with Pd(OAc)2/Cu(OAc)2  
[Table 2, entry 5] , but here decomposition of catalyst and starting material occurs. It was 
necessary to reduced the temperature of the reaction, some trials were carried out in toluene as 
well as in 1,4-dioxane at 110 °C: dioxane gave better result than toluene. The Pd(OAc)2  (0.5 
equiv) Cu(OAc)2 (4 equiv) in dioxane is the best combination of catalyst found, showing a 
better solubility than other cases, albeit the amount of Pd catalyst is excessive [Table 2, entry 
11]. In this sense the conditions in entry 10 appear the best compromise. The molar amount of 
Cu(OAc)2 is high, almost ten times that of Pd, because for the reaction is required a Pd (II) 
catalyst, and Cu(OAc)2 oxidizes Pd (0) back to Pd (II) [see below the mechanism, Figure 5.4].  
Applying the best reaction condition for carbonylation, the product 128 was recovered along 
with the side product 129 (scheme 5.7). When the reaction was carried out without base, the 
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side product 129 increased at the expense of 128. Since in the reaction using Pd(OAc)2 [see 
below the mechanism, Figure 5.4] is formed acetic acid, it reacts with the pyrrolidine 125 to 
produce amide 129, which, then, cannot undergo catalyzed cyclization on the aromatic ring. 
 
 
Scheme 5.7 
A base is then necessary to avoid the formation of side product 129. However, some acidic 
condition are necessary for the reaction to occur, then the base is added in a lower molar 
amount than Cu(OAc)2. The best reaction conditions for carbonylation of secondary amine, 
then, are those in entry 10 and 11[Table 2]. The use of a lower amount of Pd (0.2 equiv) 
afforded 56% yield of 128 in 7 h. Higher amount of catalyst (0.5 equiv) of course afforded an 
higher yield (72%), but this yield was also obtained in much longer reaction time.  
Assignment of structure to compound 128 was confirmed by NMR spectroscopy [Figure 5.3] 
 
Figure 5.3 
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Due to presence of carbonyl group on six member ring connected with the five membered 
ring, the structure of 128 is rigid and there is very little conformational freedom. In 
1
H NMR 
spectra, 6-H aromatic proton resonated at  8.01 (dd, J = 7.6, 1.4 Hz), more deshielded than 
other aromatic protons, because of the presence of the vicinal amide group, this is a 
confirmation of with the ring closure and bond formation between carbonyl group and 
aromatic ring. Effect of carbonyl group also deshielded 3-H protons at  3.60 and  3.44, 
compared to lentiginosine ( 2.76 and  2.22).  
Possible mechanism of Pd catalyzed carbonylation reaction is given below [Figure 5.4]. 
 
 
Figure 5.4 
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Pd (II), first coordinate with nitrogen to formed complex A by reduction of Pd (II) into Pd (I). 
Then elimination of acetic acid to get the complex B. Pd (I) convert into Pd (0) by coordinate 
with phenyl ring in order to get complex C. Incorporation of CO to formed  to formed 
complex D. Subsequent elimination of product 128 with Pd (0), continue cycle by oxidation of 
Pd (0) into Pd (II) with Cu (OAc) 2.  
The deprotection of 128 with TFA at 0 °C– rt for 2 h, afforded benzo[f]derivative of 
lentiginosine 121 as a white solid with 97 % yield (Scheme 5.8). 
 
 
Scheme 5.8 
Protected amide 128 was reduced with LAH in THF at 0 °C- rt overnight and afforded 127 in 
80% yield (Scheme 5.9). 
 
 
Scheme 5.9 
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Final deprotection of 127 with TFA at 0 °C to rt overnight gave benzo[f]lentiginosine 120 as a 
white solid in 90% yield (Scheme 5.10). 
 
 
Scheme 5.10 
The same reaction sequence was followed to synthesize ent-120 and ent-121. 
5.1.2.2 Synthesis of benzo[f]indolizidine from Nitrone (74) which derived from Malic 
acid 
The synthesis of benzo[f]indolizidine was extended by the use of another enantiomerically 
pure pyrrolidine N-oxide 74, derived from L-Malic acid. Alkylation of pyrrolidine N-oxide 74 
was carried out with benzylmagnesium chloride 122 at 0 °C in THF to obtain the single 
isomer 130 with 100% yield. This reaction was more selective than reaction with pyrrolidine-
N-oxides 28.  Reduction of hydroxylamine 130with Zn in acetic acid/water (1:1) at room 
temperature for 2 h afforded pyrrolidine 131 with 85% yield (Scheme 5.11).  
 
____________________________________________________________________Chapter 5 
 
119 
 
 
Scheme 5.11 
The stereochemistry of 131 was assigned by NMR analyses. In particular, a strong NOE 
interaction was present between 3-H and 4b-H, which could be assigned without doubt 
because of the proximity of tert-BuO group. Lower the NOE interaction, as expected, were 
present between 3-H and 2-H, and 4a-H [Figure 5.5]. 
 
Figure 5.5 
 
Applying the best conditions for carbonylation of secondary amine by using Pd/Cu metal 
catalysis, the carbonylation reaction was carried out on pyrrolidine 131 to obtain 132 in 45 % 
yield (Scheme 5.12). 
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Scheme 5.12 
Final deprotection of amide 132 was carried with TFA at 0 °C to rt for 1 h to obtain the 
benzo[f]indolizidine 133 in 79 % yield derived from malic acid. (Scheme 5.13) 
 
 
Scheme 5.13 
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5.2 Stereoselective synthesis of benzo[g]lentiginosine via coupling of Arynes with 
Pyrroline-N-oxides 
 
5.2.1 Introduction  
Arynes, in the past were once mainly the subject of structural curiosity. Within 14 years of the 
seminal experiments of J. D. Roberts leading to the first proposal of the structure of benzyne 
[Figure 5.4], synthetic organic chemists recognized the potential to exploit this highly reactive 
intermediate (and its substituted variants) in the total synthesis of natural products. More 
specifically, it was recognized that arynes offered the strategic advantage of rapidly 
functionalizing an aromatic ring by forming multiple carbon-carbon or carbon-heteroatom 
bonds in a single operation, often in a regioselective manner. Initially, the scope of synthetic 
applications was somewhat limited by the harsh conditions required to produce the aryne 
species. Many of these methods required strong bases, such as n-BuLi, or high temperatures. 
However, with the development of milder methods for the generation of arynes came 
increased interest in employing them in the synthesis of more complex polycyclic systems 
[Figure 5.6].
133,134
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Figure 5.6 Methods for generation of benzyne  
Most recently, the use of o-silyl aryl triflates as aryne precursors has allowed generation of the 
reactive intermediate under almost neutral conditions.
135
 The great advantage of generating a 
benzyne by the Kobayashi route is the ability to control the rate of benzyne generation by 
varying the concentration of the fluoride ion in solution. Thus, one can instantly generate a 
benzyne in THF using tetrabutylammonium fluoride (TBAF), which is quite soluble in THF. It 
is possible to slow down the rate of benzyne generation by employing CsF in MeCN (at room 
and elevated temperatures) or CsF in THF (at elevated temperatures). To further slow down 
the formation of the benzyne, CsF in toluene – MeCN mixtures can be used. The nature and 
amount of the added fluoride source, the solvent, and the temperature of the reaction can have 
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a profound effect on the overall rate and success of such aryne reactions. Arynes undergo 
numerous organic reactions [Figure 5.7].
133, 134 
 
 
Figure 5.7 Representative reactions of benzyne. 
 
The possibility of arynes to undergo 1,3-dipolar cycloaddition reactions deserve special 
mention owing to their ability to produce pharmaceutically important nitrogen containing 
heterocycles. Several dipoles have been systematically studied for their reactivity with arynes, 
leading to interesting heterocycles. However, only a few nitrones, mostly achiral ones, have 
been investigated as dipole partners for arynes.
136-138
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We choosed to employ aryne strategy for our synthesis of benzo[g]lentiginosine via coupling 
with nitrone. Nitrones have long been used as building blocks in organic synthesis. Having 
explored tartaric acid derived cyclic nitrones for highly diastereoselective 1,3-dipolar 
cycloaddition reactions, we envisioned that the reaction of these nitrones with benzyne would 
lead to benzoisoxazolines 135, which upon cleavage of N–O bond would afford o-
hydroxyaryl-substituted pyrrolidines 143. Pyrrolidines, by treatment with chloroacetyl 
chloride and subsequent ring closure mediated by Lewis acid could form the tricyclic core 
structure 145, which by reduction and deprotection could afford the target 
benzo[g]lentiginosine 148 (Scheme 5.14). 
 
 
 
 
Scheme 5.14 
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5.2.2 Result and Discussion 
5.2.2.1 Synthesis of isoxazolidine ring via cycloaddition of nitrone with aryne  
The 1,3-dipolar cycloaddition of 3,4-bis-tert-butoxypyrroline N-oxide (28) with 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate (134) afforded two diastereisomers 135 and 
136 in 1.3:1 ratio (Scheme 5.15).  
 
 
Scheme 5.15 Cycloaddition of nitrone 28 with benzyne 
 
Table 1 
No Aryne 
equiv 
Fluoride 
source 
(equiv) 
 
Condition Time Yield (%) 
1 1.6 CsF (6) Dry THF, rt 5 days 58 
2 2.4 CsF (6) Dry THF, 60 °C 2 days 56 
3 3 CsF (6) Dry THF, rt 6 days 71 
4 3 CsF (6) Dry MeCN, rt 1 day 16 
5 1.5 CsF (6) MeCN:Toluene 
(1:1), 55 °C 
3 days 36 
6 1.5 Bu4NF (4) Dry DMF, rt 5 h 68 
7 1.5 Bu4NF (4) Dry DMF , rt 2.5 h 59 
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The reactions were conducted in the same conditions used in precedent literature reports.
138
 In 
all trials however, were obtained lower yields than literature reports on similar cyclic nitrones,
 
138
 because of the formation of a side product in the reaction with a yield ranging from 40% to 
90%. The best condition resulted in carrying out the reaction in dry THF (entry 3, Table 1), 
where the reaction is slower and requires 3 equiv of the aryne,  or in dry DMF, with Bu4NF as 
the fluoride source, only 1,5 equiv of the aryne, 5 h and 2.5 h reaction time at rt (entry 6 and 7,  
Table 1). Going through complete analysis of the side product of the cycloaddition reaction, it 
was assigned to it the structure 139.   
The compound, indeed, contains a phenol substituted pyrrole ring, a substructure that recalls 
the occurrence of a cycloaddition process, but the pyrrolidine ring, besides aromatization, has 
lost a t-BuO substituent, and, moreover, has undergone a N-phenyl substitution. All these hints 
suggested that the side product 139 could derive from a decomposition of the primary 
cycloadduct 135. 
 A plausible mechanism is given below (Scheme 5.16). 
 
 
Scheme 5.16 Plausible mechanisms for conversion of cycloadduct 135 into side product 139 
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In the proposed mechanism, one of protected hydroxy group might undergo deprotection due 
to acidic conditions of the reaction. Subsequent elimination of water molecule affords a 
pyrroline ring 137 which opens to 138. This process must be driven by the consequent 
possible aromatization of the pyrroline ring.  Finally the intermediate pyrroline 138 can react 
with aryne to form the N-phenyl pyrrole 139. This process is probably favored by the presence 
of the two bulky t-BuO groups on the cycloadduct. Work is in progress to understand if with 
only one t-BuO group (nitrone derived from malic acid) this side reactivity could be 
suppressed, or to understand the role of protecting groups.  
In order to check role of protecting group, one more trial was carried out by using benzoyl 
protected nitrone. The 1,3-DC of (bis)benzoylated nitrone 140 with 2-(trimethylsilyl) phenyl 
trifluoro-methanesulfonate (134) afforded two diastereisomers 141 and 142 in 90% yield 
without obtaining side product (Scheme 5.17). 
 
 
Scheme 5.17 
The protecting group play more crucial role in 1,3-DC of nitrone with benzyne. We are 
successfully able to suppress the formation of side product which occurs in 1,3-DC reaction 
nitrone 28 with benzyne. The replacement of protecting group from tert-butyl to benzoyl 
afforded good yield of product in short reaction time.  
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5.2.2.2 Reductive cleavage of isoxazolidine ring 
Cycloadduct 135 was reduced with Zn in acetic acid/water (1:1) at 70 
o
C for 2 h to obtain o-
hydroxyaryl pyrrolidines 143 with 75% yield (Scheme 5.18). 
 
 
Scheme 5.18 Reduction of Isoxazolidine ring 
 
Further synthesis of benzo[g]lentiginosine is in progress (Scheme 5.18).  
 
 
 
Scheme 5.18 
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5.3 Conclusion 
In this chapter, it was discussed the synthesis of benzo[f]lentiginosine, by using Pd/Cu metal 
catalyzed carbonylation reaction of a secondary amine. The best reaction conditions for 
carbonylation of a cyclic secondary amine, a not trivial goal, and its further cyclization on an 
unactivated aromatic ring were indentified . The new methodology could be nicely developed 
for carbonylation of other secondary amines. By using this approach, were synthesized 
tricyclic structures which are the core structure of many natural products. In preliminary 
biological test, benzo[f]lentiginosine 120 and and lactam 121show only limited proapoptotic 
activity against different strain of cancer cells. Their glycosidase activity is still under 
scrutiny. 
By using aryne chemistry approach, we envisioned an entry to the benzo[g]indolizidine ring 
system, on the way to benzo[g]lentiginosine, that is still in progress in our laboratorie
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Experimental section 
General Remarks: All the reactions requiring anhydrous conditions were carried out under 
nitrogen, and the solvents were appropriately dried before use. Chromatographic purifications 
were performed on silica gel 60 (0.040–0.063 mm, 230–400 mesh ASTM, Merk) using flash-
column technique; Rf values refer to TLC on 0.25 mm silica gel plates (Merck F254, 
Macherey-Nagel precoated sheets) with the same eluant indicated for column chromatography 
unless otherwise stated. Melting points (m.p.) were determined on a RCH Kofler apparatus. 
Polarimetric measurements were performed on a JASCO DIP-370 polarimeter. NMR spectra 
were recorded on Varian Gemini (
1
H, 200 MHz), Varian Mercury (
1
H, 200 MHz), Varian 
Mercuryplus (
1
H, 400 MHz) instruments using CDCl3 as solvent and were referenced 
internally to solvent reference frequencies. Assignments were made on the basis of 
1
H–1H 
COSY, HMQC, HSQC and HMBC experiments. IR spectra were recorded with a Perkin-
Elmer Spectrum BX FT-IR System spectrophotometer on CDCl3 solutions. Mass spectra were 
recorded on a QP5050 Shimadzu spectrometer with a GC or direct inlet (70-eV ionizing 
voltage); relative percentages are shown in parentheses. Elemental analyses were performed 
with a Perkin-Elmer 2400 analyzer. Microwave-assisted reactions were carried out in a CEM 
Discover™ single mode microwave reactor with IR temperature sensor.  
The two series of enantiomeric compounds were synthesized starting from respectively (2R, 
3R)-(+)-tartaric acid (e.e. ≥99.5%) and (2S, 3S)-(-)-tartaric acid (e.e.99%) purchased from 
Sigma-Aldrich. 
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(3S,4S)-1-Benzyl-3,4-dihydroxypyrrolidine-2,5-dione (35) 
 
Benzylamine (18.21 mL, 0.167 mol) was slowly added to a suspension of (3S,4S)-(–)-tartaric 
acid (25.02 g, 0.167 mol) in 50% aqueous methanol (34 mL). The viscous mixture was 
concentrated under reduced pressure. Xylene (445 mL) was added to the obtained white solid 
and the reaction mixture was refluxed in a Dean-Stark apparatus set in an oil bath at 150 °C 
for 8 h. During that period, additional xylene (4x50 mL) was added. The resulting mixture was 
cooled, filtered under vacuum and the solid washed with petroleum ether. The crude imide 35 
was obtained in 81% yield (29.97 g, 0.135 mol) as a white solid and was used in the next step 
without further purification. The NMR properties of 35 are identical to those reported in the 
literature.  
(3R,4R)-1-Benzyl-3,4-dihydroxypyrrolidine-2,5-dione (ent-35) 
 
Following the same procedure as for 35, the enantiomeric ent-35 was prepared starting from 
(3R,4R)-(+)-tartaric acid. The NMR properties of ent-35 are identical to those reported in the 
literature.
 97 
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(3S,4S)-1-Benzyl-3,4-di-tert-butoxy-2,5-pyrrolidinedione (36) and (3S,4S)-1-benzyl-3-tert-
butoxy-4-hydroxy-2,5-pyrrolidinedione (37).  
 
HClO4 (60%, 49.2 µL, 0.4 mmol) was added to a suspension of imide 35 (1 g, 4.5 mmol) in 
tert-butyl acetate (45 mL, 0.1 M) at 0 °C and the reaction mixture was stirred at rt for 18 h. 
The obtained clear solution was basified to pH 9 by slow addition of a saturated aqueous 
solution of Na2CO3 (20 mL) and solid Na2CO3 at 0 °C. The two layers were separated and the 
two phases treated as follow. The tert-butyl acetate solution was washed with brine, dried over 
Na2SO4, filtered and partially distilled under reduced pressure at room temperature for 
recovering the majority of the solvent (ca 60-65%) that could be recycled or used for other 
protection reaction. The Na2SO4 used to dry the solution was thoroughly washed with CH2Cl2 
and the obtained solution combined with the distillation residue. The aqueous solution was 
extracted with CH2Cl2 (3x20 mL) and the combined organic layers were washed with brine 
(30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. Purification by 
chromatography on silica gel (eluent: CH2Cl2/ MeOH first 99.5: 0.5, then 99:1 and 98:2) of all 
the combined residues afforded 36 (1 g, 68%) as a yellow solid and 37 (0.29 g, 23%) as a 
white solid.  
36: Rf = 0.7 (CH2Cl2 / MeOH 99:1 ); mp 56.2–59 °C; []D
24
= –155.1 (c = 0.665, CHCl3); 
1
H 
NMR (CDCl3, 400 MHz):  = 7.40–7.35 (m, 2H, HPh), 7.33–7.24 (m, 3H, HPh), 4.64 (A part of 
an AB system, J = 14.0 Hz, 1H, CHHN), 4.60 (B part of an AB system, J = 14.0 Hz, 1H, 
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CHHN), 4.36 (s, 2H, 3-H + 4-H), 1.30 (s, 18H, CH3 x 6) ppm; 
13
C NMR (CDCl3, 50 MHz):  
= 173.3 (s; 2C, C-2 + C-5), 135.4 (s; CPh), 129.0 (d; 2C, CHPh), 128.6 (d; 2C, CHPh), 127.9 
(d; CHPh), 76.4 (s; 2C, CMe3), 75.0 (d; 2C, C-3 + C-4), 42.3 (t; CH2), 28.5 (q; 6C, CH3) ppm; 
IR (CDCl3): v
 
= 2980, 1718, 1393, 1371, 1118, 1080, 1025 cm
-1
; MS (EI): m/z (%) = 333 (M
+
, 
0.5), 277 (7), 221 (28), 192 (11), 164 (5), 91 (36), 57 (100), 41 (33); C19H27NO4 (333.4): 
calcd.: C, 68.44; H, 8.16; N, 4.20; found C, 68.57; H, 8.02; N, 4.17. 
37: Rf = 0.36 (CH2Cl2 / MeOH 98:2 ); mp 103.8–105.4 °C; []D
23
= –132.4 (c = 0.70, CHCl3); 
1
H NMR (CDCl3, 400 MHz):  = 7.40-7.27 (m, 5H, HPh), 4.05 (s, 2H, CH2), 4.45 (br A part of 
an AB system, J = 5.3 Hz, 1H, 4-H), 4.41 (B part of an AB system, J = 5.3 Hz, 1H, 3-H), 3.17 
(br s, OH), 1.32 (s, 9H, CH3 x 3) ppm; 
13
C-NMR (CDCl3, 100 MHz):  = 174.6 (s; C=O), 
173.1 (s; C=O), 135.0 (s; CPh), 129.0 (d; 2C, CHPh), 128.7 (d; 2C, CHPh), 128.2 (d; CHPh), 76.5 
(s; 2C, CMe3), 75.1 (d; CHO), 75.0 (d; CHO), 42.7 (t; CH2), 28.2 (q; 3C, CH3) ppm; IR 
(CDCl3): v = 3577, 2981, 1720, 1394, 1371, 1104, 1078 cm
-1
; MS (EI): m/z (%) = 277 (M
+
, 1), 
262 (6), 221 (32), 192 (8), 164 (5), 91 (55), 71 (34), 57 (100), 41 (33); C15H19NO4 (277.3): 
calcd.: C, 64.97; H, 6.91; N, 5.05; found C, 64.97; H, 7.22; N, 4.97. 
(3R,4R)-1-N-Benzyl-3,4-dihydroxypyrrolidine-1-borane (38) 
 
A solution of iodine (21 g, 83 mmol) in THF (100 mL) was added dropwise to a vigorously 
stirred ice bath cooled suspension of NaBH4 (6.24 g, 165 mmol) and 35 (7.25 g, 33 mmol) in 
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THF (153 mL) during 2 hours under nitrogen. The reaction mixture was refluxed for 6 hours 
and then the excess of borane was carefully destroyed with MeOH until no further 
effervescence was observed (35 mL). The obtained clear solution was concentrated under 
reduced pressure and the resulting white mixture was dissolved in MeOH and concentrated 
under reduced pressure three times (3x90 mL). Finally, to eliminate the last traces of MeOH, 
the product was sequentially treated and concentrated under reduced pressure first with EtOAc 
(30 mL) and then with iPr2O (30 mL). Deionized H2O (70 mL) was added to the obtained 
white residue and the mixture was first washed with petroleum ether (5x20 mL) and then 
extracted with EtOAc (8x20 mL). The combined EtOAc phases were dried over Na2SO4, 
filtered and concentrated under reduced pressure to give 38 as a white solid that was used in 
the next step without further purification. A sample purified by chromatography on silica gel 
(eluent: petroleum ether / EtOAc 2:3) afforded analytically pure 38. 
 
38: Rf = 0.36; m. p. 98 – 99 °C; []D
25 –  21.2 (c = 0.525, CHCl3); 
1
H NMR (400 MHz):  
= 7.43–7.35 (m, 5H, Ph), 4.67 (dt, J = 1.7; 6.5 Hz, 1H, 3-H), 4.09 (A part of an AB system, J 
= 13.2 Hz, 1H, CHHPh), 4.05 (B part of an AB system, J = 13.2 Hz, 1H, CHHPh), 4.02 (br d, 
J = 7.1 Hz, 1H, 4-H), 3.54 (ddd, J = 11.5; 6.6; 1.2 Hz, 1H, 2-Ha), 3.33 (dd, J = 12.0, 7.1 Hz, 
1H, 5-Ha), 3.14 (br d, J = 12.0 Hz, 1H, 5-Hb), 2.85 (dd, J = 11.5, 6.3 Hz, 1H, 2-Hb) ppm; 
13
C-
Ph), 130.7 (s; Ph), 129.3 (d; Ph), 128.4 (d; 2C, Ph), 78.8 
(d; C-4), 78.5 (d; C-3), 67.2 (t; CH2Ph), 64.5 (t; C-5), 63.8 (t; C-2) ppm; 
11
B NMR (64 MHz)  
= -8.71 ppm; IR (CDCl3): v = 3610, 3390 (br), 2955, 2381 (B-H st), 1455 (B-N st), 1169, 
1107, 1052 cm
-1
; anal. calcd. or C11H18BNO2 (207.1): C 63.80, H 8.76, N 6.76; found: C 
63.70, H 9.08, N 6.73. 
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 (3R,4R)-1-Benzylpyrrolidine-3,4-diol (39) 
N
OHHO
Bn
39  
A 3 M HCl aqueous solution (26 mL) was added to an ice bath cooled suspension of the crude 
pyrrolidine-borane adduct 38 (6.80 g) in diethyl ether (30 mL). The suspension was stirred at 
room temperature until no further effervescence and no solid at the interphase were observed. 
Then the two layers were separated and the aqueous solution was washed with EtOAc (3x10 
mL), treated with a 3 M NaOH aqueous solution (75 mL) at 0 °C, and then extracted with 
EtOAc (6x30 mL). The combined organic phases were dried over Na2SO4. After filtration and 
concentration under reduced pressure, crude pyrrolidine 39 was obtained as a white solid that 
was directly esterified. 
(3S, 4S)-1-Benzylpyrrolidine-3,4-diol (ent-39) 
Following the same procedure as for 39, pyrrolidine ent-39 was prepared starting from the 
pyrrolidine-borane adduct ent-38. 
 (3R,4R)-1-Benzyl-3,4-di-tert-butoxypyrrolidine (40) and (3R,4R)-1-benzyl-4-tert-butoxy-
3-pyrrolidinol (42).  
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HClO4 (60%, 2.4 mL, 21.5 mmol) was added to a mixture of pyrrolidine 39 (2.8 g, 14.3 
mmol) in tert-butyl acetate (145 mL, 0.1 M) at 0 °C. The reaction mixture was stirred at rt for 
5.5 h, cooled at 0 °C and then basified to pH 9 by slow addition of a saturated aqueous 
solution of Na2CO3 (20 mL) and solid Na2CO3. The two layers were separated and the two 
phases treated as follow. The tert-butyl acetate solution was washed with brine, dried over 
Na2SO4, filtered and partially distilled under reduced pressure at room temperature for 
recovering the majority of the solvent (ca 60-65%) that could be recycled or used for other 
protection reaction. The Na2SO4 used to dry the solution was thoroughly washed with CH2Cl2 
and the obtained solution combined with the distillation residue. The aqueous solution was 
extracted with CH2Cl2 (3x20 mL) and the combined organic layers were washed with brine 
(30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
material was purified by chromatography on silica gel (eluent CH2Cl2/MeOH first 99: 1, 
followed by 97: 3 and CH2Cl2/MeOH 95:5) giving 40 (3.4 g, 78%) as a yellow waxy solid and 
42 (0.51 g, 14%) as a white solid.  
40: Rf = 0.33 (CH2Cl2/MeOH 97:3); []D
23
= – 88 (c = 0.4, CHCl3); 
1
H NMR (CDCl3, 400 
MHz):  = 7.34-7.20 (m, 5H, HPh), 3.97-3.92 (m, 2H, 3-H + 4-H), 3.63 (A part of an AB 
system, J = 13.1 Hz, 1H, CHHPh), 3.49 (B part of an AB system, J = 13.1 Hz, 1H, CHHPh), 
2.78 (pseudo dd, J = 9.4, 6.4 Hz, 2H, 2-Ha + 5-Ha), 2.39 (pseudo dd, J = 9.4, 5.1 Hz, 2H, 2-Hb 
+ 5-Hb), 1.16 (s, 18H, CH3 x 6) ppm; 
13
C NMR (CDCl3, 100 MHz):  = 138.3 (s; CPh), 128.9 
(d; 2C, CHPh), 128.1 (d; 2C, CHPh), 126.9 (d; CHPh), 78.2 (d; 2C, C-3 + C-4), 73.5 (s; 2C, 
CMe3), 60.6 (t; CH2Ph), 60.3 (t; 2C, C-2 + C-5), 28.6 (q; 6C, CH3) ppm; IR (CDCl3): v
 
= 
2977, 2797, 1391, 1366, 1186 cm
-1
; MS (EI): m/z (%) = 305 (M
+
, 9), 248 (16), 232 (3), 192 
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(28), 158 (6), 91 (100), 57 (92); C19H31NO2 (305.2): calcd.: C, 74.71; H, 10.23; N, 4.59; found 
C, 74.37; H, 10.24; N, 4.95.  
42:
 
Rf = 0.23 (CH2Cl2/MeOH 95:5);
 
mp = 78.6–81.8 °C; []D
23
= – 10 (c = 0.5, CHCl3); 
1
H 
NMR (CDCl3, 400 MHz):  = 7.35-7.24 (m, 5H, HPh), 4.03-3.98 (m, 2H, 3-H + 4-H), 3.70 (A 
part of an AB system, J = 12.9 Hz, 1H, CHHPh), 3.66 (B part of an AB system, J = 12.9 Hz, 
1H, CHHPh), 3.26 (dd, J = 10.1, 6.7 Hz, 1H) and 2.82 (broad d, J = 10.4 Hz, 1H) (2-Ha and 5-
Ha), 2.68 (dd, J = 10.4, 5.1 Hz, 1H) and 2.34 (dd, J = 10.1, 5.4 Hz, 1H) (2-Hb and 5-Hb), 1.19 
(s, 9H, CH3 x 3) ppm; 
13
C-NMR (CDCl3, 50 MHz):  = 137.3 (s; CPh), 128.9 (d; 2C, CHPh), 
128.3 (d; 2C, CHPh), 127.4 (d; CHPh), 78.6 (d) and 78.2 (d) (C-3 and C-4), 74.1 (s; CMe3), 
60.6 (t) and 60.4 (t) (C-2 and C-5), 60.1 (t; CH2Ph), 28.4 (q; 3C, CH3) ppm; IR (CDCl3): v
 
= 
2978, 2801, 1392, 1366, 1192, 1090 cm
-1
; MS (EI): m/z (%) = 249 (M
+
,6), 192 (27), 91 (100), 
57(19); C15H23NO2 (249.3): calcd.: C, 72.25; H, 9.30; N, 5.62; found C, 71.99; H, 9.18; N, 
5.54. 
(3S,4S)-1-Benzyl-3,4-di-tert-butoxypyrrolidine (ent-40) and (3S,4S)-1-benzyl-4-tert-
butoxy-3-pyrrolidinol (ent-42).  
Following the same procedure as for 40 and 42, the enantiomeric pyrrolidines ent-40 and ent-
42 were prepared starting from the L-tartaric acid derivative ent-39.  
ent-40: []D
25
= + 83 (c = 0.7, CHCl3); C19H31NO2 (305.4): calcd.: C, 74.71; H, 10.23; N, 4.59; 
found C, 74.41; H, 10.41; N, 4.97. Spectral properties are identical to those of 40. 
ent-42: []D
27
= + 8 (c = 0.4, CHCl3); C15H23NO2 (249.3): calcd.: C, 72.25; H, 9.30; N, 5.62; 
found C, 72.54; H, 9.57; N, 5.85. Spectral properties are identical to those of 42. 
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(3R,4R)-3,4-Di-tert-butoxypyrrolidine (43) 
 
AcOH (4.3 mL, 75 mmol) was added to a mixture of pyrrolidine 40 (2.3 g, 7.5 mmol) and 
10% Pd/C (0.493 g, 0.46 mmol) in MeOH (48 mL) at 0 °C. The reaction mixture was stirred 
under a H2 atmosphere (1 Atm) at rt for 3 h, then filtered through a short pad of Celite 
washing with MeOH. The filtrate was concentrated under reduced pressure and the resulting 
oil was dissolved in CH2Cl2 (20 mL) and basified to pH = 9 with a saturated aqueous Na2CO3 
solution (40 mL) at 0 °C. The two layers were separated, and the aqueous solution was 
extracted with CH2Cl2 (3x40 mL). The combined organic phases were washed with brine (60 
mL), dried over Na2SO4, filtered and concentrated under reduced pressure to afford 43 (1.4 g, 
87%) as an oil, that was used in the next step without further purification.  
43: 
1
H NMR (CDCl3, 400 MHz):  = 3.86–3.81 (m, 2H, 3-H + 4-H), 3.09 (dd, J = 12.0, 5.3 
Hz, 2H, 2-Ha + 5-Ha), 2.66 (dd, J = 12.0, 3.5 Hz, 2H, 2-Hb + 5-Hb), 2.41 (br s, NH), 1.17 (s, 
18H, CH3 x 6) ppm; 
13
C NMR (CDCl3, 50 MHz):  = 79.1 (d; 2C, C-3 + C-4), 73.5 (s; 2C, 
CMe3), 53.9 (t; 2C, C-2 + C-5), 28.6 (q; 6C, CH3) ppm. 
(3S,4S)-3,4-Di-tert-butoxypyrrolidine (ent-43).  
Following the same procedure as for 43, the enantiomeric pyrrolidine ent-43 was prepared 
starting from ent-40.   
ent-43: Spectral properties are identical to those of 43. 
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(3R,4R)-3,4-Di-tert-butoxy-3,4-dihydro-2H-pyrrole 1-oxide (28). 
 
 NaHCO3 (4 g, 47.6 mmol) was added to a stirred solution of crude 43 (2 g, 9.3 mmol) in a 4:1 
mixture of CH3CN–THF (18 mL) and aqueous Na2EDTA (0.01 M, 13 mL). The reaction 
mixture was cooled at 0 °C and Oxone (7.6 g, 12 mmol) was added portionwise over 5 h. The 
mixture was stirred at 0 °C for 30 min and then diluted with EtOAc (30 mL) and deionised 
H2O (50 mL). The two phases were separated and the aqueous solution was sequentially 
extracted with EtOAc (2x20 mL) and CH2Cl2 (3x20 mL). The combined organic layers were 
washed with brine (50 mL), dried over Na2SO4 and concentrated under reduced pressure to 
afford spectroscopically pure 28 (2.023 g, 93%) as a yellow solid that can be used in the next 
step without further purification. Purification by chromatography on silica gel [eluent: 
CH2Cl2/MeOH (1% NH4OH98:2] afforded analytically pure 28 (1.7 g, 78%) as a white solid. 
28: Rf = 0.32;
 
mp = 75.4–77.2 °C; []D
27
= – 166 (c = 0.7, CHCl3); 
1
H NMR (CDCl3, 400 
MHz):  = 6.78–6.76 (m, 1H, 5-H), 4.59-4.56 (m, 1H, 4-H), 4.20–4.12 (m, 2H, 2-Ha + 3-H), 
3.71–3.64 (m, 1H, 2-Hb), 1.21 (s, 9H, CH3 x 3), 1.19 (s, 9H, CH3 x 3) ppm; 
13
C NMR (CDCl3, 
50 MHz):  = 134.9 (d; C-5), 79.0 (d; C-4), 74.8 (s; CMe3), 74.7 (s; CMe3), 74.2 (d; C-3), 68.3 
(t; C-2), 28.2 (q; 6C, CH3) ppm; IR (CDCl3): v
 
= 2978, 2935, 1588, 1392, 1367, 1260, 1187, 
1086 cm
-1
; MS (EI): m/z (%) = 229 (M
+
, 1), 173 (16), 117 (39), 100 (18), 88 (31), 70 (43), 57 
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(100), 41 (42); C12H23NO3 (229.3): calcd.: C, 62.85; H, 10.11; N,6.11; found C, 63.14; H, 
10.06; N, 6.31. 
(3S,4S)-3,4-Di-tert-butoxy-3,4-dihydro-2H-pyrrole 1-oxide (ent-28).
93
 Following the same 
procedure as for 28, the enantiomeric nitrone ent-28 was prepared starting from ent-43.  
ent-28: []D
23
= + 151 (c = 0.8, CHCl3); C12H23NO3 (229.3): calcd.: C, 62.85; H, 10.11; 
N,6.11; found C, 62.59; H, 10.49; N, 6.02. Spectral properties are identical to those of 28. 
1R,2R,7S,8aR) and (1R,2R,7R,8aS)-1,2-Di-tert-butoxyoctahydro-7-indolizinol (47a and 
47b).  
 
A mixture of nitrone 28 (229 mg, 1 mmol) and alkene 48 (905 mg, 4 mmol) was stirred at rt 
for 3 days. The reaction mixture was suspended in Et2O (10 mL), cooled at 0 °C, treated with 
glacial AcOH (2 mL) and activated Zn dust (981 mg, 15 mmol) and then stirred at rt for 24 h. 
The excess of Zn dust was filtered off and the solution basified to pH 9 with a 3 M aqueous 
NaOH solution at 0 °C. The two layers were separated and the aqueous one was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure to afford a diastereomeric mixture 
of indolizidines. Purification by column chromatography on silica gel [eluent: CH2Cl2/MeOH 
(1% NH4OH) first 97 : 3 then 95 : 5] afforded indolizidine 47a (170 mg, 60%) as a white solid 
and a mixture of 47b and a third diastereomer (40 mg, 14%) in 6:1 ratio. Further separation 
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afforded a sample of pure 47b. The excess of dipolarophile 48 could be recovered in the early 
chromatography fractions (644 mg, 95%) and reused. 
47a: Rf = 0.11 [CH2Cl2/MeOH (1% NH4OH) 97:3]; mp = 117.5-119.5; []D
26
= – 45 (c = 0.6, 
CHCl3); 
1
H NMR (CDCl3, 400 MHz):  = 3.83 (ddd, J = 7.1, 4.0, 1.7 Hz, 1H; 2-H), 3.67 (dd, 
J = 8.5, 4.0 Hz, 1H; 1-H), 3.58 (pseudo tt, J = 10.9, 4.6 Hz, 1H; 7-H), 2.93 (ddd, J = 11.2, 4.5, 
2.5 Hz, 1H; 5-Ha), 2.89 (dd, J = 10.1, 1.7 Hz, 1H; 3-Ha), 2.42 (dd, J = 10.1, 7.1 Hz, 1H; 3-Hb), 
2.21-2.15 (m, 1H; 8-Ha), 1.96 (pseudo dt, J = 2.6, 11.8 Hz, 1H; 5-Hb), 1.90–1.77 (m, 2H; 6-Ha 
+ 8a-H), 1.61 (pseudo ddt, J = 11.2, 4.5, 12.3 Hz, 1H; 6-Hb), 1.27 (pseudo q, J = 11.2 Hz, 1H; 
8-Hb), 1.20 (s, 9H, CH3 x 3), 1.16 (s, 9H, CH3 x 3) ppm; 
13
C-NMR (CDCl3,100 MHz):  = 
83.2 (d; C-1), 77.9 (d; C-2), 73.8 (s; CMe3), 73.7 (s; CMe3), 69.7 (d; C-7), 65.4 (d; C-8a), 61.1 
(t; C-3), 50.5 (t; C-5), 37.9 (t; C-8), 34.2 (t; C-6), 29.2 (q; 3C, CH3), 28.7 (q; 3C, CH3) ppm; 
IR (CDCl3): v
 
= 3689, 3608, 2978, 2257, 1602, 1391, 1367, 1216, 1190, 1067 cm
–1
; MS (EI): 
m/z (%) = 285 (M
+
, 2), 228 (51), 172 (18), 128 (9), 113 (46), 100 (16), 57 (100), 41 (54); 
C16H31NO3 (285.42): calcd: C,67.33 ; H, 10.95; N,4.91; found C, 67.29 ; H, 11.21 ; N, 4.77. 
47b: Rf = 0.23 [CH2Cl2/MeOH (1% NH4OH) 95:5]; []D
23
= – 19 (c = 0.3, CHCl3);
 1
H NMR 
(CDCl3,400 MHz):  = 3.98 (pseudo dt, J = 1.0, 6.3 Hz, 1H; 2-H), 3.73 (dd, J = 5.0, 1.0 Hz, 
1H; 1-H), 3.68 (pseudo tt, J = 11.0, 4.7 Hz, 1H; 7-H), 3.40 (dd, J = 9.4, 6.8 Hz, 1H; 3-Ha), 
3.04 (ddd, J =11.2, 4.2, 2.7 Hz, 1H; 5-Ha), 2.16–2.08 (m, 1H; 8a-H), 2.00 (pseudo dt, J = 1.9, 
11.8 Hz, 1H; 5-Hb), 1.92 (dd, J = 9.4, 5.8 Hz, 1H; 3-Hb), 1.91–1.81 (m, 2H; 6-Ha + 8-Ha), 
1.63–1.51 (m, 2H; 6-Hb + 8-Hb), 1.18 (s, 9H, CH3 x 3), 1.16 (s, 9H, CH3 x 3) ppm; 
13
C-NMR 
(CDCl3,100 MHz):  = 79.9 (d; C-1), 79.7 (d; C-2), 73.7 (s; CMe3), 73.4 (s; CMe3), 70.0 (d; 
C-7), 64.5 (d; C-8a), 63.0 (t; C-3), 50.6 (t; C-5), 35.0 (t; C-8), 34.4 (t; C-6), 28.7 (q; 3C, CH3), 
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28.6 (q; 3C, CH3) ppm; IR (CDCl3): v
 
= 2978, 2934, 1468, 1391, 1366, 1191, 1070 cm
-1
; MS 
(EI): m/z (%) = 285 (M
+
, 4), 228 (85), 212 (8), 172 (25), 113 (58), 100 (22), 70 (9), 57 (100), 
41(56) ; C16H31NO3 (285.4): calcd.: C, 67.33 ; H, 10.95 ; N, 4.91 ; found C, 67.19; H, 11.13; 
N, 4.94. 
(1S,2S,7R,8aS)- and (1S,2S,7S,8aR)-1,2-Di-tert-butoxyoctahydro-7-indolizinol (ent-47a 
and ent-47b). 
Following the same procedure as for 47a and 47b, the enantiomeric indolizidines ent-47a and 
ent-47b were prepared starting from nitrone ent-28 
ent-47a: []D
23
= + 49 (c = 0.4, CHCl3), {lit. []D
23
= + 53.0 (c = 1.02, CHCl3); []D
23
= + 49.7 
(c = 0.45, CHCl3); C16H31NO3 (285.4): calcd.: C, 67.33; H, 10.95; N, 4.91; found C, 67.22 ; H, 
11.20; N,.5.01. 
(1R,2R,7S,8aR)-Octahydroindolizine-1,2,7-triol (29). 
 
A solution of 47a (55 mg, 0.193 mmol) in TFA (0.83 mL) was stirred at rt for 24 h. After this 
time the reaction mixture was concentrated under reduced pressure. The obtained crude 
material was dissolved in MeOH and Ambersep 900-OH was added at 0 °C. The mixture was 
slowly stirred at 0 °C for 10 min and then shaken at rt for 80 min on a flat shaker at 180 rpm. 
After this time the reaction mixture was filtered through cotton wool and concentrated under 
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reduced pressure. Purification of the crude product by chromatography on silica gel (eluent: 
CH2Cl2/MeOH/NH4OH 35:19:1) afforded 29 (29 mg, 87%) as a white solid. 
29: Rf = 0.5; mp = 180–182 °C (dec); []D
26
= – 3 (c = 0.47, MeOH), {lit. ent-29: []D
22
= + 2.1 
(c = 0.36, MeOH); []D
21
= + 1.8 (c = 0.81, MeOH); 
1
H NMR (D2O, 400 MHz):  = 4.11 (ddd, 
J = 7.5, 3.9, 1.8 Hz, 1H; 2-H), 3.70 (dd, J = 8.5, 3.9 Hz, 1H; 1-H), 3.65 (pseudo tt, J = 11.1, 
4.6 Hz, 1H; 7-H), 2.97 (ddd, J = 11.2, 4.5, 2.5 Hz, 1H; 5-Ha), 2.84 (dd, J = 11.2, 1.8 Hz, 1H; 
3-Ha), 2.65 (dd, J = 11.2, 7.5 Hz, 1H; 3-Hb), 2.24–2.04 (m, 3H, 5-Hb + 8-Ha + 8a-H), 1.97–
1.89 (m, 1H; 6-Ha), 1.47 (pseudo ddt, J = 11.3, 4.5, 12.6 Hz, 1H; 6-Hb), 1.28 (pseudo q, J = 
11.4 Hz, 1H; 8-Hb) ppm; 
13
C-NMR (D2O, 50 MHz):  = 82.8 (d; C-1), 77.0 (d; C-2), 68.7 (d; 
C-7), 67.3 (d; C-8a), 59.8 (t; C-3), 50.1 (t; C-5), 36.5 (t; C-8), 33.1 (t; C-6) ppm; HRMS (ESI): 
calcd for C8H16NO3 [M+H]
+
 174.11247; found 174.11242. 
(2S, 3aS,4S,5S)-2-(2,6-Dichlorophenyl)-4,5-bis (tert-butyldimethylsilyloxy) 
hexahydropyrrolo[1,2-b][1,2]oxazole (52a): 
 
2,6-Dichlorostyrene (49, 506 mg, 2.92 mmol) was added to a suspension of nitrone 51 (1.0 g, 
2.89 mmol) in toluene (0.2 mL) and the reaction mixture was heated at 70 °C for 1 h 15 min in 
a microwave reactor (MW) using an irradiation power of 100 W. A second portion of nitrone 
(310 mg, 0,9 mmol) was added and the reaction mixture was heated in MW at 70 °C for 30 
min. The solvent was evaporated under a nitrogen stream and the residue was purified by 
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chromatography on silica gel [eluent: EtOAc (1% Et3N)/petroleum ether 1:10]. Enriched 
fractions of the diastereoisomeric adducts were obtained in 94% overall yield (1.43 g, exo-
anti:exo-syn:endo-anti ratio = 6.8:6.4:1). The major exo-anti diastereoisomer 52a was 
obtained in 46% combined yield (696 mg), calculated by
 1
H NMR of the mixed fractions, as a 
white solid.  
52a (17:1 mixture with 52b): Rf = 0.43; m.p.= 72-73 °C; []D
22 
= + 52.2 (CHCl3); 
1
H NMR 
(400 MHz):  = 7.29 (pseudo d, J = 8.0 Hz, 2H, HAr), 7.13 (dd, J = 8.5, 7.5 Hz, 1H, HAr), 5.91 
(pseudo t, J = 8.8 Hz, 1H, 2-H), 4.09-4.04 (m, 2H, 4-H, 5-H), 3.91 (ddd, J = 10.4, 4.3, 1.8 Hz, 
1H, 3a-H), 3.69 (dd, J = 12.5, 4.6 Hz, 1H, 6-Ha), 3.12-3.06 (m, 1H, 6-Hb), 2.83 (ddd, J = 
12.2, 10.4, 9.4 Hz, 1H, 3-Ha), 2.52 (ddd, J = 12.2, 8.3, 4.3 Hz, 1H, 3-Hb), 0.93 [br s, 9H, 
C(CH3)3], 0.90 [br s, 9H, C(CH3)3], 0.12 (br s, 6H, SiCH3), 0.10 (br s, 6H, SiCH3) ppm; 
13
C-
NMR (50 MHz):  = 135.7 (s; 2C, CAr),
 
132.9 (s; CAr), 129.3 (d; 3C, CHAr), 83.8 (d; C-4), 77.8 
(d; C-5), 74.7 (d; C-2), 73.2 (d; C-3a), 62.6 (t; C-6), 39.0 (t;C-3), 25.9 [q; 3C, C(CH3)3], 25.8 
[q; 3C, C(CH3)3], 18.2 [s; C(CH3)3], 18.0 [s; C(CH3)3], -4.5 (q; 2C, SiCH3), -4.7 (q, 2C, 
SiCH3) ppm; IR: v = 2956, 2931, 2857, 1564, 1472, 1439, 1259, 1108 cm
-1
; anal. calcd. for 
C24H41Cl2NO3Si2 (518.7): C 55.58, H 7.97, N 2.70; found: C 55.52, H 8.23, N 2.79. 
 
(2S,3aS,4S,5S)-and(2R,3aR,4S,5S)-2-(2-Bromophenyl)-4,5-bis(tert-
butyldimethylsilyloxy)hexahydropyrrolo[1,2-b][1,2]oxazole (53a and 53b) 
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2-Bromostyrene (50, 609 mg, 3.32 mmol) was added to a suspension of nitrone 51 (1.147 g, 
3.32 mmol) in toluene (2.5 mL) and the reaction mixture was heated at 70 °C for 3 h in MW 
using an irradiation power of 100 W. The solvent was co-evaporated with MeOH under 
reduced pressure and the residue was purified by chromatography on silica gel (eluent: 
EtOAc/petroleum ether 1:14). Enriched fractions of the diastereoisomeric adducts were 
obtained in 92% overall yield (1.618 g, exo-anti:exo-syn:endo-anti = ca 18.4:11.6:1). The exo-
anti diastereoisomer 53a was obtained in 55% combined yield (959 mg), calculated by
 1
H 
NMR of the mixed fractions, as a white solid.  
53a (ca 7:1 mixture with two minor isomers): Rf = 0.50; m.p.= 52–53 °C; []D
22
= + 6.1 
(CHCl3); 
1
H NMR (400 MHz):  = 7.62 (dd, J = 7.8, 1.6 Hz, 1H, HAr), 7.51 (dd, J = 8.0, 1.1 
Hz, 1H, HAr), 7.31 (pseudo dt, J = 1.1, 7.6 Hz, 1H, HAr), 7.12 (pseudo dt, J = 1.6, 7.6 Hz, 1H, 
HAr), 5.44 (pseudo t, J = 7.4 Hz, 1H, 2-H), 4.09 (pseudo dt, J = 4.1, 5.5 Hz, 1H, 5-H), 4.02 
(pseudo t, J = 3.8 Hz, 1H, 4-H), 3.64 (dd, J = 12.1, 5.4 Hz, 1H, 6-Ha), 3.67-3.61 (m, 1H, 3a-
H), 3.14 (dd, J = 12.1, 5.7 Hz, 1H, 6-Hb), 2.83 (ddd, J = 12.4, 6.7, 4.2 Hz, 1H, 3-Ha), 2.21 
(ddd, J = 12.4, 9.2, 8.1 Hz, 1H, 3-Hb), 0.92 [s, 9H, C(CH3)3 ], 0.88 [s, 9H, C(CH3)3 ], 0.12 (s, 
3H, SiCH3), 0.11 (s, 3H, SiCH3), 0.10 (s, 3H, SiCH3), 0.08 (s, 3H, SiCH3) ppm; 
13
C-NMR 
(100 MHz):  = 139.9 (s; CAr), 132.5 (d; CHAr), 128.8 (d; CHAr), 127.7 (d; CHAr), 127.3 (d; 
CHAr), 121.7 (s; CAr), 83.6 (d; C-4), 78.0 (d; C-5), 77.3 (d; C-2), 71.8 (d; C-3a), 62.2 (t; C-6), 
41.5 (t; C-3), 25.9 [q; 3C, C(CH3)3], 25.8 [q; 3C, C(CH3)3], 18.1 [s, C(CH3)3], 17.9 [s, 
C(CH3)3], -4.4 (q; SiCH3), -4.5 (q; SiCH3), -4.6 (q; SiCH3), -4.7 (q, SiCH3) ppm; IR: v =2955, 
2930, 2858, 1471, 1440, 1361, 1258, 1110 cm
-1
; MS (EI): m/z (%) = 529 [(M+2)
+
, 6], 527 (M
+
, 
5), 286 (3), 241 (5), 212 (3), 187 (3), 185 (3), 171 (19), 147 (25), 133 (10), 128 (10), 115 (11), 
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73 (100), 55 (76); anal. calcd. for C24H42BrNO3Si2 (528.7): C 54.52, H 8.01, N 2.65; found: C 
54.66, H 8.27, N 2.61. 
 
53b: 
1
H NMR (400 MHz) (18:1 mixture with 53a):  = 7.65 (dd, J = 7.8, 1.7 Hz, 1H, HAr), 
7.50 (dd, J = 8.0, 1.2 Hz, 1H, HAr), 7.30 (pseudo dt, J = 1.2, 7.8 Hz, 1H, HAr), 7.11 (pseudo dt, 
J = 1.7,7.6 Hz, 1H, HAr), 5.27 (dd, J = 8.8, 6.4 Hz, 1H, 2-H), 4.25 (pseudo dt, J = 3.1, 4.9 Hz, 
1H, 5-H), 4.08-4.00 (m, 2H, 3a-H, 4-H), 3.37 (dd, J = 12.5, 5.2 Hz, 1H, 6-Ha), 3.22 (dd, , J = 
12.5, 4.7 Hz, 1H, 6-Hb), 2.93 (ddd, J = 12.4, 6.4, 2.0 Hz, 1H, 3-Ha), 2.03 (pseudo dt, J = 12.4, 
8.7 Hz, 1H, 3-Hb), 0.95 [s, 9H, C(CH3)3], 0.90 [s, 9H, C(CH3)3], 0.14 (s, 3H, SiCH3), 0.12 (s, 
3H, SiCH3), 0.09 (s, 6H, SiCH3) ppm;  
 
(2S,3aS,4S,5S)- and (2R,3aR,4S,5S)-,2-(2-Bromophenyl)-4,5-di-tert-
butoxyhexahydropyrrolo[1,2-b][1,2]oxazole (54a, 54b): 
 
 
 
2-Bromostyrene (50, 595 mg, 3.27 mmol) was added to a suspension of nitrone 28 (0.5 g, 2.18 
mmol) in toluene (1.16 mL) and the reaction mixture was heated at 70 °C for 5 h in MW using 
an irradiation power of 100 W. The solvent was evaporated under a nitrogen stream and the 
residue was purified by flash chromatography on silica gel (eluent: EtOAc/petroleum ether 
1:4), affording fractions enriched of diastereoisomers, especially the minor ones in 99% 
overall yield (0.889 g). The exo-anti adduct 54a and the exo-syn isomer 54b were obtained in 
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73% and 22% yield, respectively (677 and 191 mg), calculated by
 1
H NMR of the mixed 
fractions, as colourless oils.  
54a (6.7:1 mixture of 54a and 54c): Rf = 0.40; []D
25
= + 12.8 (c = 0.51, CHCl3); 
1
H NMR 
(CDCl3, 400 MHz):  = 7.59 (dd, J = 7.8, 1.7 Hz, 1H, HAr), 7.50 (dd, J = 8.0, 1.2 Hz, 1H, HAr), 
7.30 (pseudo dt, J = 1.2, 7.6 Hz, 1H, HAr), 7.11 (pseudo dt, J = 1.7, 7.7 Hz, 1H, HAr), 5.51 
(pseudo t, J = 7.3 Hz, 1H, 2-H), 3.97 (pseudo dt, J = 8.0, 5.6 Hz, 1H, 5-H), 3.87 (dd, J = 5.3, 
4.1 Hz, 1H, 4-H), 3.57 (dd, J = 10.7, 5.9 Hz, 1H, 6-Ha), 3.60-3.55 (m, 1H, 3a-H), 3.02 (dd, J = 
10.7, 8.0 Hz, 1H, 6-Hb), 2.82 (ddd, J = 12.5, 7.1, 5.3 Hz, 1H, 3-Ha), 2.23 (ddd, J = 12.5, 9.0, 
7.5 Hz, 1H, 3-Hb), 1.22 (s, 9H, CH3x3), 1.19 (s, 9H, CH3x3) ppm; 
13
C-NMR (CDCl3, 100 
MHz):  = 140.1(s; CAr),
 
132.4 (d; CHAr), 128.8 (d; CHAr), 127.7 (d; CHAr), 127.3 (d; CHAr), 
121.8 (s; CAr), 81.6 (d; C-4), 77.3 (d; C-2), 76.2 (d; C-5), 74.1 (s; Me3CO), 74.0 (s; Me3CO), 
70.1 (d; C-3a), 60.3 (t; C-6), 41.6 (t; C-3), 28.7 (q; 3C, CH3), 28.5 (q; 3C, CH3) ppm; IR 
(CDCl3): v
 
= 2977, 2935, 2872, 1472, 1390, 1365, 1190, 1105 cm
-1
; MS (EI): m/z (%) = 413 
[(M+2)
+
, 6], 411 (M
+
, 6), 356 (12), 354 (12), 300 (6), 298 (6), 284 (2), 282 (2), 228 (7), 226 
(8), 116 (8), 57 (100), 55 (36); anal. calcd. for C20H30BrNO3 (412.4): C 58.25, H 7.33, N 3.40; 
found C 57.94, H 7.41, N 3.24.  
54b (6.9:1 mixture of 54b and 54d): Rf = 0.22; []D
25
= + 58.2 (c = 0.9, CHCl3); 
1
H NMR 
(CDCl3, 400 MHz):  = 7.65 (dd, J = 7.8, 1.7 Hz, 1H, HAr), 7.50 (dd, J = 8.0, 1.2 Hz, 1H, HAr), 
7.30 (pseudo dt, J = 1.2, 7.6 Hz, 1H, HAr), 7.10 (pseudo dt, J = 1.7, 7.7 Hz, 1H, HAr), 5.29 
(pseudo t, J = 7.3 Hz, 1H, 2-H), 4.11 (pseudo dt, J = 5.1, 6.5 Hz, 1H, 5-H), 3.96-3.86 (m, 2H, 
3a-H, 4-H), 3.40 (dd, J = 13.1, 6.3 Hz, 1H, 6-Ha), 3.09 (dd, J = 13.1, 6.8 Hz, 1H, 6-Hb), 3.02 
(ddd, J = 12.4, 6.8, 2.9 Hz, 1H, 3-Ha), 2.01 (pseudo dt, J = 12.4, 8.0 Hz, 1H, 3-Hb), 1.22 (s, 
9H, CH3x3), 1.20 (s, 9H, CH3x3) ppm; 
13
C-NMR (CDCl3, 100 MHz):  = 140.9(s; CAr),
 
132.4 
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(d; CHAr), 128.6 (d; CHAr), 127.6 (d; CHAr), 127.2 (d; CHAr), 121.7 (s; CAr), 78.6 (d; C-2), 
77.4 (d; C-4), 76.4 (d; C-5), 74.0 (s; Me3CO), 73.6 (s; Me3CO), 66.6 (d; C-3a), 60.7 (t; C-6), 
38.7 (t; C-3), 28.5 (q; 6C, CH3) ppm; IR (CDCl3): v
 
= 2977, 2934, 2907, 2872, 1568, 1472, 
1390, 1365, 1193, 1096, 1020 cm
-1
; MS (EI): m/z (%) = 413 [(M+2)
+
, 3], 411 (M
+
, 3), 356 (8), 
354 (7), 300 (5), 298 (5), 284 (2), 282 (2), 228 (5), 226 (6), 116 (7), 57 (100), 55 (36); anal. 
calcd. for C20H30BrNO3 (412.4): C 58.25, H 7.33, N 3.40; found C 58.40; H 7.35; N 3.60.  
54c: (6.7:1 mixture of 54a and 54c): 
1
H NMR (CDCl3, 400 MHz, discernible signals): δ = 
7.74 (dd, J = 7.8, 1.7 Hz, 1 H, HAr), 7.49 (dd, J = 7.9, 1.2 Hz, 1 H, HAr), 7.29 (pseudo dt, J = 
1.2, 7.5 Hz, 1 H, HAr), 5.28 (dd, J = 9.9, 6.1 Hz, 1 H, 2-H), 4.05 (pseudo dt, J = 386 4.1, 5.7 
Hz, 1 H, 5-H), 3.84 (pseudo t, J = 3.8 Hz, 1 H, 4-H), 3.70 (pseudo dt, J = 3.5, 8.3 Hz, 1 H, 3a-
H), 3.53 (dd, J = 11.8, 5.6 Hz, 1 H, 6-Ha), 3.25 (dd, J = 11.8, 5.9 Hz, 1 H, 6-Hb), 3.06 (ddd, J 
= 12.2, 7.8, 6.1 Hz, 1 H, 3-Ha), 2.01 (ddd, J = 12.2, 9.9, 8.6 Hz, 1 H, 3-Hb), 1.21 [s, 9 H, 
C(CH3)3], 1.16 [s, 9 H, C(CH3)3] ppm. 13C 391 NMR (CDCl3, 100 MHz, discernible 
signals): δ = 82.4 (d; C-4), 80.1 (d; C-2), 79.0 (d; C-5), 73.9 (s; Me3CO), 72.6 (d; C-3a), 61.8 
(t; C-6), 41.8 (t; C-3), 28.6 (q; 3 C, CH3), 28.5 (q; 3 C, CH3) ppm. 
 
54d: (6.9:1 mixture of 54b and 54d): 
1
H NMR (CDCl3, 400 MHz, discernible signals): δ = 
7.57 (dd, J = 7.8, 1.7 Hz, 1 H, HAr), 7.13 396 (pseudo dt, J = 1.7, 7.7 Hz, 1 H, HAr), 5.20 (dd, 
J = 9.8, 6.2 Hz, 1 H, 2-H), 4.27 (pseudo dt, J = 9.1, 6.2 Hz, 1 H, 5-H), 3.55 (dd, J = 13.9, 6.4 
Hz, 1 H, 6-Ha), 2.90 (dd, J = 13.9, 9.1 Hz, 1 H, 6-Hb), 2.65 (ddd, J = 12.4, 8.6, 6.2 Hz, 1 H, 3-
Ha), 2.35–2.27 (m, 1 H, 3- Hb), 1.21 [s, 9 H, C(CH3)3], 1.13 [s, 9 H, C(CH3)3] ppm. 13C 
NMR 401 (CDCl3, 100 MHz, discernible signals): δ = 132.5 (d; CHAr), 128.9 (d; CHAr), 
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127.5 (d; CHAr), 127.3 (d; CHAr), 78.9 (d; C-2), 77.6 (d; C-4), 76.0 (d; C-5), 66.5 (d; C-3a), 
58.9 (t; C-6), 37.9 (t; C-3) ppm. 
 
 (2R,3aR,4R,5R)- and (2S,3aS,4R,5R)-,2-(2-bromophenyl)-4,5-di-tert-
butoxyhexahydropyrrolo[1,2-b][1,2]oxazole (ent-54a and ent-54b): 
Following the same procedure used to prepare 54a and 54b, synthesized ent-54a and ent-54b  
ent-54a: []D
25
=  – 12.844 (c = 0.545, CHCl3); 
ent-54b: []D
25
=  – 64.704 (c = 0.525, CHCl3); 
 
(1S)-1-(2,6-Dichlorophenyl)-2-[(2S,3S,4S)-3,4-bis(tert-butyldimethylsilyloxy)pyrrolidin-2-
yl]ethanol (55a):  
 
 
A 17:1 mixture of isoxazolidines 52a and 52b (63 mg, 0.119 mmol of 52a and 3 mg of 52b) 
was mixed with zinc powder (36 mg, 0.56 mmol) in AcOH:H2O = 9:1 (1.08 mL) and the 
suspension was heated in an oil bath at 60 °C for 4 h and then filtered through cotton wool. 
The solid residue was washed with EtOAc, the solution was basified to pH=9 with a saturated 
aq. NaHCO3 solution and then extracted with EtOAc (5x10 mL). The combined organic 
phases were dried over Na2SO4, filtered and concentrated under reduced pressure. 
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Chromatography on silica gel (eluent: initially CH2Cl2, then CH2Cl2/MeOH with 1% NH4OH 
15:1) afforded pyrrolidine 55a in 72% yield (45 mg) as a white solid.  
55a: Rf = 0.30 (CH2Cl2/MeOH with 1% NH4OH 15:1); m.p.= 113-114 °C; []D
25
= + 14.2 
(CHCl3); 
1
H NMR (400 MHz):  = 7.27 (pseudo d, J = 8.0 Hz, 2H, HAr), 7.10 (dd, J = 8.4, 7.6 
Hz, 1H, HAr), 5.69 (dd, J = 9.7, 3.2 Hz, 1H, CHOH), 4.00-3.97 (m, 1H, 4-H), 3.87-3.84 (m, 
1H, 3-H), 3.24 (pseudo dt, J = 8.7, 3.6 Hz, 1H, 2-H), 3.11 (dd, J = 11.9, 4.6 Hz, 1H, 5-Ha), 
2.84 (dd, J = 11.9, 2.4 Hz, 1H, 5-Hb), 2.46 (ddd, J = 14.5, 9.7, 3.8 Hz, 1H, CHHCHOH), 1.80 
(ddd, J = 14.5, 8.6, 3.1 Hz, 1H, CHHCHOH), 0.87 [s, 9H, C(CH3)3], 0.86 [s, 9H, C(CH3)3 ], 
0.07 (s, 3H, SiCH3), 0.066 (s, 3H, SiCH3), 0.058 (s, 3H, SiCH3), 0.04 (s, 3H, SiCH3) ppm; 
13
C-NMR (50 MHz):  = 138.1 (s; CAr), 134.2 (s; 2C, CAr), 129.3 (d; 2C, CHAr), 128.4 (d; 
CHAr), 83.7 (d; C-3), 79.9 (d; C-4), 70.0 (d; CHOH), 64.6 (d; C-2), 53.4 (t; C-5), 36.3 (t; 
CH2CHOH), 25.8 [q; 6C, C(CH3)3], 18.0 [s; 2C, C(CH3)3], -4.4 (q; SiCH3), -4.5 (q; 2C, 
SiCH3), -4.6 (q; SiCH3) ppm; IR: v =  3600, 3200 (br), 2954, 2923, 2862, 1582, 1562, 1472, 
1437, 1258, 1089 cm
-1
; MS (EI): m/z (%) = [521 (M+2)
+
, 2]; 519 (M
+
, 2), 504 (1), 484 (1), 462 
(2), 352 (2), 330 (5), 276 (5), 171 (63), 73 (88), 56 (100); anal. calcd. for C24H43Cl2NO3Si2 
(520.68): C 55.36, H 8.32, N 2.69; found: C 55.04, H 8.05, N 2.62. 
 
(1S)-and(1R)-1-(2-Bromophenyl)-2-[(2S,3S,4S)-3,4-bis(tert-
butyldimethylsilyloxy)pyrrolidin-2-yl]ethanol (56a and 56b):  
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Following the same procedure used to prepare 55a, pyrrolidines 56a and 56b were obtained 
starting from a mixture of cycloadducts 53a and 53b.  
 
56a: white solid, 88% yield, Rf = 0.34 [eluent: CH2Cl2/MeOH (1% NH4OH) 20:1]; m.p.= 
102-103 °C; []D
25
= + 12.1 (CHCl3); 
1
H NMR (400 MHz):  = 7.65 (dd, J = 7.8, 1.7 Hz, 1H, 
HAr), 7.48 (dd, J = 7.9, 1.2 Hz, 1H, HAr), 7.33 (pseudo dt, J = 1.2, 7.5 Hz, 1H, HAr), 7.09 
(pseudo dt, J = 1.7, 7.6, Hz, 1H, HAr), 5.28 (dd, J = 6.4, 3.2 Hz, 1H, CHOH), 3.98-3.94 (m, 
1H, 4-H), 3.82-3.80 (m, 1H, 3-H), 3.16 (dd, J = 11.9, 4.9 Hz, 1H, 5-Ha), 3.02 (pseudo dt, J = 
9.6, 2.7 Hz, 1H, 2-H), 2.89 (dd, J = 11.9, 2.8 Hz, 1H, 5-Hb), 2.14 (ddd, J = 14.6, 9.6, 3.2 Hz, 
1H, CHHCHOH), 1.88 (ddd, J = 14.6, 6.4, 3.3 Hz, 1H, CHHCHOH), 0.89 [s, 9H, C(CH3)3], 
0.79 [s, 9H, C(CH3)3], 0.08 (s, 3H, SiCH3), 0.06 (s, 3H, SiCH3), 0.00 (s, 3H, SiCH3), -0.07 (s, 
3H, SiCH3) ppm; 
13
C-NMR (100 MHz):  = 143.7 (s; CAr), 132.5 (d; CHAr), 128.2 (d; CHAr), 
127.9 (d; CHAr), 127.3 (d; CHAr), 121.2 (s; CAr), 84.0 (d; C-3), 79.9 (d; C-4), 71.6 (d; CHOH), 
64.4 (d; C-2), 53.2 (t; C-5), 36.2 (t; CH2CHOH), 25.8 [q; 3C, C(CH3)3], 25.7 [q; 3C, C(CH3)3], 
17.9 [s; C(CH3)3], 17.8 [s; C(CH3)3], -4.6 (q; SiCH3), -4.67 (q; SiCH3), -4.71 (q; SiCH3), -4.8 
(q; SiCH3) ppm. IR: ν = 3661, 3190, 2930, 2858, 1471, 1463, 1258, 1088, 1082 cm
-1
; MS (EI): 
m/z (%) = 531 [(M+2)
+
, 1], 529 (M
+
, 1), 450 (2), 432 (5), 171 (54), 97(44), 83 (45), 71 (59), 57 
(100); anal. calcd. for C24H44BrNO3Si2 (530.69): C 54.32, H 8.36, N 2.64; found: C 54.32, H 
8.28, N 2.68. 
 
56b: white solid; m.p.= 155-156 °C; []D
26
= + 46.2 (CHCl3); 
1
H NMR (400 MHz):  = 7.65 
(dd, J = 7.8, 1.6 Hz, 1H, HAr), 7.49 (dd, J = 7.9, 1.2 Hz, 1H, HAr), 7.33 (pseudo dt, J = 1.2, 7.5 
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Hz, 1H, HAr), 7.10 (pseudo dt, J = 1.6, 7.6, Hz, 1H, HAr), 5.31 (pseudo t, J = 4.6 Hz, 1H, 
CHOH), 3.94 (pseudo dt, J = 4.6, 1.6 Hz, 1H, 4-H), 3.74 (dd, J = 4.1, 1.6 Hz, 1H, 3-H), 3.24 
(dd, J = 12.4, 4.6 Hz, 1H, 5-Ha), 3.19 (pseudo dt, J = 11.3, 3.6 Hz, 1H, 2-H), 2.69 (dd, J = 
12.4, 1.6 Hz, 1H, 5-Hb), 2.11 (ddd, J = 14.7, 11.3, 4.2 Hz, 1H, CHHCHOH), 1.93 (ddd, J = 
14.7, 5.0, 3.1 Hz, 1H, CHHCHOH), 0.87 [s, 9H, C(CH3)3], 0.82 [s, 9H, C(CH3)3], 0.033 (s, 
3H, SiCH3), 0.031 (s, 3H, SiCH3), 0.02 (s, 3H, SiCH3), -0.01 (s, 3H, SiCH3) ppm; 
13
C-NMR 
(100 MHz):  = 143.7 (s; CAr), 132.7 (d; CHAr), 128.3 (d; CHAr), 127.8 (d; CHAr), 127.3 (d; 
CHAr), 121.4 (s; CAr), 80.4 (d; C-3), 78.4 (d; C-4), 71.5 (d; CHOH), 57.4 (d; C-2), 52.9 (t; C-
5), 32.8 (t; CH2CHOH), 25.8 [q; 3C, C(CH3)3], 25.7 [q; 3C, C(CH3)3], 18.0 [s; C(CH3)3], 17.8 
[s; C(CH3)3], -4.6 (q; SiCH3), -4.67 (q; SiCH3), -4.68 (q; SiCH3), -4.9 (q, SiCH3) ppm. 
 
(1S)- and (1R)-1-(2-bromophenyl)-2-[(2S,3S,4S)-3,4-di-tert-butoxypyrrolidin-2-yl]ethanol 
(57a and 57c):  
 
A 6.7:1 mixture of isoxazolidines 54a and 54c (686 mg, 1.66 mmol) and zinc powder (544 
mg, 8.32 mmol) in AcOH:H2O = 9:1 (15.9 mL) was heated in an oil bath at 80 °C for 5 h and 
then diluted with MeOH and filtered through cotton wool. The filtrate was concentrated under 
reduced pressure, the residue was dissolved in CH2Cl2, and the solution was basified to pH=9 
with a saturated aq. NaHCO3 solution and solid Na2CO3 at 0 °C. The obtained suspension was 
sequentially extracted with CH2Cl2 (3x30 mL) and EtOAc (2x30 mL). The combined organic 
phases were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under 
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reduced pressure. Filtration on silica gel [eluent: CH2Cl2/MeOH (1% NH4OH) 95:5] afforded 
a 6.2:1 mixture of pyrrolidines 57a and 57c in 96% yield (658 mg) as a yellow viscous oil.  
 
57a (6.2:1 mixture with 57c): Rf = 0.20;
 
[]D
25
= – 15.1 (c = 0.6, CHCl3); 
1
H NMR (CDCl3, 
400 MHz):  = 7.66 (dd, J = 7.8, 1.7 Hz, 1H, HAr), 7.48 (dd, J = 7.9, 1.2 Hz, 1H, HAr), 7.33 
(pseudo dt, J = 1.2, 7.5 Hz, 1H, HAr), 7.09 (pseudo dt, J = 1.7, 7.6 Hz, 1H, HAr), 5.31 (dd, J = 
5.9, 3.5 Hz, 1H, CHOH), 4.94-4.15 (br s, 2 H, NH, OH) 3.85-3.80 (m, 1H, 4-H), 3.66 (pseudo 
t, J = 2.2 Hz, 1H, 3-H), 3.16 (dd, J = 12.1, 5.6 Hz, 1H, 5-Ha), 3.03 (pseudo dt, J = 10.2, 2.7 
Hz, 1H, 2-H), 2.92 (dd, J = 12.1, 4.3 Hz, 1H, 5-Hb), 2.21 (ddd, J = 14.7, 10.2, 3.5 Hz, 1H, 
CHHCHOH), 1.96 (ddd, J = 14.7, 5.9, 3.2 Hz, 1H, CHHCHOH), 1.18 (s, 9H, CH3x3), 1.06 (s, 
9H, CH3x3) ppm; 
13
C-NMR (CDCl3, 100 MHz):  = 143.5 (s; CAr),
 
132.5 (d; CHAr), 128.2 (d; 
CHAr), 128.1 (d; CHAr), 127.3 (d; CHAr), 121.1 (s; CAr), 83.1 (d; C-3), 79.2 (d; C-4), 73.9 (s; 
Me3CO), 73.8 (s; Me3CO), 71.8 (d; CHOH), 63.0 (d; C-2), 52.3 (t; C-5), 34.8 (t; CH2CHOH), 
28.6 (q; 3C, CH3), 28.5 (q; 3C, CH3) ppm; IR (CDCl3): v
 
= 3500-2500 br, 3068, 2979, 2934, 
2873, 1464, 1391, 1365, 1235, 1191, 1071, 1023 cm
-1
; MS (EI): m/z (%) = 415 [(M+2)
+
, 1], 
413 (M
+
, 1), 358 (1), 356 (1), 342 (1), 340 (1), 334 (1), 260 (5), 228 (3), 187 (5), 185 (6), 148 
(9), 116 (34), 98 (12), 57 (100).  
 
57c (6.2:1 mixture of 57a/57c): 
1
H NMR (CDCl3, 400 MHz, discernible signals):  = 5.13 (dd, 
J= 10.2, 1.1 Hz, 1H, CHOH), 3.87 (pseudo dt, J= 2.3, 5.9 Hz, 1H, 4-H), 3.60 (pseudo t, J= 2.2 
Hz, 1H, 3-H), 3.35 (pseudo dt, J= 12.1, 2.2 Hz, 1H, 2-H), 3.24 (dd, J= 12.6, 6.4 Hz, 1H, 5-
Ha), 2.83 (dd, J= 12.6, 5.5 Hz, 1H, 5-Hb), 1.69-1.58 (m, 1H, CHHCHOH), 1.19 (s, 9H, 
CH3x3), 1.15 (s, 9H, CH3x3) ppm; 
13
C-NMR (CDCl3, 100 MHz) discernible signals:  = 143.8 
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(s; CAr),
 
132.3 (d; CHAr), 128.2 (d; CHAr), 127.6 (d; CHAr), 127.5 (d; CHAr), 121.4 (s; CAr), 
84.1 (d; C-3), 79.9 (d; C-4), 74.1 (s; Me3CO), 73.9 (d; CHOH), 73.6 (s; Me3CO), 66.5 (d; C-
2), 52.2 (t; C-5), 37.0 (t; CH2CHOH), 28.7 (q; 3C, CH3), 28.5 (q; 3C, CH3) ppm. 
 
(1R)-1-(2-bromophenyl)-2-[(2R,3S,4S)-3,4-di-tert-butoxypyrrolidin-2-yl]ethanol(57b): 
Following the same procedure used to prepare 57a, the diastereomeric pyrrolidine 57b was 
obtained starting from a mixture of cycloadducts 54b and 54d.  
 
57b: 
1
H NMR (CDCl3, 400 MHz):  = 7.64 (dd, J = 7.7, 1.7 Hz, 1H, HAr), 7.48 (dd, J = 7.9, 
1.2 Hz, 1H, HAr), 7.33 (pseudo dt, J = 1.2, 7.6 Hz, 1H, HAr), 7.09 (pseudo dt, J = 1.7, 7.7 Hz, 
1H, HAr), 5.29 (pseudo t, J = 4.3 Hz, 1H, CHOH), 4.20-2.92 (br s, 2 H, NH, OH) 3.87 (pseudo 
dt, J = 6.2, 3.5 Hz, 1H, 4-H), 3.64 (dd, J = 5.7, 3.6 Hz, 1H, 3-H), 3.26 (dd, J = 12.5, 6.2 Hz, 
1H, 5-Ha), 3.06 (pseudo dt, J = 9.4, 5.4 Hz, 1H, 2-H), 2.66 (dd, J = 12.5, 3.4 Hz, 1H, 5-Hb), 
2.06-2.00 (m, 2H, CH2CHOH), 1.14 (s, 9H, CH3x3), 1.08 (s, 9H, CH3x3) ppm; 
13
C-NMR 
(CDCl3, 100 MHz):  = 143.8 (s; CAr),
 
132.6 (d; CHAr), 128.2 (d; CHAr), 128.0 (d; CHAr), 
127.2 (d; CHAr), 121.2 (s; CAr), 80.0 (d; C-3), 77.9 (d; C-4), 73.7 (s; Me3CO), 73.5 (s; 
Me3CO), 72.1 (d; CHOH), 56.8 (d; C-2), 51.8 (t; C-5), 31.8 (t; CH2CHOH), 28.6 (q; 3C, CH3), 
28.3 (q; 3C, CH3) ppm.  
 
(1R)-1-(2-bromophenyl)-2-[(2R,3R,4R)-3,4-di-tert-butoxypyrrolidin-2-yl]ethanol(ent 
57a): 
Following the same procedure used to prepare 57a, the diastereomeric pyrrolidine ent-57a was 
obtained starting from a mixture of cycloadducts ent-54a.  
[]D
25
= + 17.748 (c = 0.835, CHCl3). 
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(2S,3S,3aS,5S)-2,3-Bis(tert-butyldimethylsilyloxy)-1,2,3,3a,4,5-hexahydropyrrolo[1,2-
a]quinolin-5-ol (62a): 
 
 
Method A: DBU (40 μL, 0.267 mmol) and degassed tBuOH (2.6 mL) were added to a mixture 
of 56a (69.8 mg, 0.132 mmol), CuI (2.5 mg, 0.013 mmol), copper powder (1.0 mg, 0.015 
mmol) and L-proline (3.0 mg, 0.026 mmol) under nitrogen atmosphere in a microwave vial. 
The reaction mixture was heated at 100 °C for 10 h in MW and then concentrated. The crude 
product was dissolved in CHCl3, filtered through a short pad of Celite
®
 and concentrated 
under reduced pressure. Purification by chromatography on silica gel (eluent: petroleum 
ether/EtOAc 20:1) afforded 62a in 30% yield (18 mg) as a white solid. 
 
Method B: Degassed DMF (0.3 mL) was added to a mixture of 56a (100 mg, 0.19 mmol), CuI 
(4.5 mg, 0.024 mmol), copper powder (14 mg, 0.22 mmol), K3PO4 (81 mg, 0.38 mmol), and 
L-proline (4.7 mg, 0.04 mmol) under nitrogen atmosphere. The reaction mixture was heated at 
100 °C for 48 h in an oil bath and then concentrated. The crude product was dissolved in 
CH2Cl2, filtered through a short pad of celite®/Na2SO4 and concentrated under reduced 
pressure. Purification by chromatography on silica gel afforded 62a in 37% yield (31 mg) as a 
white solid.  
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Method C: Degassed tBuOH/H2O (1:1, 0.6 mL) and THF (0.15 mL) were added to a mixture 
of 56a (22 mg, 0.04 mmol), CuI (2.4 mg, 0.013 mmol), copper powder (1.0 mg, 0.015 mmol), 
K3PO4 (17 mg, 0.08 mmol), and L-proline (2.8 mg, 0.024 mmol) under nitrogen atmosphere in 
a microwave vial. The reaction mixture was heated at 100 °C for 5 h in MW and then filtered 
through a short pad of Celite®/Na2SO4. The solution was concentrated under reduced 
pressure. Purification by chromatography on silica gel afforded 62a in 46% yield (8 mg) as a 
white solid. 
 
62a: Rf = 0.45 (petroleum ether/EtOAc 9:1); m.p.= 142-144 °C; []D
24
= + 67.2 (c = 1.0, 
CHCl3); 
1
H NMR (400 MHz):  = 7.38 (pseudo dt, J = 7.6, 1.2 Hz, 1H, 6-H), 7.12 (dt, J = 8.1, 
7.3, 1.5, 0.6 Hz, 1H, 8-H), 6.67 (pseudo dt, J = 0.8, 7.4 Hz, 1H, 7-H), 6.30 (dd, J = 8.1, 0.8 
Hz, 1H, 9-H), 4.86 (br ddd, J = 11.0, 8.8, 5.5 Hz, 1H, 5-H), 4.23 (pseudo dt, J = 7.7, 6.7 Hz, 
1H, 2-H), 3.78 (dd, J = 8.0, 6.7 Hz, 1H, 3-H), 3.51 (dd, J = 9.4, 7.7 Hz, 1H, 1-Ha), 3.38 (ddd, 
J = 11.9, 8.0, 3.0 Hz, 1H, 3a-H), 3.01 (dd, J = 9.4, 6.7 Hz, 1H, 1-Hb), 2.47 (ddd, J = 11.5, 5.5, 
3.0 Hz, 1H, 4-Ha), 1.71 (d, J = 8.8 Hz, 1H, OH), 1.58 (pseudo q, J = 11.5 Hz, 1H, 4-Hb), 0.92 
[s, 9H, C(CH3)3], 0.91 [s, 9H, C(CH3)3], 0.14 (s, 3H, SiCH3), 0.12 (s, 3H, SiCH3), 0.11 (s, 3H, 
SiCH3), 0.10 (s, 3H, SiCH3) ppm; 
13
C-NMR (100 MHz):  = 143.2 (s; CAr), 128.6 (d; C-8), 
125.3 (d; C-6), 124.7 (s; CAr), 115.9 (d; C-7), 109.4 (d; C-9), 82.2 (d; C-3), 76.6 (d; C-2), 67.1 
(d; C-5), 59.5 (d; C-3a), 52.2 (t; C-1), 35.8 (t; C-4), 25.9 [q; 3C, C(CH3)3], 25.8 [q; 3C, 
C(CH3)3], 18.0 [s; C(CH3)3], 17.9 [s; C(CH3)3], -3.8 (q; SiCH3), -4.2 (q; SiCH3), -4.4 (q; 
SiCH3), -4.5 (q, SiCH3) ppm; IR: ν = 3586, 2955, 2929, 2857, 1605, 1500, 1472, 1462, 1259, 
1156, 1113 cm
-1
; MS (EI): m/z (%) = 449 (M
+
, 65), 434 (2), 430 (7), 392 (12), 374(10), 168 
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(56), 161 (69), 143 (48), 132 (19), 73 (100); anal. calc. for C24H43NO3Si2 (449.77): C 64.09, H 
9.64, N 3.11; found: C 64.48, H 9.36, N 2.76. 
 
(2S,3S,3aS,5S)-2,3-Di-tert-butoxy-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinolin-5-ol 
(63a):  
 
 
 
The Mixed solvent tBuOH/H2O (1:1) (3 mL) were added to a mixture of 57a/57c (103 mg, 
0.248 mmol of 57a and 14 mg of 57c), CuI (23.6 mg, 0.124 mmol), copper powder (7.9 mg, 
0.124 mmol), K3PO4 (105.5 mg, 0.497 mmol) and L-proline (28.6 mg, 0.248 mmol) under 
nitrogen atmosphere in a vial. Nitrogen was bubbled through the reaction mixture to remove 
oxygen. The reaction mixture was heated at 90 °C in an oil bath for 12 h and then was filtered 
through a small pad of celite. The solution was diluted with H2O and sequentially extracted 
with CH2Cl2 (3x20 mL) and EtOAc (2x20 mL). The combined organic phases were washed 
with NH4OH (1% H2O solution) and brine, dried over Na2SO4, filtered and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel [eluent: CH2Cl2/MeOH 
(1% NH4OH) 98:2] afforded 63a in 74% yield (61.2 mg) as a white solid.  
 
63a:
 
Rf = 0.42; m.p. = 167-169 °C;
 
[]D
23
= + 151.76 (c = 0.42, CHCl3); 
1
H NMR (CDCl3, 400 
MHz):  = 7.38 (pseudo dt, J = 7.5, 1.3 Hz, 1H, 6-H); 7.12 (dddd, J = 8.1, 7.4, 1.5, 0.6 Hz, 
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1H, 8-H), 6.67 (pseudo dt, J = 0.9, 7.4 Hz, 1H, 7-H), 6.31 (dd, J = 8.1, 0.9 Hz, 1H, 9-H), 4.92-
4.82 (m, 1H, 5-H), 4.09-4.03 (m, 1H, 2-H), 3.74 (dd, J = 8.6, 7.2 Hz, 1H, 3-H), 3.45 (dd, J = 
9.6, 7.9 Hz, 1H, 1-Ha), 3.33 (ddd, J = 11.8, 8.6, 2.8 Hz, 1H, 3a-H), 3.04 (dd, J = 9.6, 6.5 Hz, 
1H, 1-Hb), 2.56 (ddd, J = 11.5, 5.7, 2.8 Hz, 1H, 4-Ha), 1.73 (br d, J = 7.9 Hz, 1H, OH), 1.59 
(pseudo q, J = 11.5 Hz, 1H, 4-Hb) 1.26 (s, 9H, CH3x3), 1.24 (s, 9H, CH3x3) ppm; 
13
C-NMR 
(CDCl3, 100 MHz):  = 143.4 (s; CAr), 128.6 (d; C-8), 125.5 (d; C-6), 124.8 (s; CAr), 115.9 (d; 
C-7), 109.5 (d; C-9), 80.3 (d; C-3), 75.2 (d; C-2), 74.3 (s; Me3CO), 73.9 (s; Me3CO), 67.2 (d; 
C-5), 57.9 (d; C-3a), 52.1 (t; C-1), 35.9 (t; C-4), 29.4 (q; 3C, CH3), 28.6 (q; 3C, CH3) ppm; IR 
(CDCl3): v
 
= 3619, 3587, 3069, 3043, 2934, 2977, 2934, 1605, 1497, 1462, 1364, 1193, 1091 
cm
-1
; MS (EI): m/z (%) = 333 (M
+
, 21), 314 (1), 276 (12), 258 (5), 220 (2), 202 (22), 186 (4), 
161 (13), 130 (10), 71 (14), 69 (15), 57 (100); anal. calc. for C20H31NO3 (333.4): C 72.04, H 
9.37, N 4.20; found C 71.79, H 9.75, N 4.40. 
 
(2R,3R,3aR,5R)-2,3-Di-tert-butoxy-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinolin-5-ol 
(ent-63a):  
Following the same procedure as for 62a, the enantiomeric trihydroxy-benzo[e]indolizidine 
ent-63a was prepared starting from 28 and nitrone ent-28. 
[]D
23
= – 150.80 (c = 0.42, CHCl3). 
 
(3S,4S)-2-[(S)-2-(2-bromophenyl)-2-hydroxyethyl] pyrrolidine-3,4-diol (65)  
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Pyrrolidine 57a (38 mg, 0.092 mmol) was dissolved in TFA (0.5 mL) at 0 °C and the solution 
was stirred at rt for 2 h. The excess of TFA was co-evaporated with toluene (4 × 3 mL) under 
reduced pressure (each addition of toluene was done at 0 °C) and then the residue was co-
evaporated with MeOH (3 × 3 mL) to remove the last traces of toluene.The crude product 65 
(25 mg) was used in the next step without further purification. 
(2S, 3S, 3aS, 5S)-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinoline-2,3,5-triol (64) –  
 
 
The mixed solvents tBuOH: H2O (1:1) (0.8 mL) were added to a mixture of 65 (25 mg, 0.083 
mmol), CuI (7.9 mg, 0.041 mmol), copper powder (2.63 mg, 0.041 mmol), K3PO4 (35.13 mg, 
0.165 mmol) and L-proline (9.53 mg, 0.083 mmol) under nitrogen atmosphere in a vial. 
Nitrogen was bubbled through the reaction mixture to remove oxygen. The reaction mixture 
was heated at 90 °C for 12 h in an oil bath and then was filtered through a small pad of Celite 
washing with MeOH. The solution was diluted with H2O and sequentially extracted with 
CH2Cl2 and EtOAc. The combined organic phases were washed with NH4OH (1% H2O 
solution) and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography on silica gel [eluent: CH2Cl2 / MeOH (1% 
NH4OH) 90:10] to afford 64 in 40% yield (7.3 mg, 0.033mmol) as a white solid. 
64: Rf = 0.25; m.p. 161–163 °C (dec.). []D
25
= + 85.06 (c = 0.45, MeOH); 1H NMR (CD3OD, 
400 MHz): δ = 7.31 (pseudo dt, J =7.6, 1.3 Hz, 1 H, 6-H); 7.05–7.00 (m, 1 H, 8-H), 6.59 
__________________________________________________________Experimental Section 
 
160 
 
(pseudo dt, J= 0.9, 7.5 Hz, 1 H, 7-H), 6.30 (dd, J = 8.1, 0.9 Hz, 1 H, 9-H), 4.79(br. dd, J = 
11.4, 5.5 Hz, 1 H, 5-H), 4.20 (pseudo dt, J = 7.9,6.9 Hz, 1 H, 2-H), 3.66 (dd, J = 8.3, 7.1 Hz, 1 
H, 3-H), 3.53 (dd, J = 9.7, 7.9 Hz, 1 H, 1-Ha), 3.56–3.29 (m, 1 H, 3a-H), 3.02 (dd, J= 9.7, 6.7 
Hz, 1 H, 1-Hb), 2.46 (ddd, J = 11.6, 5.5, 2.9 Hz, 1 H, 4-Ha), 1.58 (pseudo q, J = 11.6 Hz, 1 H, 
4-Hb) ppm.  
13C NMR(CD3OD, 100 MHz): δ = 144.8 (s; CAr), 129.2 (d; C-6), 126.6 (d;C-8), 126.4 (s; 
CAr), 116.9 (d; C-7), 110.6 (d; C-9), 82.8 (d; C-3),76.6 (d; C-2), 67.5 (d; C-5), 61.3 (d; C-3a), 
52.8 (t; C-1), 36.4 (t; C-4) ppm. 
 
(2R,3R,3aS,5S)-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinoline-2,3,5-triol (ent-64) –  
Following the same procedure as for 64a, the enantiomeric trihydroxy-benzo[e]indolizidine 
ent-64a was prepared starting from 50 and nitrone ent-28. 
[]D
25
= – 88.19 (c = 0.455, MeOH). 
 
(2S,3S,3aS,5S)-2,3-di-tert-butoxy-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinolin-5-yl  
acetate (66) 
 
Quinolin-5-ol 63a (55 mg, 0.165 mmol) and a catalytic amount of DMAP were dissolved in 
dry pyridine (1.6 mL) at 0 °C under nitrogen atmosphere. After 10 min, acetic anhydride 
(0.237 mL, 0.33 mmol) was added dropwise to the reaction mixture at 0 °C under nitrogen 
__________________________________________________________Experimental Section 
 
161 
 
atmosphere. The reaction mixture was stirred at 0 °C for 20 min, then at rt for 3 h, and then 
was concentrated under reduced pressure. The residue was sequentially co-evaporated with 
toluene (3 × 3 mL) and MeOH (2 × 3 mL) under reduced pressure to facilitate the removal of 
all volatiles. The residue was dissolved in CH2Cl2, the insoluble salts were filtered through 
cotton, and the filtrate was concentrated under reduced pressure. Crude 66 (60 mg, 0.16 
mmol) was obtained as a colourless oil and was used in the next step without further 
purification. Acetate 66 undergoes a SN2 hydrolysis of C-5 acetate group on silica gel 
affording the epimerized alcohol in low yield along with decomposition products.  
1
H NMR (CDCl3, 400 MHz):  = 7.12 (dddd, J = 8.1, 7.4, 1.5, 0,7 Hz, 1H, 8-H); 7.04 (pseudo 
dt, J = 7.6, 1.2 Hz, 1H, 6-H), 6.64 (pseudo dt, J = 0.9, 7.5 Hz, 1H, 7-H), 6.35 (dd, J = 8.1, 0.9 
Hz, 1H, 9-H), 6.02 (br dd, J = 10.9, 6.0 Hz, 1H, 5-H), 4.07 (ddd, J = 7.9, 7.0, 6.3 Hz, 1H, 2-
H), 3.75 (dd, J = 8.4, 7.0 Hz, 1H, 3-H), 3.46 (dd, J = 9.6, 7.9 Hz, 1H, 1-Ha), 3.33 (ddd, J = 
12.1, 8.4, 2.7 Hz, 1H, 3a-H), 3.06 (dd, J = 9.6, 6.3 Hz, 1H, 1-Hb), 2.60 (ddd, J = 11.4, 6.0, 2.7 
Hz, 1H, 4-Ha), 2.18 (s, 3H, CH3CO), 1.63 (pseudo q, J = 11.5 Hz, 1H, 4-Hb) 1.24 [s, 9H, 
C(CH3)3], 1.23 [s, 9H, C(CH3)3] ppm; 
13
C-NMR (CDCl3, 100 MHz):  = 171.1 (s; C=O), 
143.9 (s; CAr), 128.8 (d; C-8), 125.9 (d; C-6), 120.1 (s; CAr), 115.8 (d; C-7), 109.9 (d; C-9), 
80.4 (d; C-3), 75.3 (d; C-2), 74.2 (s; Me3CO), 73.9 (s; Me3CO), 69.0 (d; C-5), 57.6 (d; C-3a), 
52.2 (t; C-1), 31.3 (t; C-4), 29.4 [q; 3C, C(CH3)3], 28.6 [q; 3C, C(CH3)3], 21.4 (q; CH3CO) 
ppm.  
(2S,3S,3aS)-2,3-di-tert-butoxy-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinoline (67) 
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Crude quinolin-5-yl acetate 66 (60 mg, 0.16 mmol) was dissolved in MeOH (1.9 mL) and 
hydrogenated in the presence of 10% Pd/C (0.34 mg, 0.32 mmol) at rt and atmospheric 
pressure overnight. Then reaction mixture was filtered through a short pad of Celite washing 
with MeOH. The filtrate was concentrated under reduced pressure and the residue was 
purified by flash chromatography (eluent: EtOAc/petroleum ether 5:95) to afford quinoline 67 
(41.9 mg, 0.132 mmol) as a white solid and in 83% yield based on protected triol 63.   
Rf = 0.5 (petroleum ether/EtOAc, 95:1); m.p. 87-89 °C;
 
[]D
25
=  + 143.33 (c = 0.375, CHCl3). 
1
H NMR (CDCl3, 400 MHz): = 7.05 (pseudo dt, J = 1.1, 7.7 Hz, 1H, HAr); 7.25 (br d, J = 7.3 
Hz, 1H, HAr), 6.56 (pseudo dt, J = 0.9, 7.3 Hz, 1H, HAr), 6.34 (br d, J = 8.0 Hz, 1H, HAr), 4.09 
(pseudo q, J = 7.2 Hz, 1H, 2-H), 3.69 (dd, J = 8.5, 7.3 Hz, 1H, 3-H), 3.50 (dd, J = 9.5, 8.0 Hz, 
1H, 1-Ha), 3.19 (ddd, J = 11.2, 8.5, 3.0 Hz, 1H, 3a-H), 3.06 (dd, J = 9.5, 6.6 Hz, 1H, 1-Hb), 
2.86-2.72 (m, 2H, 5-H), 2.30-2.24 (m, 1H, 4-Ha), 1.52 (pseudo dq, J = 6.0, 11.7 Hz, 1H, 4-
Hb), 1.26 (s, 9H, CH3x3), 1.24 (s, 9H, CH3x3) ppm; 
13
C-NMR (CDCl3, 100 MHz):  = 144.2 
(s; CAr), 128.5 (d; CHAr), 127.1 (d; CHAr), 121.2 (s; CAr), 115.4 (d; CHAr), 109.3 (d; CHAr), 
80.5 (d; C-3), 75.2 (d; C-2), 74.1 (s; Me3CO), 73.8 (s; Me3CO), 59.4 (d; C-3a), 52.2 (t; C-1), 
29.5 (q; 3C, CH3), 28.6 (q; 3C, CH3),  27.5 (t; C-5), 25.5 (t; C-4) ppm; IR (CDCl3): v
 
= 2977, 
2933, 2845, 1602, 1501, 1475, 1460, 1391, 1363, 1190, 1088 cm
-1
; MS (EI): m/z (%) = 317 
(M
+
, 45), 260 (30), 204 (48), 170 (12), 145 (46), 132 (27), 117 (12), 57 (100) ; anal. calcd. for 
C20H31NO2 (317.4): C, 75.67; H, 9.84; N, 4.41; found C, 75.78.; H, 10.06; N, 4.43. 
(2R,3R,3aS)-2,3-di-tert-butoxy-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinoline (ent-67)  
Following the same procedure as for 67, the enantiomeric di-tert-hydroxy-
benzo[e]indolizidine ent-67 was prepared. 
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[]D
22
=  – 146.07 (c = 0.42, CHCl3). 
 
(2S,3S,3aS)-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinoline-2,3-diol (68) 
 
Ether 67 (40.5 mg, 0.127 mmol) was dissolved in TFA (1.27 mL) at 0 °C and the solution was 
stirred at rt for 20 h. The excess of TFA was co-evaporated with toluene (4 × 3 mL) under 
reduced pressure (each addition of toluene was done at 0 °C) and then the residue was co-
evaporated with MeOH (3 × 3 mL) to remove the last traces of toluene. Purification of the 
crude product by chromatography on silica gel [eluent: CH2Cl2 / MeOH (1% NH4OH) 95:5] 
gave 68 (27.3 mg, 0.133 mmol) as a white solid in 91% yield.   
Rf = 0.25; m.p. 144 -146 °C;
 
[]D
24
= + 113.47 (c = 0.69, MeOH); 
1
H NMR (CDCl3, 400 MHz): 
 = 7.00-6.94 (m, 1H, HAr); 6.89 (dm, J = 7.4 Hz, 1H, HAr), 6.50 (pseudo dt, J = 1.0, 7.4 Hz, 
1H, HAr), 6.32 (br d, J = 7.8 Hz, 1H, HAr), 4.22 (pseudo dt, J = 7.9, 6.9 Hz, 1H, 2-H), 3.62 (dd, 
J = 8.2, 7.2 Hz, 1H, 3-H), 3.56 (dd, J = 9.7, 7.9 Hz, 1H, 1-Ha), 3.17 (ddd, J = 11.2, 8.2, 3.1 
Hz, 1H, 3a-H), 3.04 (dd, J = 9.7, 6.7 Hz, 1H, 1-Hb), 2.84-2.71 (m, 2H, 5-H), 2.31-2.23 (m, 
1H, 4-Ha), 1.49 (pseudo dq, J = 6.6, 11.4 Hz, 1H, 4-Hb) ppm; 
13
C-NMR (CD3OD, 100 MHz): 
 = 145.6 (s; CAr), 129.5 (d; CHAr), 128.1 (d; CHAr), 122.5 (s; CAr), 116.8 (d; CHAr), 110.8 
(d; CHAr), 83.0 (d; C-3), 76.6 (d; C-2), 63.0 (d; C-3a), 53.0 (t; C-1), 28.5 (t; C-5), 26.7 (t; C-
4) ppm; MS (EI): m/z (%) = 205 (M
+
, 63), 185 (1), 167 (6), 145 (100), 132 (36), 130 (45), 117 
(73), 91 (19), 51 (15). 
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(2R,3R,3aS)-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinoline-2,3-diol (ent-68) 
Following the same procedure as for 68, the enantiomeric di-hydroxy-benzo[e]indolizidine 
ent-68 was prepared. 
[]D
28
= – 114.88 (c = 0.5, MeOH);  
 
(2R,3aR,4S)-, (2S,3aS,4S)-, (2S,3aR,4S)-, and (2R,3aS,4S)-2-(2-bromophenyl)-4-(tert-
butoxy)hexahydropyrrolo[1,2-b]isoxazole (76, 77, 78, and 79) and (3S,3aR,4S)-3-(2-
bromophenyl)-4-(tert-butoxy)hexahydropyrrolo[1,2-b]isoxazole (80) 
 
 
2-Bromostyrene (50, 524 mg, 2.86 mmol) was added to a solution of nitrone 74 (0.3 g, 1.91 
mmol) in toluene (1.01 mL) and the reaction mixture was heated at 85 °C for 3 h in the MW 
using an irradiation power of 100 W. The solvent was evaporated under a nitrogen stream and 
the residue was purified by flash chromatography on silica gel (eluent: EtOAc/petroleum ether 
3:7) to give a 12:1 mixture of the major adduct exo-anti-76 with endo-anti-78 (437 mg, 67%), 
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the regioisomer 80 (8 mg, 1%), endo-syn-79 (15 mg, 2%), and the second major adduct exo-
syn-77 (114 mg, 18%) obtained as colourless oils.  
 
76 (exo-anti): (12:1 mixture with 78): Rf = 0.5; []D
22 
= + 34.64 (c = 0.83, CHCl3); 
1
H NMR 
(CDCl3, 400 MHz):  = 7.70 (dd, J = 7.8, 1.7 Hz, 1H, HAr), 7.49 (dd, J = 8.0, 1.2 Hz, 1H, HAr), 
7.31 (pseudo dt, J = 1.2, 7.6 Hz, 1H, HAr), 7.11 (pseudo dt, J = 1.7, 7.6 Hz, 1H, HAr), 5.30 
(pseudo t, J = 7.1 Hz, 1H, 2-H), 4.01 (pseudo dt, J = 6.9, 4.6 Hz, 1H, 4-H), 3.56 (ddd, J = 8.0, 
4.0, 3.0 Hz, 1H, 3a-H), 3.45 (pseudo dt, J = 12.7, 7.3 Hz, 1H, 6-Ha), 3.39 (pseudo dt, J = 12.7, 
6.6 Hz, 1H, 6-Hb), 2.76 (ddd, J = 12.7, 7.0, 3.0 Hz, 1H, 3-Ha), 2.36-2.22 (m, 2H, 3-Hb, 5-Ha), 
1.80-1.70 (m, 1H, 5-Hb), 1.21 (s, 9H, CH3x3) ppm;
13
C-NMR (CDCl3, 100 MHz):  = 140.9 (s; 
CAr), 132.3 (d; CHAr), 128.7 (d; CHAr), 127.7 (d; CHAr), 127.2 (d; CHAr), 121.3 (s; CAr), 73.6 
(s; CMe3), 72.8 (d; C-3a), 55.7 (t; C-6), 41.8 (t; C-3), 33.7 (t; C-5), 28.5 (q; 3C, CH3) ppm; IR 
(CDCl3): v
 
= 2977, 1568, 1466, 1440, 1390, 1364, 1253, 1188, 1044, 1019 cm
-1
; MS (EI): m/z 
= 340.26, calcd. for C16H22BrNO2 [M + H]
+
: 342.13; [M + Na]
+
: 361.97; anal. calcd. for 
C16H22BrNO2 (340.26): C, 56.48; H, 6.52; N, 4.12; found C 56.15, H 6.68, N 4.37.  
78 (endo-anti): (1:12 mixture with 76) Detectable signals: 
1
H NMR (CDCl3, 400 MHz):  = 
5.20 (dd, J= 9.0, 6.9 Hz, 1H, 2-H), 3.91 (pseudo dt, J= 6.6, 2.6 Hz, 1H, 4-H), 3.68 (ddd, J = 
8.8, 5.1, 2.8 Hz, 1H, 3a-H), 2.48-2.37 (m, 1H, 5-Ha), 1.13 (s, 9H, CH3x3) ppm; 
77 (exo-syn) : Rf = 0.15; []D
23 
= – 39.22 (c = 0.72, CHCl3); 
1
H NMR (CDCl3, 400 MHz):  = 
7.65 (dd, J = 7.8, 1.7 Hz, 1H, HAr), 7.50 (dd, J = 8.0, 1.2 Hz, 1H, HAr), 7.30 (pseudo dt, J = 
1.2, 7.6 Hz, 1H, HAr), 7.10 (pseudo dt, J= 1.7, 7.6 Hz, 1H, HAr), 5.30 (dd, J = 8.5, 6.3 Hz, 1H, 
2-H), 4.11 (m, 1H, 4-H), 3.79 (ddd, J = 8.3, 6.5, 2.5 Hz, 1H, 3a-H), 3.34-3.18 (m, 2H, 6-H x 
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2), 3.00 (ddd, J = 12.1, 6.3, 2.5 Hz, 1H, 3-Ha), 1.98-1.88 (m, 3H, 3-Hb, 5-H x 2,) 1.23 (s, 9H, 
CH3x3);
13
C-NMR (CDCl3, 100 MHz):  = 140.8 (s; CAr), 132.4 (d; CHAr), 128.6 (d; CHAr), 
127.6 (d; CHAr), 127.1 (d; CHAr), 121.8 (s; CAr), 78.5 (d; C-2), 73.8 (s; CMe3), 71.4 (d; C-4), 
68.9 (d; C-3a), 54.1 (t; C-6), 38.5 (t; C-3), 33.4 (t; C-5), 28.3 (q; 3C, CH3) ppm; IR (CDCl3): v
 
= 2976, 1568, 1472, 1440, 1390, 1364, 1185, 1108, 1047, 1016 cm
-1
; MS (EI): m/z = 340.26, 
calcd. for C16H22BrNO2 [M + H]
+
: 342.14; [M + Na]
+
: 361.98; anal. calcd. for C16H22BrNO2 
(340.26): C, 56.48; H, 6.52; N, 4.12; found C 55.51, H 6.47, N 4.72.  
79(endo-syn): Rf = 0.28; 
1
H NMR (CDCl3, 400 MHz):  = 7.64 (dd, J = 7.8, 1.6 Hz, 1H, HAr), 
7.50 (dd, J = 8.0, 1.1 Hz, 1H, HAr), 7.28 (pseudo dt, J = 0.9, 7.5 Hz, 1H, HAr), 7.11 (pseudo dt, 
J = 1.7, 7.7 Hz, 1H, HAr),  5.25 (dd, J = 9.6, 6.4 Hz, 1H, 2-H), 4.11 (dd, J = 15.0, 7.5 Hz, 1H, 
3a-H), 3.85-3.78 (m, 1H, 4-H), 3.49 (ddd, J = 11.3, 9.1, 4.7 Hz, 1H, 6-Ha), 2.96 (ddd, J = 
13.6, 11.3, 6.3 Hz, 1H, 6-Hb), 2.65 (ddd, J = 12.4, 8.8, 6.4 Hz, 1H, 3-H), 2.32 (ddd, J = 12.4, 
9.6, 6.0 Hz, 1H, 3-H), 2.11 (dddd, J =  Hz, 1H, 5-Ha), 1.96 (dddd, J = Hz, 1H, 5-Hb), 1.13 (s, 
9H, CH3x3).  
80 (regioisomer): 
1
H NMR (CDCl3, 400 MHz):  = 7.55 (dd, J = 7.8, 1.6 Hz, 1H, HAr), 7.53 
(dd, J = 8.0, 1.2 Hz, 1H, HAr), 7.32 (pseudo dt, J = 1.2, 7.6 Hz, 1H, HAr), 7.09 (ddd, J= 8.0, 
7.4, 1.6 Hz, 1H, HAr), 4.23 (dd, J= 8.5, 7.2 Hz, 1H, 2-Ha), 4.12-4.05 (m, 2H, 3-H, 4-H), 3.69 
(dd, J= 8.5, 6.2 Hz, 1H, 2-Hb), 3.56 (pseudo t, J = 3.6 Hz, 1H, 3a-H), 3.43-3.30 (m, 2H, 6-H x 
2), 2.76 (dddd, J = 12.9, 8.9, 7.3, 6.6 Hz, 1H, 5-Ha), 1.71 (dddd, J = 12.9, 6.5, 4.5, 3.6 Hz, 1H, 
5-Hb), 2.36-2.22 (m, 2H, 3-Hb, 5-Ha), 1.11 (s, 9H, CH3x3) ppm; 
13
C-NMR (CDCl3, 100 
MHz):  = 140.8 (s; CAr), 132.6 (d; CHAr), 128.7 (d; CHAr), 128.3 (d; CHAr), 128.2 (d; CHAr), 
124. 1 (s; CAr), 81.1 (d; C-3a), 77.7 (d; C-4), 73.9 (s; CMe3), 72.9 (t; C-2), 55.4 (t; C-6), 53.3 
(d; C-3), 33.2 (t; C-5), 28.4 (q; 3C, CH3) ppm; 
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(R)-1-(2-bromophenyl)-2-[(2R,3S)-3-(tert-butoxy)pyrrolidin-2-yl]ethanol (81)  
 
A mixture of isoxazolidines 76 and 78 (12:1 ratio; 78 mg, 0.23 mmol) and zinc powder (75 
mg, 1.15 mmol) in AcOH/H2O (9:1) (2.20 mL) was heated in an oil bath at 90 °C for 2 h. The 
reaction mixture was diluted with MeOH, filtered through cotton wool and then concentrated 
under reduced pressure. The residue was dissolved in CH2Cl2 and the solution was basified to 
pH = 9 with a saturated aq. NaHCO3 solution and solid Na2CO3 at 0 °C. The two phases were 
separated. The aqueous phase was sequentially extracted with CH2Cl2 (3x10 mL) and EtOAc 
(2x10 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered 
and concentrated under reduced pressure. Purification of the crude product by chromatography 
on silica gel [eluent: CH2Cl2/MeOH (1% NH4OH) 90:10] afforded pyrrolidines 81 (64.3 mg) 
in 82% yield as a white solid.  
81: Rf = 0.31; m.p = 99-101 °C; []D
24
= + 74.92 (c = 0.79, CHCl3); 
1
H NMR (CDCl3, 400 
MHz):  = 7.66 (dd, J = 7.8, 1.7 Hz, 1H, HAr), 7.48 (dd, J = 7.9, 1.1 Hz, 1H, HAr), 7.33 
(pseudo dt, J = 1.1, 7.5 Hz, 1H, HAr), 7.09 (dt, J = 1.7, 7.6 Hz, 1H, HAr), 5.25 (dd, J = 7.1, 3.2 
Hz, 1H, CHOH), 4.32-3.66 (m, 2H, NH, OH), 3.96 (pseudo dt, J = 6.8, 3.7 Hz, 1H,3-H), 3.17-
2.99 (m,3H, 2-H,5-Ha, 5-Hb), 2.14-2.03 (m, 1H, 4-Ha), 1.96 (ddd, J = 14.5, 7.7, 3.2Hz, 1H, 
CHHCHOH), 1.84 (ddd, J = 14.5, 7.1, 3.8 Hz, 1H, CHHCHOH), 1.74-1.65 (m, 1H, 4-Hb), 
1.13 (s, 9H, CH3x3) ppm; 
13
C-NMR (CDCl3, 100 MHz):  = 143.6 (s; CAr),
 
132.4 (d; CHAr), 
128.3 (d; CHAr), 128.0 (d; CHAr), 127.4 (d; CHAr), 121.1 (s; CAr), 73.7 (d; C-3), 71.8 (d; 
CHOH), 63.8 (d, C-2), 44.4 (t, C-5), 35.7 (t, CH2CHOH), 35.1 (t, C-4), 28.5 (q, 3C, CH3) 
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ppm; IR (CDCl3): v
 
=  2976, 1601,1567, 1464, 1440, 1391, 1236, 1190, 1122, 1087, 1023 cm
-
1
; MS (EI): m/z (%) = 341.10, calcd. for C16H22BrNO2 [M + H]
+
: 342.10; [M + Na]
+
: 364.16; 
anal. calcd. for C16H24BrNO2 (341.10): C, 56.15; H, 7.07; N, 4.09; found C 55.90, H 7.30, N 
3.87.  
(S)-1-(2-bromophenyl)-2-[(2S,3S)-3-(tert-butoxy)pyrrolidin-2-yl]ethanol (82) 
 
Following the same procedure used to prepare 81, pyrrolidine 82 (62mg, 0.18 mmol) was 
obtained in 84% yield as a white solid starting from 77 (73 mg, 0.22 mmol).  
82: Rf = 0.21;
 
m.p = 58-60 °C; []D
25
=  – 45.78  (c = 1.025, CHCl3); 
1
H NMR (CDCl3, 400 
MHz):  = 7.64 (dd, J = 7.7, 1.5 Hz, 1H, HAr), 7.49 (dd, J = 7.9, 1.2 Hz, 1H, HAr), 7.32 (dt, J = 
1.1, 7.5 Hz, 1H, HAr), 7.09 (dt, J = 1.7, 7.6 Hz, 1H, HAr), 5.29 (pseudo t, J = 4.7Hz, 1H, 
CHOH )  4.97-3.81 (m, 2H, NH, OH), 3.93-3.87 (m, 1H, 3-H), 3.17 (ddd, J = 11.7, 9.0, 5.5 
Hz, 1H, 5-Ha), 2.94 (pseudo dt, J = 9.9, 4.6 Hz, 1H, 2-H), 2.83 (ddd, J = 11.7, 9.1, 6.4 Hz, 1H, 
5-Hb), 2.10-1.85 (m, 3H, CHHCHOH, 4-Ha), 1.71(dddd, J = 13.2, 9.0, 6.4, 4.2 Hz, 1H, 4-Hb), 
1.1 (s, 9H, CH3x3) ppm; 
13
C-NMR (CDCl3, 100 MHz):  = 144.2 (s; CAr),
 
132.6 (d; CHAr), 
128.2 (d; CHAr), 127.9 (d; CHAr), 127.2 (d; CHAr), 121.4 (s; CAr), 73.6 (d; C-3), 71.6 (d; 
CHOH), 59.1 (d, C-2), 43.7 (t, C-5), 34.3 (t, CH2CHOH), 33.7 (t, C-4), 28.3 (q, 3C, CH3) 
ppm; IR (CDCl3): v
 
= 2976, 1601,1567, 1464, 1438, 1390, 1364, 1231, 1191, 1112, 1078, 
1023 cm
-1
; anal. calcd. for C16H24BrNO2 (341.10): C, 56.15; H, 7.07; N, 4.09; found C 56.10, 
H 6.97, N 4.05.  
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(3S,3aR,5R)-3-(tert-butoxy)-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinolin-5-ol (83) 
 
The mixed solvent tBuOH/H2O (1:1) (1.65 mL) was added to a mixture of 81 (28 mg, 0.082 
mmol), CuI (7.8 mg, 0.041 mmol), copper powder (2.62 mg, 0.041 mmol), K3PO4 (34.9 mg, 
0.165 mmol) and L-proline (9.47 mg, 0.082 mmol) under nitrogen atmosphere in a vial. 
Nitrogen was bubbled through the reaction mixture to remove oxygen. The reaction mixture 
was heated at 90 °C in an oil bath for 12 h and then was filtered through a small pad of celite
®
. 
The solution was diluted with H2O and sequentially extracted with CH2Cl2 (3x10 mL) and 
EtOAc (2x10 mL). The combined organic phases were washed with NH4OH (1% H2O 
solution) and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification by flash chromatography on silica gel [eluent: CH2Cl2/MeOH (1% NH4OH) 98:2] 
afforded 83 (15.2 mg) in 71% yield as a colourless oil.  
83:
 
Rf = 0.32; []D
23
=  – 58.179  (c = 0.56 , CHCl3); 
1
H NMR (CDCl3, 400 MHz):  = 7.38 
(pseudo dt, J = 7.5, 1.3 Hz, 1H, HAr), 7.13 (dddd, J = 8.1, 7.4, 1.5, 0.7 Hz, 1H, HAr), 6.67 
(pseudo dt, J = 1.0, 7.4 Hz, 1H, HAr), 6.35 (dd, J = 8.1, 1.0 Hz, 1H, HAr), 4.96-4.85 (m, 1H, 5-
H), 3.82-3.72 (m, 1H, 3-H), 3.36-3.28 (m, 2H, 3-Ha, 1-Ha), 3.22 (pseudo dt, J = 7.9, 9.2 Hz, 
1H, 1-Hb), 2.56 (ddd, J = 11.5, 5.6, 2.9 Hz, 1H, 4-Ha), 2.28 (ddt, J = 12.4, 2.5, 7.5 Hz, 1H, 2-
Ha), 1.89 (pseudo dq, J = 12.4, 9.3 Hz, 1H, 2-Hb), 1.70 (br d, J = 7.4 Hz, 1H, OH)1.50 
(pseudo q, J = 11.5 Hz, 1H, 4-Hb), 1.24 (s, 9H, CH3x3) ppm; 
13
C-NMR (CDCl3, 100 MHz):  
= 143.7 (s; CAr),
 
128.6 (d; CHAr), 125.4 (d; CHAr), 124.8 (s; CAr), 115.7 (d; CHAr), 109.4 (d; 
CHAr), 73.7 (d; C-3), 67.3 (d; C-5), 59.8 (d, C-3a), 44.4 (t, C-1), 35.8 (t, C-4), 32.7 (t, C-2), 
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28.6 (q, 3C, CH3) ppm;  IR (CDCl3): v
 
= 2977, 2854, 1605,1501, 1481, 1461, 1364, 1189, 
1096, 1045 cm
-1
; anal. calc. for C16H23NO2 (261.17): C, 73.53; H, 8.87; N, 5.36; found C, 
73.15; H, 8.55; N, 5.04. 
 
(3S,3aS,5S)-3-(tert-butoxy)-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinolin-5-ol (84) 
 
Following the same procedure used to prepare 83, quinoline 84 (14.7 mg, 0.06 mmol) was 
obtained in 68% yield as a colourless oil starting from 82 (28.5 mg, 0.08 mmol).  
84:
 
Rf = 0.42; []D
23
= + 104.29 (c = 0.585, CHCl3); 
1
H NMR (CDCl3, 400 MHz):  = 7.38 
(pseudo dt, J = 7.5, 1.3 Hz, 1H, HAr), 7.11 (dddd, J = 8.1, 7.3, 1.6, 0.7 Hz, 1H, HAr), 6.64 
(pseudo dt, J = 0.9, 7.4 Hz, 1H, HAr), 6.39 (dd, J = 8.1, 0.9 Hz, 1H, HAr), 4.94 (dd, J = 11.2, 
5.5 Hz, 1H, 5-H), 4.11 (pseudo dt, J = 1.1, 4.0 Hz, 1H, 3-H), 3.62 (pseudo dt, J = 11.6, 3.6 Hz, 
1H, 3a-H), 3.34 (pseudo dt, J = 7.9, 9.0, 1H, 1-Ha), 3.24 (pseudo dt, J = 2.5, 8.8, 1H, 1-Hb), 
2.12 (ddd, J = 12.0, 5.5, 3.4 Hz, 1H, 4-Ha), 2.08-1.93 (m, 2H, 2-Ha, 2-Hb), 1.94  (pseudo q, J 
= 11.6 Hz, 1H, 4-Hb), 1.87-1.69 (m, 1H, OH), 1.19 (s, 9H, CH3x3) ppm; 
13
C-NMR (CDCl3, 
100 MHz):  = 144.2 (s; CAr),
 
128.5 (d; CHAr), 125.2 (d; CHAr), 124.8 (s; CAr), 115.2 (d; 
CHAr), 110.2 (d; CHAr), 71.8 (d; C-3), 67.8 (d; C-5), 59.9 (d, C-3a), 45.2 (t, C-1), 33.5 (t, C-4), 
32.6 (t, C-2), 28.3 (q, 3C, CH3) ppm; IR (CDCl3): v
 
= 2976, 2858, 1605,1502, 1476, 1461, 
1364, 1319, 1187, 1105, 1042 cm
-1
. 
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(Z)-N-benzylidene-1-phenylmethanamine oxide (86)
 124
 
 
 
 
NaHCO3 (1.06 g, 12.67 mmol) was added to a stirred solution of dibenzylamine (0.5 g, 2.53 
mmol) in a 4:1 mixture of CH3CN–THF (4.68 mL) and aqueous Na2EDTA (0.01 M, 3.54 
mL). The reaction mixture was cooled at 0 °C and then oxone (2.18 g, 3.55 mmol) was added 
portionwise over 1.5 h. The mixture was stirred at 0 °C for another 1hour. The reaction 
mixture was diluted with EtOAc (20 mL) and deionised H2O (30 mL). The two phases were 
separated and the aqueous solution was sequentially extracted with EtOAc (2x20 mL) and 
CH2Cl2 (3x20 mL) respectively. The combined organic layers were washed with brine (30 
mL), dried over Na2SO4 and concentrated under reduced pressure. Purification of the crude 
product by chromatography on silica gel (eluent: EtOAc/petroleum ether 5:5) afforded 
pyrrolidine 86 (0.512 g, 2.43 mmol) in 96% yield as a white solid.  
 
(3S*,5R*) and (3S*,5S*)-2-benzyl-5-(2-bromophenyl)-3-phenylisoxazolidine (87 and 88) 
 
2-Bromostyrene (0.254 mL, 1.962 mmol) was added to a solution of the nitrone 86 (0.2 g, 
0.95 mmol) in xylene (1.9 mL) and the reaction mixture was heated at 150 °C for 6 h in oil 
bath. The solvent was evaporated under a nitrogen stream to obtain a mixture of adducts 87 
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and 88. The residue was purified by flash chromatography on silica gel (eluent: 
EtOAc/petroleum ether 3:97) to afford an inseparable mixture of 87 and 88 (0.309 g, 0.78 
mmol, ca. 3.1:1 ratio) in 83% yield as a colourless oil.  
87 (ca 3.1:1 mixture with isomers 88): Rf = 0.35; 
1
H NMR (CDCl3, 400 MHz):  = 7.65 (d, J = 
7.8 Hz, 1H, HAr), 7.54-7.22 (m, 12H, HAr ), 7.07 (pseudo dt, J = 1.8 Hz, 7.5 Hz, 1H, HAr), 5.44 
(dd, J = 8.4, 6.5 Hz, 1H, 5-H), 4.08 (A part of an AB system, J = 14.3 Hz, CH2Ph), 4.00 (dd, J 
= 9.4, 7.3 Hz, 1H, 3-H), 3.82 (B part of an AB system, J = 14.0 Hz, CH2Ph), 3.41 (ddd, J = 
12.6, 8.4, 7.3 Hz, 1H, 4-Ha), 2.22 (ddd, J = 12.6, 9.4, 6.5 Hz, 1H, 4-Hb). 
13
C-NMR 
(CDCl3,100 MHz):  = 143.4 (s; CAr), 139.0 (s; CAr), 137.8 (s; CAr), 132.2 (d; CHAr), 129.0 (d; 
2C, CHAr), 128.6 (d; 2C, CHAr), 128.2 (d; CHAr), 128.1 (d; 2C, CHAr), 127.9 (d; CHAr), 127.8 
(d; 2C, CHAr), 127.5 (d; CHAr), 127. 2 (d; CHAr  x 2), 120.9 (s; CAr), 77.3 (d; C-5), 71.2 (d; C-
3), 60.2 (t; CH2Ph), 47.7 (t; C-4) ppm; IR: v = 3030, 2984, 2926, 2870, 1603, 1568, 1495, 
1354, 1202, 1120 cm
-1
; MS (EI): m/z (%) = 396 (M
+2
,16 ), 394 (M,15), 273 (39), 271 (41), 
194 (17), 192 (100), 92 (73), 77 (69), 51 (45); anal. calcd. for C22H20BrNO (394.30): C, 67.01; 
H, 5.11; N, 3.55; found C, 66.66.; H, 5.14; N, 3.57. 
88: 
1
H NMR (CDCl3, 400 MHz):  = 7.65 (d, J = 7.8 Hz, 1H, HAr), 7.54-7.22 (m, 12H, HAr), 
7.13 (pseudo dt, J = 1.8, 7.7 Hz, 1H, HAr), 5.52 (dd, J = 8.8, 5.6 Hz, 1H, 5’-H), 4.10 (A part of 
an AB system, J = 14.3 Hz, CH2Ph), 3.95-3.89 (m, 1H, 3-H), 3.92 (B part of an AB system, J 
= 14.3 Hz, CH2Ph’), 2.98 (pseudo dt, J = 9.0, 12.5 Hz, 1H, 4-Ha), 2.43 (ddd, J = 12.5, 7.8, 5.6 
Hz, 1H, 4-Hb). 
13
C-NMR (CDCl3, 100 MHz):  =141.5 (s; CAr’), 132.5 (d; CHAr’), 129.0 (d; 
2C, CHAr), 128.7 (d; 2C, CHAr), 128.6 (d; CHAr), 128.2 (d; 2C, CHAr), 127.9 (d; CHAr), 127.8 
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(d; 2C, CHAr), 127.3 (d; CHAr), 127. 2 (d; CHAr x 2), 121.5 (s; CAr), 77.4 (d; C-5), 69.8 (d; C-
3), 59.8 (t; CH2Ph), 46.7 (t; C-4) ppm; 
(1R*,3S*) and (1S*,3S*)-3-(benzylamino)-1-(2-bromophenyl)-3-phenylpropan-1-ol (89 
and 90) 
 
A mixture of isoxazolidines 87 and 88 (3.1:1 ratio; 0.22 g, 0.56 mmol) and zinc powder (0.18 
g, 2.8 mmol) in AcOH:H2O [9:1 (v/v), 5.4 mL] was heated in an oil bath at 85 °C for 3 h. The 
reaction mixture was diluted with MeOH, filtered through cotton wool and then filtrate was 
concentrated under reduced pressure. The white residue was dissolved in CH2Cl2, and the 
solution was basified up to pH = 9 with a saturated aq. NaHCO3 solution and solid Na2CO3 at 
0 °C. The two phases were separated. The aqueous phase was sequentially extracted with 
CH2Cl2 (3x30 mL) and EtOAc (2x20 mL). The combined organic phases were washed with 
brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give a crude 
mixture of the two diastereomeric amino alcohols 89 and 90 in ca 2:1 ratio (calculated by 
1
H 
NMR). Purification of the crude product by chromatography on silica gel [eluent: EtOAc (1% 
TEA) /petroleum ether 20:80] afforded 89 (93 mg, 42%) and a ca 1:1 mixture of 89 and 90 
(111 mg, 50%) in 92% overall yield as yellow viscous oils.  
89: Rf = 0.29; 
1
H NMR (CDCl3, 400 MHz):  = 7.71 (dd, J = 7.8, 1.7 Hz, 1H, HAr), 7.46 (dd, J 
= 7.9, 1.1 Hz, 1H, HAr ), 7.42-7.24 (m, 11H, HAr), 7.08 (pseudo dt, J = 1.8, 7.6, 1H, HAr ), 5.30 
(dd, J = 10.3, 1.8  Hz, 1H, 1-H), 4.04  (dd, J = 11.3, 2.5 Hz, 1H, 3-H), 3.72 (A part of an AB 
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system, J = 12.6 Hz, CH2Ph), 3.65 (B part of an AB system, J = 12.6 Hz, CH2Ph), 2.14 
(pseudo dt, J = 14.5, 2.2 Hz, 1H, 2-Ha), 1.73 (ddd, J = 14.5, 11.3, 10.3 Hz, 1H, 2-Hb). 
13
C-
NMR (CDCl3,100 MHz):  =143.6 (s; CAr), 142.7 (s; CAr), 138.9 (s; CAr), 132.3 (d; CHAr), 
128.9 (d; 2C, CHAr), 128.6 (d, 2C, CHAr), 128.4 (d, 3C, CHAr),  127.6 (d; CHAr), 127.5 (d; 
CHAr), 127.4 (d; CHAr), 127.3 (d; CHAr), 126.3 (d; 2C, CHAr), 121.4 (s, CAr), 74.1 (d; C-4), 
63.2 (d; C-2), 51.1 (t; CH2Ph), 44.2 (t; C-3) ppm; IR: v = 3209, 3107, 3066, 3029, 2911, 2856, 
1601, 1568, 1494, 1453, 1201, 1124, 1095, 1025 cm
-1
; MS (EI): m/z (%) = 196 (93), 194 (3), 
157 (1), 155 (1), 108 (6), 106 (12), 91 (100), 79 (4), 77 (16); anal. calcd. for C22H22BrNO 
(396.32): C, 66.67; H, 5.60; N, 3.53; found C, 66.29.; H, 5.64; N, 3.43 
90: 
1
H NMR (CDCl3, 300 MHz) Detectable signal:  = 5.26-5.21 (m, 1H, 1-H), 3.82 (dd, J = 
9.1, 2.9 Hz, 1H, 3-H), 2.26 (ddd, J = 14.7, 9.2, 3.8 Hz, 1H, 2-H).  
(2S*,4R*) and (2S*,4S*)-1-benzyl-2-phenyl-1,2,3,4-tetrahydroquinolin-4-ol (91a and 91b) 
 
The Mixed solvent tBuOH/H2O (1:1) (1.34 mL) were added to a mixture of 89 and 90 (ca 1:1 
ratio; 26.5 mg, 0.067 mmol), CuI (6.4 mg, 0.033 mmol), copper powder (2.12 mg, 0.033 
mmol), K3PO4 (28.4 mg, 0.134 mmol) and L-proline (7.7 mg, 0.067 mmol) under nitrogen 
atmosphere in a vial. The nitrogen was bubbled through the reaction mixture to remove 
oxygen. The reaction mixture was heated at 90 °C for 12 h in oil bath and then was filter 
through small pad of Celite
®
. The solution was diluted with H2O and sequentially extracted 
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with CH2Cl2 (3x10 mL) and EtOAc (2x10 mL). The combined organic phases were 
sequentially washed with NH4OH (1% H2O solution) and brine, dried over Na2SO4, filtered 
and concentrated under reduced pressure. Purification by flash chromatography (eluent: 
CH2Cl2) afforded 91a and 91b (10:1 trans-cis diastereomeric ratio; 9.2 mg, 0.029 mmol) in 
44% overall yield as a yellow oil along with recovered 89 (4 mg, 30%). 
91 (ca. 10:1 mixture): Rf = 0.32; 
1
H NMR (CDCl3, 400 MHz):  = 7.36-7.12 (m, 12H, HAr), 
6.73 (pseudo dt, J = 1.0, 7.3 Hz, 2H, HAr), 4.80  (dd, J = 9.0, 4.8 Hz, 1H, 4-H), 4.79 (A part of 
an AB system, J = 17 Hz, CH2Ph), 4.71 (dd, J = 11, 5.5 Hz, 1H, 2-H),  4.18 (B part of an AB 
system, J = 17 Hz, CH2Ph), 2.51 (pseudo ddd, J = 11.5, 9.0, 4.8 Hz, 1H, 3-Ha), 1.35 (d, J = 
9.0 Hz, 1H, 3-Hb). 
13
C-NMR (CDCl3,100 MHz):  =144.4 (s; CAr), 142.5 (s; CAr), 138.3 (s; 
CAr), 129.3 (d; CHAr), 128.9 (d; 2C, CHAr), 128.8 (d, CHAr), 128.5 (d, 2C, CHAr),  127.2 (d; 
CHAr), 126.8 (d; CHAr), 126.6 (d; 2C, CHAr), 126.5 (d; 2C, CHAr), 125.1 (s; CAr), 116.6 (d, 
CHAr), 111.8 (d; CHAr), 66.5 (d; C-4), 59.6 (d; C-2), 53.1 (t; CH2Ph), 39.4 (t; C-3) ppm; IR: v 
= 3107, 3064, 3029, 2924, 1604, 1574, 1495, 1452, 1346, 1226, 1124, 1053 cm
-1
; MS (EI): 
m/z (%) = 315 (M
+
), 297 (15), 296 (12), 220 (33), 206 (23), 205 (15), 128 (14), 91 (100); anal. 
calcd. for C22H21NO (315.41): C, 83.78; H, 6.71; N, 4.44; found C, 83.03.; H, 6.39; N, 4.20 
(3S*,5R*) and (3S*,5S*)-5-(2-bromophenyl)-3-(4-methoxyphenyl)-2-methylisoxazolidine 
(93 and 94) 
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2-Bromostyrene 50 (0.078 mL, 0.605 mmol) was added to a solution of nitrone 92 (200 mg, 
1.21 mmol) in toluene (2.4 mL) and the reaction mixture was heated at 110 °C overnight in oil 
bath. The solvent was evaporated under a nitrogen stream and the residue was purified by 
flash chromatography on silica gel (eluent: EtOAc/petroleum ether 5:95) to give the cis 
diastereoisomer 93 (106.5 mg, 0.306 mmol) in 51% yield and the trans diastereoisomer 94 
(103.5 g, 0.297 mmol) in 49% yield as colourless oils  
93: Rf = 0.24; 
1
H NMR (CDCl3, 400 MHz):  = 7.89 (dd, J = 7.8, 1.6 Hz, 1H, HAr), 7.51 (dd, J 
= 7.9, 1.2 Hz, 1H, HAr),7.37 (pseudo dt, J = 1.2, 7.6 Hz, 1H, HAr), 7.20 (m, 2H, HAr), 7.12 
(pseudo dt, J = 1.7, 7.6 Hz, 1H, HAr), 6.85-6.80 (m, 2H, HAr), 5.44 (dd, J = 8.3, 6.6 Hz, 1H, 5-
H), 3.77 (s, 3H, OCH3), 3.71-3.60 (m, 1H, 3-H), 3.33 (ddd, J = 12.6, 8.3, 7.1 Hz, 1H, 4-Ha), 
2.67 (s, 3H, NCH3), 2.19 (ddd, J = 12.6, 9.8, 6.6 Hz, 1H, 4-Hb); 
13
C-NMR (CDCl3, 100 MHz): 
 = 159.3 (s; CAr), 143.5 (s; CAr), 132.3 (d; CHAr), 130.3 (s; CAr), 128.9 (d; 2C, CHAr), 128.3 
(d, CHAr), 127.6 (d, CHAr),  127.1 (d; CHAr), 120.9 (s; CAr), 114.0 (d; 2C, CHAr), 77.2 (d; C-5), 
73.5 (d; C-3), 55.2 (q; OCH3), 48.0 (t; C-4), 43.2 (q; NCH3) ppm; IR: v = 3069, 2960, 2838, 
1611, 1513, 1465, 1439, 1248, 1173, 1036, 1020 cm
-1
; MS (EI): m/z (%) = 350 (M+2, 1), 348 
(M
+
, 2), 303 (7), 301 (7), 165 (100), 166 (11), 164 (97), 135 (22), 133 (10), 91 (17), 77 (28); 
anal. calcd. for C17H18BrNO2 (348.23): C, 58.63; H, 5.21; N, 4.02; found C, 58.75; H, 5.20; N, 
3.94 
94: Rf = 0.15; 
1
H NMR (CDCl3, 400 MHz):  = 7.69 (dd, J = 7.8, 1.5 Hz, 1H, HAr), 7.54 (dd, J 
= 7.9, 1.2 Hz, 1H, HAr), 7.38 - 7.30 (m,3H, HAr), 7.15 (pseudo dt, J = 1.7, 7.7 Hz, 2H, HAr), 
6.92-6.87 (m, 2H, HAr),  5.51 (dd, J = 8.9, 5.6 Hz, 1H, 5-H), 3.81 (s, 3H, OCH3), 3.67 - 3.48 
(m,1H, 3-H), 3.00 - 2.88 (m, 1H, 4-Ha), 2.71 (s, 3H, NCH3), 2.40 (ddd, J = 12.6, 7.7, 5.6 Hz, 
1H, 4-Hb); 
13
C-NMR (CDCl3,100 MHz):  = 159.4 (s; CAr), 141.3 (s; CAr), 132.6 (d; CHAr), 
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130.5 (s; CAr), 128.9 (d; 2C, CHAr), 128.7 (d, CHAr), 127.4 (d, CHAr),  127.1 (d; CHAr), 121.7 
(s; CAr), 114.1 (d; 2C, CHAr), 77.2 (d; C-5), 72.3 (d; C-3), 55.2 (q; OCH3), 46.7 (t; C-4), 43.1 
(q; NCH3) ppm; IR: v = 3069, 2960, 2838, 1611, 1513, 1470, 1442, 1304, 1278, 1175, 1035  
cm
-1
; MS (EI): m/z (%) = 349 (M+1, 4), 347 (M
+
, 4), 303 (4), 301 (5), 185 (18), 183 (17), 165 
(100), 164 (88), 91 (22), 89 (13), 77 (40), 75 (16); anal. calcd. for C17H18BrNO2 (348.23): C, 
58.63; H, 5.21; N, 4.02; found C, 58.71; H, 5.20; N, 3.99. 
(1R*,3S*)-1-(2-bromophenyl)-3-(4-methoxyphenyl)-3-(methylamino)propan-1-ol (95) 
                                            
A mixture of isoxazolidine 93 (0.222 g, 0.637 mmol) and zinc powder (0.208 g, 3.19 mmol) in 
AcOH:H2O [9:1(v/v), 5.5 mL] was heated in an oil bath at 85 °C for 3 h. The reaction mixture 
was diluted with MeOH and filtered through cotton wool. The filtrate was concentrated under 
reduced pressure and the residue was dissolved in CH2Cl2. The solution was basified to pH = 9 
with a saturated aq. solution of NaHCO3 and solid Na2CO3 at 0 °C. The two phases were 
separated and the aqueous phase was extracted with CH2Cl2 (3x30 mL) and EtOAc (2x20 
mL). The combined organic phases were sequentially washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. Purification of the crude product by 
chromatography on silica gel [eluent: CH2Cl2 / MeOH (1%NH4OH) 93:7] afforded 95 (210 
mg, 0.6 mmol) in 94% overall yield as a colourless viscous oil. 
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95: Rf = 0.31; 
1
H NMR (CDCl3, 400 MHz):  = 7.70 (dd, J = 7.8, 1.7 Hz, 1H, HAr), 7.46 (dd, J 
= 8.0, 1.2 Hz, 1H, HAr ), 7.36-7.31 (m, 1H, HAr), 7.17-7.12 (m, 1H, HAr), 7.08 (dt, J = 1.7, 7.6 
Hz, 1H, HAr), 6.90-6.85 (m, 2H, HAr), 5.29 (dd, J = 10.3, 1.9 Hz, 1H, 1-H), 3.80 (dd, J = 11.2, 
2.6, Hz, 1H, 3-H), 3.80 (s, 3H, OCH3), 2.31 (s, 3H, NCH3), 2.08 (pseudo dt, J = 14.4, 2.3 Hz, 
1H, 2-Ha), 1.68 (ddd, J = 14.4, 11.2, 10.3, 1H, 2-Hb), 
13
C-NMR (CDCl3, 100 MHz):  =158.9 
(s; CAr), 143.8 (s; CAr), 134.7 (s; CAr), 132.3 (d; CHAr), 128.3 (d; 2C, CHAr), 127.6 (d, CHAr), 
127.4 (d, CHAr),  127.3 (d; CHAr), 121.4 (s; CAr), 114 (d; 2C, CHAr), 74.1 (d; C-1), 64.8 (d; C-
3), 55.3 (q; OCH3), 43.7 (t; C-2), 33.2 (q; NCH3) ppm; IR: v = , 2952, 2909, 2803, 1609, 1513, 
1464, 1442, 1306, 1248, 1177, 1034  cm
-1
; MS (EI): m/z (%) = 350 (M), 187 (4), 185 (7), 165 
(1), 163 (1), 151 (50), 91 (22), 77 (51), 42 (100); anal. calcd. for C17H20BrNO2 (350.25): C, 
58.30; H, 5.76; N, 4.00; found C, 58.08; H, 5.59; N, 3.79; 
(1S*,3R*)-1-(2-bromophenyl)-3-(4-methoxyphenyl)-3-(methylamino)propan-1-ol (96) 
 
Following the same procedure to prepare 95, the diastereomeric amino alcohol 96 (0.23 g, 
0.66 mmol, 91% yield, white solid) was obtained starting from 94 (0.25 g, 0.72 mmol).  
96: Rf = 0.48; m.p = 100–102 °C ;
1
H NMR (CDCl3, 400 MHz):  = 7.71 (dd, J = 7.7, 1.7 Hz, 
1H, HAr), 7.46 (dd, J = 7.9, 1.2 Hz, 1H, HAr),7.37 (pseudo dt, J = 1.2, 7.7 Hz, 1H, HAr), 7.16-
7.11 (m, 2H, HAr), 7.11 (pseudo dt, J = 1.7, 7.5 Hz, 1H, HAr), 6.89-6.84 (m, 2H, HAr), 5.22 (dd, 
J = 6.0, 3.6 Hz, 1H, 1-H), 3.80 (s, 3H, OCH3), 3.64 (dd, J = 8.8, 3.0, Hz, 1H, 3-H), 2.35 (s, 
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3H, NCH3), 2.22 (ddd, J = 14.7, 8.8, 3.6 Hz, 1H, 2-Ha), 2.04 (ddd, J = 14.7, 6.0, 3.0 Hz, 1H, 
2-Hb), 
13
C-NMR (CDCl3, 100 MHz):  =158.8 (s; CAr), 143.7 (s; CAr), 133.8 (s; CAr), 132.6 
(d; CHAr), 128.3 (d; CHAr), 127.7 (d; CHAr), 127.6 (d; 2C, CHAr), 127.3 (d; CHAr),  121.3 (s; 
CAr), 113.9 (d; 2C, CHAr), 71.5 (d; C-1), 61.5 (d; C-3), 55.3 (q; OCH3), 40.1 (t; C-2), 33.3 (q; 
NCH3) ppm; IR: v = , 3065, 2954, 2913, 2838, 1610, 1513, 1464, 1442, 1305, 1240, 1177, 
1036 cm
-1
; MS (EI): m/z (%) = 350 (M), 318 (3), 320 (3), 187 (3), 185 (6), 152 (4), 150 (100), 
91 (19), 77 (42); anal. calcd. for C17H20BrNO2 (350.25): C, 58.30; H, 5.76; N, 4.00; found C, 
58.23; H, 5.89; N, 3.95 
(2S*,4R*)-2-(4-methoxyphenyl)-1-methyl-1,2,3,4-tetrahydroquinolin-4-ol (97) 
 
The mixed solvent tBuOH: H2O [1:1 (v/v), 1.45 mL] was added to a mixture of 95 (25.5 mg, 
0.073 mmol), CuI (6.93 mg, 0.036 mmol), copper powder (2.31 mg, 0.036 mmol), K3PO4 
(30.91 mg, 0.147 mmol) and L-proline (8.38 mg, 0.073 mmol) under nitrogen atmosphere in a 
vial. Nitrogen was bubbled through the reaction mixture to remove oxygen. The reaction 
mixture was heated at 90 °C for 12 h in an oil bath and then was filtered through a small pad 
of Celite
®
. The solution was diluted with H2O and sequentially extracted with CH2Cl2 (3x10 
mL) and EtOAc (2x5 mL). The combined organic phases were washed with NH4OH (1% H2O 
solution) and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification by flash chromatography on silica gel [eluent: EtOAc/petroleum ether (1% TEA) 
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20:80] afforded 97 (7.4 mg, 0.027 mmol) in 38% yield as a yellow liquid along with unreacted 
starting material 95 (8.6 mg, 0.024 mmol). 
97: Rf = 0.21; 
1
H NMR (CDCl3, 400 MHz):  = 7.26 -7.19 (m, 4H, HAr), 6.88 (Pseudo dt, J = 
2.5, 9.3 Hz, 2H, HAr), 6.76 - 6.70 (m, 2H, HAr), 4.66 (dd, J = 5.3, 3.5 Hz, 1H, 4-H), 4.42 (dd, J 
= 9.5, 4.3, Hz, 1H, 2-H), 2.81 (s, 3H, OCH3), 2.76 (s, 3H, NCH3), 2.18 (ddd, J = 11.6, 7.2, 6.1 
Hz, 1H, 3-Ha), 2.08 (dt, J = 9.6, 3.5 Hz, 1H, 3-Hb), 
13
C-NMR (CDCl3, 100 MHz):  =158.8 
(s; CAr), 146.4 (s; CAr), 135.6 (s; CAr), 129.5 (d; CHAr), 128.3 (d; CHAr), 127.9 (d; 2C, CHAr), 
124.3 (s; CHAr),  116.2 (d; CHAr), 114.1 (d; 2C, CHAr), 112.1 (d; CHAr), 65.3 (d; C-4), 58.8 (d; 
C-2), 55.2 (q; OCH3), 39.6 (t; C-3), 37.2 (q; NCH3) ppm; IR: v = 2956, 2927, 2838, 1605, 
1511, 1501, 1373, 1247, 1173, 1040   cm
-1
; MS (EI): m/z (%) = 269 (M
+
), 251 (32), 250 (47), 
220 (2), 144 (100), 91 (2), 77 (9), 51 (5); anal. calcd. for C17H19NO2 (269.34): C, 75.81.30; H, 
7.11; N, 5.20; found C, 75.38; H, 7.04; N, 4.58 
(2S*,4S*)-2-(4-methoxyphenyl)-1-methyl-1,2,3,4-tetrahydroquinolin-4-ol (98) 
 
Following the same procedure to prepare 97, the diastereomeric quinoline 98 (17 mg, 0.063 
mmol, 71% yield, yellow waxy solid) was obtained starting from 96 (31 mg, 0.09 mmol). 
98: Rf = 0.42; 
1
H NMR (CDCl3, 400 MHz):  = 7.35 (Pseudo dt, J = 1.4, 7.3 Hz, 1H, HAr), 
7.23 (dt, J = 7.3, 8.6 Hz, 1H, HAr), 7.14 (pseudo dt, J = 2.5, 9.3 Hz, 2H, HAr), 6.86 (pseudo dt, 
J = 2.5, 9.3 Hz, 2H, HAr), 6.77 - 6.70 (m, 2H, HAr), 4.83 (dd, J = 12.3, 7.5 Hz, 1H, 4-H), 4.45 
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(dd, J = 7.7, 4.8, Hz, 1H, 2-H), 3.79 (s, 3H, OCH3), 2.80 (s, 3H, NCH3), 2.43 (dt, J = 4.7, 6.0 
Hz, 1H, 3-Ha), 2.24 (dt, J = 7.6, 13.2 Hz, 1H, 3-Hb), 
13
C-NMR (CDCl3, 100 MHz):  =158.7 
(s; CAr), 145.7 (s; CAr), 134.8 (s; CAr), 129.1 (d; CHAr), 127.6 (d; 2C, CHAr), 127.3 (d; CHAr), 
125.7 (s; CHAr),  116.5 (d; CHAr), 114.2 (d; 2C, CHAr), 111.5 (d; CHAr), 66.6 (d; C-4), 61.2 (d; 
C-2), 55.2 (q; OCH3), 41.1 (t; C-3), 37.7 (q; NCH3) ppm; IR: v = 2957, 2838, 1606, 1510, 
1455, 1339, 1247, 1171, 1097, 1037 cm
-1
; MS (EI): m/z (%) = 269 (M
+
), 251 (27), 250 (39), 
206 (6), 144 (100), 77 (8); anal. calcd. for C17H19NO2 (269.34): C, 75.81.30; H, 7.11; N, 5.20; 
found C, 75.52; H, 7.23; N, 5.41 
(3S*,5R*) and (3S*,5S*)-5-(2-bromophenyl)-2-methyl-3-(4-nitrophenyl) isoxazolidine 
(100 and 101) 
 
2-Bromostyrene 50 (0.079 mL, 0.61 mmol) was added to a solution of nitrone 99 (220 mg, 
1.22 mmol) in chlorobenzene (2.4 mL) and the reaction mixture was heated at 150 °C for 3 h 
in an oil bath. The solvent was evaporated under a nitrogen stream and the residue was 
purified by flash chromatography on silica gel (eluent: EtOAc/petroleum ether 10:90), to 
afford an inseparable mixture of 100 and 101 (2.4:1 ratio; 219.5 mg, 0.604 mmol) in 99% 
overall yield as a yellow oil. A pure sample of the major isomer 100 was obtained after 
repeated purification and used for the characterization. 
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100: Rf = 0.4; 
1
H NMR (CDCl3, 400 MHz):  = 8.17 – 8.13 (m, 2H, HAr), 7.80 (dd, J = 7.8, 1.6 
Hz, 1H, HAr),7.50–7.46 (m, 3H, HAr), 7.37 (pseudo dt, J = 1.0, 7.8 Hz, 1H, HAr), 7.13 (pseudo 
dt, J = 1.7, 7.7 Hz, 1H, HAr), 5.49 (dd, J = 8.2, 6.4 Hz, 1H, 5-H), 3.88 (pseudo t, J = 8.3 Hz, 
1H, 3-H), 3.46 (ddd, J = 12.7, 8.2, 7.7 Hz, 4-Ha), 2.74 (s, 3H, NCH3), 2.15 (ddd, J = 12.7, 9.0, 
6.4 Hz, 1H, 4-Hb); 
13
C-NMR (CDCl3, 100 MHz):  =147.0 (s; CAr), 146.9 (s; CAr), 142.5 (s, 
CAr), 132.4 (d; CHAr), 128.6 (d; CHAr), 128.4 (d; 2C, CHAr), 127.6 (d, CHAr), 126.8 (d, CHAr),  
123.9 (d; 2C, CHAr), 121 (s; CAr), 77.3 (d; C-5), 72.7 (d; C-3), 48.0 (t; C-4), 43.5 (q; NCH3) 
ppm; IR: v = 3065, 2960, 2852, 1606, 1524, 1466, 1440, 1351, 1109, 1042, 1021 cm
-1
; MS 
(EI): m/z (%) = 365 (M
+2
, 2), 263 (M
+
, 3), 318 (30), 316 (29), 272 (17), 270 (18), 193 (3), 191 
(21), 181 (8), 179 (100), 77 (42);  
101: 
1
H NMR (CDCl3, 300 MHz) Detectable signal:  = 8.26 – 8.20 (m, 2H, HAr), 7.67 (dd, J 
= 7.1, 1.6 Hz, 1H, HAr), 7.17 (dt, J = 1.7, 7.5 Hz, 1H, HAr), 5.00 (dd, J = 8.8, 6.2 Hz, 1H, 5-H), 
3.79 (pseudo t, J = 7.9 Hz, 1H, 3-H), 2.90 (pseudo dt, J = 12.6, 8.7 Hz, 4-H), 2.50 (ddd, J = 
12.6, 8.1, 6.2 Hz, 4-H). 
 (1S*,3R*) and (1S*,3S*)-3-(4-aminophenyl)-1-(2-bromophenyl)-3-
(methylamino)propan-1-ol (102 and 103)  
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A mixture of isoxazolidines 100 and 101 (2.4:1 ratio; 0.04 g, 0.11 mmol) and zinc powder 
(0.037 g, 0.56 mmol) in AcOH:H2O [9:1 (v/v), 0.98 mL] was heated in an oil bath at 80 °C for 
3 h. The reaction mixture was diluted with MeOH and filtered through cotton wool. The 
filtrate was concentrated under reduced pressure and the residue was dissolved in CH2Cl2, The 
solution was basified to pH = 9 with a saturated aq. NaHCO3 solution and solid Na2CO3 at 0 
°C. The two phases were separated. The aqueous phase was sequentially extracted with 
CH2Cl2 (3x10 mL) and EtOAc (2x10 mL). The combined organic phases were washed with 
brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification of 
the crude product by chromatography on silica gel [eluent: CH2Cl2 / MeOH (2% NH4OH) 9:1] 
afforded a mixture of 102 and 103 (2.2:1 ratio; 0.025 g, 0.07 mmol) in 62% yield as a yellow 
viscous oil. A pure sample of the major compound 102 was obtained after repeated 
purification and used for the characterization. 
102: Rf = 0.4; 
1
H NMR (CDCl3, 400 MHz):  = 7.69 (dd, J = 7.8, 1.6 Hz, 1H, HAr), 7.45 (dd, J 
= 8.0, 1.2 Hz, 1H, HAr),7.32 (pseudo dt, J = 1.0 7.5 Hz, 1H, HAr), 7.07 (pseudo dt, J = 1.7, 7.6 
Hz, 1H, HAr), 7.04-7.00 (m, 2H, HAr), 6.69-6.62 (m, 2H, HAr), 5.27 (dd, J = 10.4, 1.8 Hz, 1H, 
1-H), 3.76 (dd, J = 11.2, 2.6  Hz, 1H, 3-H), 2.65 (br s, 1H, NH),  2.31 (s, 3H, NCH3), 2.08 
(pseudo dt, J = 14.4,  2.3 Hz, 1H, 2-Ha); 1.71 (pseudo dt, J = 14.4, 10.8 Hz, 1H, 2-Hb); 
13
C-
NMR (CDCl3, 50 MHz):  = 145.3 (s; CAr), 143.5 (s; CAr), 132.0 (d; CHAr), 131.7 (s; CAr), 
127.9 (d; CHAr), 127.2 (d; 2C, CHAr), 127.0 (d, CHAr), 121.1 (d, CHAr), 119.8 (s; CAr),114.8 
(d; 2C, CHAr), 73.7 (d; C-1), 64.5 (d; C-3), 43.1 (t; C-2), 32.8 (q; NCH3) ppm; IR: v = 2950, 
2914, 1624, 1586, 1466, 1442, 1275, 1180, 1074, 1017 cm
-1
; MS (EI): m/z (%) = 359, 357, 
337, 335, 306, 304, 136 (10), 134 (100), 91 (5), 77 (10); anal. calcd. for C16H17BrN2O3 
(364.04): C, 57.32 ; H, 5.71; N, 8.36; found C, 56.50 ; H, 5.36 ; N, 7.57. 
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103: 
1
H NMR (CDCl3, 300 MHz) Detectable signal:  = 5.23 (dd, J = 5.9, 3.5 Hz, 1-H), 3.82 
(dd, J = 11.1, 2.5 Hz, 3-H), 2.34 (s, 3H, NCH3). 
(2S*,4R*)- and (2S*,4S*)-2-(4-aminophenyl)-1-methyl-1,2,3,4-tetrahydroquinolin-4-ol 
(104a and 104b)  
 
The mixed solvent tBuOH: H2O (1:1) (1.49 mL) was added to a mixture of 102 and 103 (1:1 
ratio; 25 mg, 0.07 mmol), CuI (7.1 mg, 0.037 mmol), copper powder (2.37 mg, 0.037 mmol), 
K3PO4 (31.66 mg, 0.15 mmol) and L-proline (8.6 mg, 0.07 mmol) under nitrogen atmosphere 
in a vial. Nitrogen was bubbled through the reaction mixture to remove oxygen. The reaction 
mixture was heated at 90 °C for 12 h in an oil bath and then was filtered through a small pad 
of Celite
®
. The solution was diluted with H2O and sequentially extracted with CH2Cl2 (3x10 
mL) and EtOAc (2x5 mL). The combined organic phases were washed with NH4OH (1% H2O 
solution) and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification by flash chromatography [eluent: EtOAc/petroleum ether (1% TEA) 6:4] afforded 
104a and 104b (7:1 trans-cis diastereomeric ratio; 9.3 mg, 0.036 mmol) in 50 % overall yield 
as yellow oils.  
104a (ca. 7:1 mixture with 104b): Rf = 0.34; 
1
H NMR (CDCl3, 400 MHz):  = 7.17-7.13 (m, 
2H, HAr), 6.99 (pseudo dt, J = 2.3, 8.8 Hz, 2H, HAr), 6.61-6.54 (m, 4H, HAr), 4.58 (dd, J = 5.4, 
3.5 Hz, 1H, 4-H), 4.28 (dd, J = 9.5, 4.4 Hz, 1H, 2-H), 2.68 (s, 3H, NCH3), 2.08 (ddd, J = 11.5, 
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9.4, 6.3 Hz, 1H, 3-Ha), 2.01 (dd, J = 9.4, 3.6 Hz, 1H, 3-Hb); 
13
C-NMR (CDCl3, 50 MHz):  
=146.2 (s; CAr), 145.4 (s; CAr), 129.4 (d; CHAr), 129.0 (s; CAr), 128.2 (d; CHAr), 127.9 (d, 2C, 
CHAr),  127.5 (d; CHAr), 116.3 (s; CAr), 116.0 (d; CHAr), 115.2 (d; 2C, CHAr), 65.40 (d; C-4), 
58.91 (d; C-2), 39.66 (t; C-3), 29.73 (q; NCH3) ppm; IR: v = 3380, 2925, 1622, 1515, 1495, 
1372, 1264, 1099, 1042 cm
-1
; MS (EI): m/z (%) = 255 (M
+1
, 3), 254 (M
+
, 22), 235 (10), 220 
(11), 144 (12), 119 (82), 91 (10), 77 (16), 43 (100); anal. calcd. for C16H18N2O (254.14): C, 
75.56 ; H, 7.13; N, 11.01; found C, 74.40; H, 6.80; N, 10.71. 
104b (ca. 1:7 mixture with 104a), detectable signal of cis-isomer : 
1
H NMR (CDCl3, 400 
MHz):  = 7.35 (dm, J = 7.4, 1H, HAr), 7.02-6.98 (m, 2H, HAr), 4.81 (dd, J = 7.3, 4.8 Hz, 1H, 
4-H), 2.80 (s, 1H, N-Me), 2.41 (pseudo dt, J = 13.3, 4.8 Hz, 1H, 3-H), 2.24 (pseudo dt, J = 
13.3, 7.5 Hz, 1H, 3-Hb). 
(3R*,4S*,5S*)- and (3R*,4R*,5R*)-ethyl-5-(2-bromophenyl)-3-(4-methoxyphenyl)-2-
methylisoxazolidine-4-carboxylate (106 and 107) 
 
A mixture of 2-bromophenylacrylate 105 (100 mg, 0.392 mmol) and nitrone 92 (323.7 mg, 
1.96 mmol) was heated without solvent at 90 °C for 48 h in an oil bath. The reaction mixture 
was purified by flash chromatography on silica gel (eluent: EtOAc/petroleum ether 8:92) to 
afford the trans-trans adduct 106 (92.4 mg, 0.22 mmol) in 56% yield and the cis-trans adduct 
107 (43.2 mg, 0.10 mmol) in 26% yield as colourless oils.  
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106: Rf = 0.27; 
1
H NMR (CDCl3, 400 MHz):  = 7.94 (dd, J = 7.8, 1.6 Hz, 1H, HAr), 7.50 (dd, 
J = 8.0, 1.2 Hz, 1H, HAr),7.39 (pseudo dt, J = 1.2, 7.8 Hz, 1H, HAr), 7.21-7.16 (m, 2H, HAr), 
7.14 (pseudo dt, J = 1.7, 7.7  Hz, 1H, HAr), 6.86-6.81 (m, 2H, HAr), 5.69 (d, J = 5.2 Hz, 1H, 5-
H), 4.22-4.14 (m, 2H, CH2), 3.79 (d, J = 8.9 Hz, 1H, 3-H), 3.78 (s, 3H, OCH3), 3.31 (dd, J = 
8.9, 5.2 Hz, 1H, 4-H), 2.69 (s, 3H, NCH3), 1.20 (t, J = 7.1 Hz, 3H, CH2CH3); 
13
C-NMR 
(CDCl3, 50 MHz):  =171.6 (s; CO), 159.7 (s; CAr), 142 (s; CAr), 132.3 (d; CHAr), 128.9 (d; 
2C, CHAr), 128.7 (d; CHAr), 128.5 (s; CAr), 128.0 (d; CHAr),  127.2 (d; CHAr), 121.1 (s; CAr), 
114.1 (d; 2C, CHAr), 80.1 (d; C-5), 78 (d; C-3), 65.8 (d; C-4), 61.2 (t; C-CH2), 55.2 (q; OCH3), 
42.7 (q; NCH3 ), 14.2 (q; CH2CH3Me) ppm; IR: v = 2963, 2846, 1729, 1612, 1514, 1248, 
1175, 1034, 1021 cm
-1
; MS (EI): m/z (%) = 421 (M+1, 8), 420 (M
+
, 1), 223 (1), 221 (2), 167 
(1), 165 (100), 91 (3), 77 (10); anal. calcd. for C20H22BrNO4 (420.30): C, 57.15; H, 5.28; N, 
3.33; found C, 57.18; H, 5.45; N, 3.32 
107: Rf = 0.14; 
1
H NMR (CDCl3, 400 MHz):  = 7.69 (dd, J = 7.7, 1.0 Hz, 1H, HAr), 7.55 (dd, 
J = 8.0, 1.2 Hz, 1H, HAr), 7.36 (pseudo dt, J = 1.1, 7.6 Hz, 1H, HAr), 7.29-7.24 (m, 2H, HAr), 
7.17 (pseudo dt, J = 1.7, 7.6 Hz, 1H, HAr), 6.89-6.84 (m, 2H, HAr), 5.89 (d, J = 5.6 Hz, 1H, 5-
H), 3.94 (br d, J = 8.7 Hz, 1H, 3-H), 3.85- 3.76 (m, 1H, CHH), 3.79 (s, 3H, OCH3), 3.74-3.64 
(m, 1H, CHH), 3.48-3.39 (m, 1H, 4-H), 2.74 (s, 3H, NCH3), 0.85 (t, J = 7.1 Hz, 3H, CH2CH3); 
13
C-NMR (CDCl3, 50 MHz):  =170 (s; CO), 159.2 (s; CAr), 139.2 (s; CAr), 132.9 (d; CHAr), 
129.2 (d; 2C, CHAr),129 (d; CHAr), 127.8 (d; CHAr), 127.1 (d; CHAr),  126.5 (s; CAr), 121.9 (s; 
CAr), 113.4 (d; 2C, CHAr), 79.4 (d; C-5), 74.9 (d; C-3), 61.6 (d; C-4), 60.4 (t; CH2), 54.9 (q; 
OCH3), 42.8 (q; NCH3 ), 13.4 (q; CH2CH3) ppm; IR: v = 2936, 2839, 1731, 1612, 1513, 1466, 
1438, 1380, 1250, 1176, 1035  cm
-1
; MS (EI): m/z (%) = 421 (M+1, 5), 420 (M
+
, 1), 223 (1), 
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221 (1), 167 (1), 165 (100), 91 (4), 77 (8); anal. calcd. for C20H22BrNO4 (420.30): C, 57.15; H, 
5.28; N, 3.33; found C, 57.18; H, 5.45; N, 3.32 
(2S*,3S*)-ethyl-3-(2-bromophenyl)-3-hydroxy-2-[(R*)-(4-methoxyphenyl) 
(methylamino)methyl]propanoate (108). 
 
The mixture of isoxazolidine 106 (221.5 mg, 0.53 mmol) and zinc powder (172.2 mg, 26.35 
mmol) in AcOH:H2O [9:1 (v/v), 5.1 mL] was heated in an oil bath at 85 °C for 3 h. The 
reaction mixture was diluted with MeOH, filtered through cotton wool and then concentrated 
under reduced pressure. The residue was dissolved in CH2Cl2 and the solution was basified to 
pH = 9 with a saturated aq. NaHCO3 solution and solid Na2CO3 at 0 °C. The two phases were 
separated. The aqueous phase was sequentially extracted with CH2Cl2 (3x30 mL) and EtOAc 
(2x20 mL). The combined organic phases were washed with brine, dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification of the crude product by 
chromatography on silica gel [eluent: EtOAc/petroleum ether (1% TEA) 6:4] afforded 108 
(222 mg, 0.52 mmol) in 99% yield as a white solid. 
108: Rf = 0.29; m.p. 106-108 °C;  
1
H NMR (CDCl3, 400 MHz):  = 7.58 (dd, J = 7.8, 1.6 Hz, 
1H, HAr), 7.48 (dd, J = 8.0, 1.2 Hz, 1H, HAr ),7.32 (pseudo dt, J = 1.2, 7.6 Hz, 1H, HAr), 7.21-
7.16 (m, 2H, HAr), 7.09 (ddd, J = 8.0, 7.4, 1.6 Hz, 1H, HAr), 6.88-6.82 (m, 2H, HAr), 5.62 (d, J 
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= 9.3 Hz, 1H, 1-H), 4.00 (d, J = 10.8, Hz, 1H, 3-H), 3.78 (s, 3H, OCH3), 3.61-3.44 (m, 2H, 
CH2), 3.15 (dd, J = 10.8, 9.2 Hz, 1H, 2-H), 2.32 (s, 3H, NCH3), 0.67 (t, J = 7.1 Hz, 3H, 
CH2CH3); 
13
C-NMR (CDCl3, 50 MHz):  =169.6 (s; CO), 159.2 (s; CAr), 140.4 (s; CAr), 132.7 
(d; CHAr), 131.3 (s; CAr), 129.6 (d; CHAr), 129.2 (d; CHAr), 128.3 (d; 2C, CHAr), 127.5 (d; 
CHAr), 123.1 (s; CAr), 113.9 (d; 2C, CHAr), 75.9 (d; C-5), 67.2 (d; C-3), 60.1 (d; C-4), 58.1 (t; 
CH2), 55.2 (q; OCH3), 33.3 (q; NCH3 ), 13.5 (q; CH2CH3) ppm; IR: v = 2983, 2926, 1727, 
1610, 1513, 1466, 1442, 1301, 1250, 1178, 1033  cm
-1
; MS (EI): m/z (%) = 422 (M), 185 (1), 
183 (1), 150 (100), 91 (2), 77 (7); anal. calcd. for C20H24BrNO4 (422.31): C, 56.88; H, 5.73; 
N, 3.32; found C, 56.89; H, 5.74; N, 3.27 
(2R*,3R*)-ethyl-3-(2-bromophenyl)-3-hydroxy-2-[(R*)-(4-methoxyphenyl) 
(methylamino)methyl]propanoate (109). 
 
Following the same procedure to prepare 108, the amino alcohol 109 (68 mg, 0.16 mmol) was 
obtained in 84% yield as a white solid starting from 107 (80 mg, 0.19 mmol).  
109: Rf = 0.21; m.p. 124-126 
0
C;  
1
H NMR (CDCl3, 400 MHz):  = 7.76 (dd, J = 7.7, 1.4 Hz, 
1H, HAr), 7.60 (dd, J = 7.9, 1.1 Hz, 1H, HAr), 7.43 (pseudo dt, J = 0.9, 7.5 Hz, 1H, HAr), 7.20 
(pseudo dt, J = 1.6, 7.6 Hz, 1H, HAr), 6.97-6.92 (m, 2H, HAr), 6.82-6.77 (m, 2H, HAr), 5.54 (d, 
J = 2.6 Hz, 1H, 1-H), 4.25-4.04 (m, 2H, CH2), 3.76 (s, 3H, OCH3), 3.52 (d, J = 2.6 Hz, 1H, 3-
H), 3.24 (pseudo t, J = 2.6 Hz, 1H, 2-H), 2.27 (s, 3H, NCH3), 1.22 (t, J = 7.1 Hz, 3H, 
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CH2CH3); 
13
C-NMR (CDCl3, 50 MHz):  = 172.0 (s; CO), 158.5 (s; CAr), 142.1 (s; CAr), 133.1 
(d; CHAr),  131.2 (s; CAr), 128.8 (d; CHAr), 128.3 (d; CHAr), 128 (d; 2C, CHAr), 127.3 (d; 
CHAr), 121.2 (s; CAr), 113.7 (d; 2C, CHAr), 75.5 (d; C-5), 61.1 (d; C-3), 60.7 (d; C-4), 55.2 (t; 
CH2), 53.0 (q; OCH3), 33.5 (q; NCH3 ), 14.1 (q; CH2CH3) ppm; IR: v = 2983, 2938, 1733, 
1716, 1608, 1558, 1456, 1373, 1251, 1181, 1033  cm
-1
; MS (EI): m/z (%) = 422 (M), 185 (1), 
183 (1), 150 (100), 91 (2), 77 (7); anal. calcd. for C20H24BrNO4 (422.31): C, 56.88; H, 5.73; 
N, 3.32; found C, 57.07; H, 5.88; N, 3.33 
(2S*,3R*,4R*)-ethyl-4-hydroxy-2-(4-methoxyphenyl)-1-methyl-1,2,3,4- 
tetrahydroquinoline-3-carboxylate (110). 
 
The mixed solvent tBuOH: H2O (1:1) (1.89 mL) was added to a mixture of 108 (40 mg, 0.095 
mmol), CuI (9.02 mg, 0.047 mmol), copper powder (3.01 mg, 0.047 mmol), K3PO4 (40.21 mg, 
0.19 mmol) and L-proline (10.9 mg, 0.095 mmol) under nitrogen atmosphere in a vial. 
Nitrogen was bubbled through the reaction mixture to remove oxygen. The reaction mixture 
was heated at 90 °C for 12 h in an oil bath and then was filtered through a small pad of 
Celite
®
. The solution was diluted with H2O and sequentially extracted with CH2Cl2 (3x10 mL) 
and EtOAc (2x5 mL). The combined organic phases were washed with NH4OH (1% H2O 
solution) and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification by flash chromatography [eluent: EtOAc/petroleum ether (1% TEA) 20:80], 
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afforded 110 (6.6 mg, 0.02 mmol) in 20% yield as a colourless oil, along with recovery of the 
starting material 108 (3.4 mg, 0.008 mmol). 
110: Rf = 0.31; 
1
H NMR (CDCl3, 400 MHz):  = 7.34 (dd, J = 7.4, 1.0 Hz, 1H, HAr), 7.23 (dt, 
J = 1.6, 8.5 Hz, 1H, HAr),7.16 (pseudo dt, J = 2.5, 9.3 Hz, 2H, HAr), 6.85 (Pseudo dt, J = 2.5, 
9.3 Hz, 2H, HAr), 6.74 (dt, J = 1.0, 7.4 Hz, 1H, HAr), 6.68 (d, J = 8.2 Hz, 1H, HAr), 4.80 (d, J = 
7.2 Hz, 1H, 2-H), 4.76 (dd, J = 7.2 , 3.5 Hz, 1H, 4-H), 4.04 (dd, J = 14.2, 7.1 Hz, 2H, CH2), 
3.79 (s, 3H, OCH3), 3.06 (dd, J = 7.2, 3.5 Hz, 1H, 3-H), 2.79 (s, 3H, NCH3), 1.06 (t, J = 7.1 
Hz, 3H); 
13
C-NMR (CDCl3, 50 MHz):  =172.4 (s; CO),159 (s; CAr), 144.9 (s; CAr), 132.9 (s; 
CAr), 129.3 (d; CHAr),  128.2 (d; 2C, CHAr), 127.3 (d; CHAr), 123.3 (s; CAr), 116.4 (d; CHAr), 
113.9 (d; 2C, CHAr), 111.1 (d; CHAr), 65.9 (d; C-2), 61.4 (d; C-4), 60.9 (t; CH2), 55.3 (q; 
OCH3), 51.4 (d; C-3),  37.3 (q; NCH3), 14 (q; CH2CH3) ppm; IR: v = 2935, 2854, 1718, 1607, 
1511, 1499, 1374, 1247, 1175, 1035 cm
-1
; MS (EI): m/z (%) = 342 (M+1, 10), 341 (M+, 51), 
250 (100), 161 (25), 91 (9), 77 (23); anal. calcd. for C20H23NO4 (341.4): C, 70.36; H, 6.79; N, 
4.10; found C, 70.02; H, 6.81; N, 3.95 
(3S*,4R*,5R*) and (3S*,4S*,5S*)-ethyl 5-(2-chloropyridin-3-yl)-3-(4-methoxyphenyl)- 
2-methylisoxazolidine-4-carboxylate (113, 114). 
 
 
The mixture of (E)-ethyl 3-(2-chloropyridin-3-yl) acrylate 112 (100 mg, 0.47 mmol), nitrone 
92 (390.26 mg, 2.36 mmol) was heated under solvent free condition at 90 °C for 48 h in an oil 
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bath. Purification by flash chromatography on silica gel [eluent: EtOAc/petroleum ether (2% 
TEA) 2:8] afforded the trans-trans adduct 113 (132.2 mg, 0.35 mmol) in 74% yield, the cis-
trans adduct 114 (35.1 mg, 0.09 mmol) in 20% yield as a colourless oil along with unreacted 
nitrone 92 (283.2 mg, 1.71 mmol). 
113: Rf = 0.14; 
1
H NMR (CDCl3, 400 MHz):  = 8.32 (dd, J = 4.7, 1.9 Hz, 1H, HAr), 8.25 (dd, 
J = 7.7, 1.9 Hz, 1H, HAr),7.33 (dd, J = 7.7, 4.7 Hz, 1H, HAr), 7.16-7.11 (m, 2H, HAr), 6.85-6.80  
(m, 2H, HAr), 5.66 (d, J = 4.9 Hz, 1H, 5-H), 4.19 (q, J = 7.1 Hz, 1H, CH2), 3.78 (s, 3H, OCH3), 
3.76 (br d, J = 8.8 Hz, 4-H), 3.30 (dd, J = 4.9, 8.0 Hz, 1H, 3-H ), 2.67 (s, 3H, NCH3), 1.20 (t, J 
= 7.1 Hz, 3H, CH2CH3); 
13
C-NMR (CDCl3, 50 MHz):  = 171.4 (s; CO), 159.8 (s; CAr), 148.5 
(s; CAr), 148.4 (d; CHAr), 137.3 (s; CAr), 136.8 (d; CHAr), 128.9 (d; 2C, CHAr), 128.1 (s; CAr), 
122.7 (d; CHAr), 114.2 (d; CHAr), 78 (d; C-5), 77.4 (d; C-3), 65.3 (d; C-4),  61.3 (t; C-CH2), 
55.5 (q; OCH3), 42.4 (q; NCH3), 14.1 (q; CH2CH3) ppm;  IR: v = 2996, 2839, 1731, 1615, 
1514, 1407, 1373, 1305, 1250, 1182, 1082, 1033 cm
-1
; MS (EI): m/z (%) = 378 (M
+2
, 3), 376 
(M, 7), 222 (3), 167 (1), 165 (100), 91 (4), 77 (8); anal. calcd. for C19H21ClN2O4 (376.12): C, 
60.56; H, 5.62; N, 7.43; found C, 59.06; H, 5.55; N, 7.59. 
114 Rf = 0.16 
1
H NMR (CDCl3, 400 MHz):  = 8.32 (dd, J = 4.8, 1.9 Hz, 1H, HAr), 8.03 (dd, J 
= 7.7, 1.9 Hz, 1H, HAr), 7.30 (dd, J = 7.7, 4.8 Hz, 1H, HAr), 7.27-7.22 (m, 2H, HAr), 6.90-6.83  
(m, 2H, HAr), 5.83 (d, J = 5.7 Hz, 1H, 5-H), 3.89 (br s, 1H, 4-H), 3.86-3.76 (m, 1H, CHH), 
3.79 (s, 3H, OCH3), 3.72-3.63 (m, 1H, CHH), 3.42 (br s, 1H, 3-H ), 2.71 (s, 3H, NCH3), 0.84 
(t, J = 7.2 Hz, 3H, CH2CH3); IR: v = 2964, 2838, 1733, 1612, 1567, 1531, 1409, 1380, 1250, 
1181, 1082, 1034. 
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 (2R*,3R*)-ethyl-3-(2-chloropyridin-3-yl)-3-hydroxy-2-[(S)-(4-methoxyphenyl) 
(methylamino)methyl]propanoate (116). 
 
A mixture of isoxazolidine 113 (96 mg, 0.255 mmol) and Mo(CO)6 (67.25 mg, 0.255 mmol) 
in CH3CN:H2O [9:1 (v/v), 5.09 mL] was refluxed in an oil bath for 3 h and then was 
concentrated under a nitrogen stream. The obtained residue was diluted with CH2Cl2, and the 
solution was added with silica gel. The slurry was leaved in the presence of air for 1 h and 
then directly loaded on a chromatography column. Chromatography on silica gel [eluent: 
DCM/MeOH (1% NH4OH) 97:3] afforded 116 (77.8 mg, 0.205 mmol) in 81% yield as a 
colourless viscous solid.  
116: Rf = 0.29; 
1
H NMR (CDCl3, 400 MHz):  = 8.29 (dd, J = 4.7, 2.0 Hz, 1H, HAr), 7.94 (dd, 
J = 7.7, 1.9 Hz, 1H, HAr),7.26 (dd, J = 7.6, 4.7 Hz, 1H, HAr), 7.19-7.15 (m, 2H, HAr), 6.88-6.83 
(m, 2H, HAr), 5.59 (d, J = 9.4 Hz, 1H, 1-H), 4.00 (d, J = 10.8 Hz, 1H, 3-H), 3.78 (s, 3H, 
OCH3), 3.63-3.50 (m, 2H, CH2), 3.07 (dd, J = 10.8, 9.4 Hz, 1H, 2-H), 2.32 (s, 3H, NCH3), 
0.70 (t, J = 7.1 Hz, 3H, CH2CH3); 
13
C-NMR (CDCl3, 50 MHz):  =168.0 (s; CO), 159.3 (s; 
CAr), 149.5 (s; CAr), 149.2 (d; CHAr), 138 (d; CHAr),  135.8 (s; CAr), 131.1 (s; CAr),  128 (d; 2C, 
CHAr), 123.2 (d; CHAr), 112.4 (d; 2C,CHAr), 73.5 (d; C-1), 67 (d; C-3), 60.1 (t; CH2), 57.8 (q; 
OCH3), 55.2 (d; C-2),  33.5 (q; NCH3 ), 13.2 (q; CH2CH3) ppm; IR: v = 2983, 2936, 2839, 
1723, 1610, 1580, 1513, 1464, 1372, 1305, 1251, 1178, 1095 cm
-1
; MS (EI): m/z (%) = 342, 
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251 (3), 190 (2), 161 (6), 150 (100), 133 (3), 78 (4), 42 (20) ; anal. calcd. for C19H23ClN2O4 
(378.85): C, 60.24; H, 6.12; N, 7.39; found C, 60.99; H, 6.08; N, 7.60 
 (2S*,3R*,4R*)-ethyl-4-hydroxy-2-(4-methoxyphenyl)-1-methyl-1,2,3,4- 
tetrahydro-1,8-naphthyridine-3-carboxylate (117). 
 
 
The mixed solvent tBuOH: H2O (1:1) (1.95 mL) was added to a mixture of 116 (37 mg, 0.098 
mmol), CuI (27.90 mg, 0.146 mmol), copper powder (9.31 mg, 0.146 mmol), K3PO4 (41.46 
mg, 0.195 mmol) and L-proline (11.24 mg, 0.098 mmol) under nitrogen atmosphere in a vial. 
Nitrogen was bubbled through the reaction mixture to remove oxygen. The reaction mixture 
was heated at 90 °C for 12 h in oil bath and then was filtered through small pad of Celite
®
. 
The solution was diluted with H2O and sequentially extracted with CH2Cl2 (3x10 mL) and 
EtOAc (2x5 mL). The combined organic phases were washed with NH4OH (1% H2O solution) 
and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. Purification 
by flash chromatography [eluent: EtOAc/petroleum ether (1% TEA) 5:5] afforded 117 (11 mg, 
0.032 mmol) with 33% yield as a white solid along with unreacted starting material 116 (3.6 
mg, 0.009 mmol). 
117: Rf = 0.32; m.p. 123-125 °C; 
1
H NMR (CDCl3, 400 MHz):  = 8.13 (dd, J = 5, 1.8 Hz, 1H, 
HAr), 7.59 (pseudo dt, J = 1.8, 7.2 Hz, 1H, HAr),7.12 (pseudo dt, J = 2.5, 9.3 Hz, 2H, HAr), 6.62 
(Pseudo dt, J = 2.5, 9.3 Hz, 2H, HAr), 4.96 (d, J = 5.2 Hz, 1H, 2-H), 4.64 (dd, J = 8.1 , 4.2 Hz, 
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1H, 4-H), 4.09 (t, J = 7.1 Hz, 2H, CH2), 3.79 (s, 3H, OCH3), 3.10 (pseudo t, J = 5.2 Hz, 1H, 3-
H), 3.04 (s, 3H, NCH3), 1.12 (t, J = 7.1 Hz, 3H, CH2CH3); 
13
C-NMR (CDCl3, 50 MHz):  = 
172.1 (s; CO), 159.1 (s; CAr), 147.5 (s; CAr), 133.9 (d; CHAr), 131.7 (s; CAr), 131.0 (s; CAr),  
127.6 (d; 2C, CHAr), 118.7 (s; CAr), 114.1 (d; 2C,CHAr), 112.2 (d; CAr), 64.6 (d; C-2), 61.4 (d; 
C-4), 61.2 (t; CH2), 55.3 (q; OCH3), 49.6 (d; C-3),  35.4 (q; NCH3), 14.1 (q; CH2CH3) ppm ; 
IR: v = 2935, 2839, 1713, 1602, 1512, 1494, 1406, 1338, 1250, 1176, 1034 cm
-1
; MS (EI): m/z 
(%) = 343 (M, 5), 342 (M, 26), 251 (100), 17 (7), 161 (46), 108 (45), 91 (6); anal. calcd. for 
C19H22N2O4 (342.39): C, 66.65; H, 6.48; N, 8.18; found C, 66.57; H, 6.13; N, 7.87. 
 
(2R, 3R, 4R)-2-benzyl-3,4-di-tert-butoxypyrrolidine (125) 
 
Benzylmagnesium chloride 122 (2.0 M solution in THF, 2.10 mL) was added dropwise to a 
solution of nitrone 28 (0.5 g, 2.18 mmol) in dry THF (8.5 mL) at 0 °C under nitrogen 
atmosphere. The resulting mixture was stirred for 3 h at rt and then the reaction was quenched 
with saturated aqueous NH4Cl at 0 °C. The two phases were separated and the aqueous phase 
was sequentially extracted with CH2Cl2 (3x30 mL) and EtOAc (3x20 mL). The combined 
organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The obtained mixture of crude compounds 123 and 124 (0.7 g, 2.18 mmol) 
was dissolved in AcOH: H2O [1:1(v/v), 21.2 mL] at 0 °C and then activated zinc powder (2.8 
g, 43.6 mmol) was added. The suspension was stirred at rt for 2 h, diluted with MeOH and 
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filtered through cotton wool. The filtrate was concentrated under reduced pressure and the 
residue was dissolved in EtOAc. The solution was basified to pH = 9 with a saturated aq. 
NaHCO3 solution and solid Na2CO3 at 0 °C. The two phases were separated and the aqueous 
phase was sequentially extracted with EtOAc (3x30 mL) and CH2Cl2 (2x30 mL). The 
combined organic phases were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification of the crude product by chromatography on 
silica gel [eluent: CH2Cl2 / MeOH (1% NH4OH) 92:8] afforded the major isomer 125 (0.44 g, 
1.43mmol) in 66% yield as a colourless oil and a mixture of both isomers 125 and 126 (0.18 g, 
0.6 mmol, 3:1 ratio) in 27% yield. 
125:Rf = 0.39; 
1
H NMR (CDCl3, 400 MHz):  = 7.32-7.22 (m, 4H, HAr), 7.21-7.16 (m, 1H, 
HAr), 3.82 (pseudo dt, J = 5.4, 2.5 Hz, 1H, 4-H), 3.64 (pseudo t, J = 2.7 Hz, 1H, 3-H), 3.14-
3.06 (m, 1H, 2-H), 3.10 ( dd, J = 11.6, 5.4 Hz, 1H, 5-Ha), 2.99 (dd, J = 13.3, 6.6 Hz, 1H, 
CH2Ph), 2.85 (dd, J = 11.6, 2.9 Hz, 1H, 5-Hb),  2.70 (dd, J = 13.3, 8.5 Hz, 1H, CH2Ph), 2.15 
(br s, 1H, NH), 1.20 (s, 9H, CH3x3), 1.09 (s, 9H, CH3x3),;
 13
C-NMR (50 MHz):  =139.8 (s; 
CAr), 129.1 (d; 2C, CHAr), 128.2 (d; 2C, CHAr), 125.9 (d; CHAr), 82.1 (d; C-3), 79.1 (d; C-4), 
66.4 (d; C-2), 53.2 (t; C-5), 39.2 (t; C-CH2Ph), 28.6 (q; 3C, C-CH3), 28.5 (q; 3C, C-CH3) 
ppm; IR (CDCl3): v
 
= 2977, 1455, 1390, 1366, 1191, 1076, 1023 cm
-1
; MS (EI): m/z (%) = 306 
(M+1), 248 (1), 214 (37), 192 (16), 102 (56), 91 (15), 57 (100); anal. calcd. for C19H31NO2 
(305.24): C, 74.71; H, 10.23; N, 4.59; found C, 74.53; H, 10.03; N, 4.09 
 
(2S,3S,4S)-2-benzyl-3,4-di-tert-butoxypyrrolidine (ent-125) 
Following the same procedure used to prepare pyrrolidine 125, the enantiomeric ent-125 was 
obtained starting from nitrone ent-28. 
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(1R, 2R, 10aR)-1,2-di-tert-butoxy-2,3,10,10a-tetrahydropyrrolo[1,2-b]isoquinolin-5(1H)-
one (128) 
 
1,4-Dioxane (2.8 mL) was added to a mixture of 125 (87.5 mg, 0.286 mmol), Pd(OAc)2 (32.1 
mg, 0.14 mmol), Cu(OAc)2 (208.1 mg, 1.14 mmol), and t-BuOK (96.4 mg, 0.86 mmol). The 
reaction mixture was heated in an oil bath at 110 °C for 24 h under CO atmosphere and then 
was filtered through a small pad of Celite
 ®
. The filtrate was diluted with H2O and sequentially 
extracted with CH2Cl2 (3x10 mL) and EtOAc (2x10 mL). The combined organic phases were 
washed with NH4OH solution (2% H2O solution) as well as brine, dried over Na2SO4, filtered 
and concentrated under reduced pressure. Purification of the crude product by chromatography 
on silica gel [eluent: EtOAc (1% TEA) /petroleum ether 30:70] afforded 128 (68.7 mg, 0.21 
mmol) in 72% yield as a yellow waxy solid. 
128:Rf = 0.47; .). []D
24
= +76.80 (c = 0.62, CHCl3); 
1
H NMR (CDCl3, 400 MHz):  = 8.02(dd, 
J = 7.6, 1.4 Hz, 1H, HAr), 7.40 (pseudo dt, J = 7.4, 1.4 Hz, 1H, HAr), 7.32 (pseudo tt, J = 7.5, 
1.0 Hz, 1H, HAr), 7.19 (br d, J = 7.5 Hz, 1H, HAr), 4.00-3.85 (m, 3H, 1-H, 2-H, 3-Ha), 3.61 
(ddd, J= 13.4, 7.4, 4.1 Hz, 1H,10a-H), 3.45 (dd, J = 11.7, 5.8 Hz, 1H, 3-Hb), 3.06 (dd, J = 
15.0, 4.1 Hz, 10-Ha), 2.91 (br pseudo t, J = 14.2 Hz, 1H, 10-Hb), 1.27 (s, 9H, CH3x3), 1.22 (s, 
9H, CH3x3); 
13
C-NMR (50 MHz):  =163.1 (s; CO), 137.2 (s; CAr), 131.5 (d; CHAr)129.6 (s; 
CAr), , 127.5 (d; CHAr), 127.2 (d; CHAr), 127 (d; CHAr), 80.9 (d; C-1), 74(d; C-2), 59.1 (d; C-
10a), 49.4 (t; C-3), 33.1 (t; C-10), 29.3 (q; 3C, C-CH3), 28.5 (q; 3C, C-CH3) ppm; IR 
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(CDCl3): v
 
= 2978, 1644, 1464, 1366, 1192, 1115, 1090  cm
-1
; MS (EI): m/z (%) = 331 (M
+
, 
7), 274 (18), 218 (87), 158 (6), 91 (4), 57 (100) ; anal. calcd. for C20H29NO3 (331.21): C, 
72.47; H, 8.82; N, 4.23; found C, 72.54; H, 8.46; N, 4.40. 
 
(1S,2S,10aS)-1,2-di-tert-butoxy-2,3,10,10a-tetrahydropyrrolo[1,2-b]isoquinolin-5(1H)-one 
(ent-128) 
Following the same procedure used to prepare pyrrolidine 128, the enantiomeric ent-128 was 
obtained starting from ent-125. 
[]D
26
= -74.98 (c = 1.0, CHCl3) 
 
(1R,2R,10aR)-1,2-dihydroxy-2,3,10,10a-tetrahydropyrrolo[1,2-b]isoquinolin-5(1H)-one 
(121) 
 
The compound 128 (28 mg, 0.08 mmol) was dissolved in TFA (0.8 mL) at 0 °C and the 
solution was stirred at rt for 2 h. The excess of TFA was co-evaporated with toluene (4 × 3 
mL) under reduced pressure (each addition of toluene was done at 0 °C) and then the residue 
was co-evaporated with MeOH (3 × 3 mL) to remove the last traces of toluene. Purification of 
the crude product by chromatography on silica gel [eluent: CH2Cl2 / MeOH (1% NH4OH) 
90:10] gave 121 (18 mg, 0.08 mmol) in 97% yield as a white solid.    
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121:Rf = 0.41;m.p. 220-222 °C (Decomposed); []D
26
= +374.30 (c = 0.5, MeOH);  
1
H NMR 
(CDCl3, 400 MHz):  = 7.90 (dd, J = 7.7, 1.1 Hz, 1H, HAr), 7.48 (pseudo dt, J = 1.4, 7.5 Hz, 
1H, HAr), 7.35 (pseudo tm, J = 7.6 Hz, 1H, HAr),  7.31 (br d, J = 7.5, 1H, HAr), 4.16 (pseudo q, 
J = 6.6 Hz, 1H, 2-H), 3.92 (pseudo t, J = 6.7 Hz, 1H, 1-H), 3.88 (dd, J = 12.5, 7.3 Hz, 1H, 3-
Ha), 3.68 (ddd, J = 13.6, 7.1, 4.2 Hz, 1H, 10a-H), 3.50 (dd, J = 12.5, 6.4 Hz, 1H, 3-Hb), 3.16 
(dd, J = 15.4, 4.2 Hz, 1H, 10-Ha), 2.95 (br pseudo t, J = 13.9 Hz, 1H, 10-Hb); 
13
C-NMR (50 
MHz):  =165.3 (s; CO), 139.2 (s; CAr), 134.9 (s; CAr), 133.3 (d; CHAr), 129.7 (d; CHAr), 128.7 
(d; CHAr), 128.1 (d; CHAr), 82.6 (d; C-1), 75.1(d; C-2), 62.4 (d; C -10a), 50.7 (t; C-3), 33.6 (t; 
C-10) ppm; MS (EI): m/z (%) = 219 (M
+
, 27),  176 (22), 132 (100), 103 (10), 91 (27), 78 (5); 
anal. calcd. for C20H29NO3 (219.09): C, 65.74; H, 5.98; N, 6.39; found C, 65.71; H, 5.58; N, 
6.04 
(1S,2S,10aS)-1,2-dihydroxy-2,3,10,10a-tetrahydropyrrolo[1,2-b]isoquinolin-5(1H)-one  
(ent-121) 
Enantiomeric ent-121 was prepared following the same procedure used for the synthesis of 
pyrrolidine 121. 
[]D
25
= -375.49 (c =0.55, MeOH). 
 
 (1R,2R,10aR)-1,2-di-tert-butoxy-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinoline 
(127) 
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A solution of lithium aluminium hydride (1.0 M solution in THF, 1.8 mL) was added 
dropwise to a solution of 128 (100 mg, 0.30 mmol) in dry THF (5.5 mL) at 0 °C under 
nitrogen atmosphere. The reaction mixture was stirred overnight at rt and then the reaction 
was quenched with saturated aqueous NH4Cl at 0 °C. The two phases were separated and the 
aqueous phase was sequentially extracted with CH2Cl2 (3x10 mL) and EtOAc (2x10 mL). The 
combined organic phases were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification of the crude product by chromatography on 
silica gel [eluent: EtOAc (1% TEA) /petroleum ether 15:85] afforded 127 (76 mg, 0.24 mmol) 
in 80% yield as a white solid. 
127:Rf = 0.24; m.p. = 105–107 °C; []D
25
= +43.98 (c = 0.58, CHCl3); 
1
H NMR (CDCl3, 400 
MHz):  = 7.15-7.07 (m, 3H, HAr), 7.04-6.99 (m, 1H, HAr), 4.01 (d, J = 14.6 Hz, 1H, 5-Ha), 
3.94 (ddd, J = 6.8, 3.6, 1.8 Hz, 1H, 2-H), 3.80 (dd, J = 7.7, 3.6 Hz, 1H, 1-H), 3.38 (br d, J = 
14.6 Hz, 1H, 5-Hb), 3.13 (dd, J = 10.2, 1.8, Hz, 3-Ha),  3.01 (dd, J = 15.6, 3.9 Hz, 1H, 10-Ha), 
2.81 (br dd, J = 15.6, 10.9 Hz, 1H, 10-Hb), 2.62 (br pseudo t, J = 8.0 Hz, 1H, 3-Hb),  2.36-
2.24 (m, 1H, 10a-H), 1.27 (s, 9H, CH3x3), 1.20 (s, 9H, CH3x3); 
13
C-NMR (50 MHz):  =134.3 
(s; CAr), 134.2 (s; CAr),  128.9 (d; CHAr), 126.3 (d; CHAr), 126 (d; CHAr), 125.5 (d; CHAr), 84.8 
(d; C-1), 77.3 (d; C-2), 64.1 (d; C-10a), 62 (t; C-3), 56.1 (t; C-5), 33.5 (t; C-10 ), 29.3 (q; 3C, 
CH3), 28.8 (q; 3C, CH3) ppm; IR (CDCl3): v
 
= 2978, 2935, 1395, 1366,1258, 1190, 1161, 
1072, 1021  cm
-1
; MS (EI): m/z (%) = 317 (M
+
, 8), 274 (1), 218 (7), 204 (34), 158 (3), 144 
(20), 91 (5), 57 (100); anal. calcd. for C20H31NO2 (317.24): C, 75.67; H, 9.84; N, 4.41; found 
C, 75.59; H, 9.89; N, 4.45. 
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(1S,2S,10aS)-1,2-di-tert-butoxy-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinoline    
(ent-127) 
Enantiomeric ent-127 was prepared following the same procedure used for the synthesis of 
pyrrolidine 127. 
[]D
21
= +45.26 (c = 1.04, CHCl3) 
 (1R,2R,10aR)-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinoline-1,2-diol (120)  
 
Ether 127 (60 mg, 0.19 mmol) was dissolved in TFA (1.9 mL) at 0 °C and the solution was 
stirred at rt for overnight. The excess of TFA was co-evaporated with toluene (4 × 3 mL) 
under reduced pressure (each addition of toluene was done at 0 °C) and then the residue was 
co-evaporated with MeOH (3 × 3 mL) to remove the last traces of toluene. Purification of the 
crude product by chromatography on silica gel [eluent: CH2Cl2 / MeOH (1% NH4OH) 90:10] 
gave 120 (34.8 mg, 0.17 mmol) in 90% yield as a white solid. 
120:Rf = 0.29;m.p. 154-156 °C; (Decomposed)
 ; 
 []D
25
= + 276.2 (c = 0.67, CH3OH);
 1
H NMR 
(CD3OD, 400 MHz):  =7.16-7.04 (m, 4H, HAr), 4.09 (ddd, J = 7.0, 3.6, 2.1 Hz, 1H, 2-H), 4.01 
(d, J = 14.6 Hz, 1H, 5-Ha), 3.77 (dd, J = 7.7, 3.5 Hz, 1H, 1-H), 3.42 (br d, J = 14.6 Hz, 1H, 5-
Hb), 3.10 (dd, J = 15.8, 4.1, Hz, 10-Ha),  3.08 (dd, J = 10.6, 2.1, 1H, 3-Ha), 2.81 (br dd, J = 
15.8, 10.9, 1H, 10-Hb), 2.73 (dd, J = 10.6, 7.0 Hz, 1H, 3-Hb),  2.34 (ddd, J = 10.9, 7.7, 4.1 
Hz, 1H, 10a-H); 
13
C-NMR (50 MHz):  =135.1 (s; CAr), 135.15 (s; CAr),  130.1 (d; CHAr), 
127.6 (d; 2C, CHAr), 127.1 (d; CHAr), 85.9 (d; C-1), 77.7 (d; C-2), 67.7 (d; C-10a), 62.5 (t; C-
3), 56.8 (t; C-5), 34.1 (t; C-10 ) ppm; MS (EI): m/z (%) = 205 (M
+
,55), 132 (24), 117 (56), 
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91(8), 78 (12). anal. calcd. for C20H31NO2 (205.11): C, 70.22; H, 7.37; N, 6.82; found C, 
70.30; H, 7.03; N, 6.67 
(1S,2S,10aS)-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinoline-1,2-diol (ent-120)  
Enantiomeric ent-120 was prepared following the same procedure used for the synthesis of 
pyrrolidine 120. 
[]D
25
= - 275.6 (c = 0.67, MeOH) 
 
(2S,3R)-2-benzyl-3-tert-butoxypyrrolidine (131) 
 
A solution of benzylmagnesium chloride 122 (2.0 M solution in THF, 1.54 mL) was added 
dropwise to a solution of the pyrrolidine N-oxide 74 (0.3 g, 1.9 mmol) in dry THF (6.34 mL) 
at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 2 h at rt and then the 
reaction was quenched with saturated aqueous NH4Cl at 0 °C. The two phases were separated 
and the aqueous phase was sequentially extracted with CH2Cl2 (3x30 mL) and EtOAc (3x20 
mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The obtained crude product 130 (0.47 g, 1.91 mmol) was 
dissolved in AcOH:H2O [1:1(v/v),18.6 mL] at 0 
o
C and activated zinc powder (2.5 g, 38.1 
mmol) was added. The reaction mixture was stirred at rt for 2 h, diluted with MeOH, filtered 
through cotton wool and then concentrated under reduced pressure. The residue was dissolved 
in EtOAc, and the solution was basified to pH = 9 with a saturated aq. NaHCO3 solution and 
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solid Na2CO3 at 0 °C. The two phases were separated and the aqueous phase was sequentially 
extracted with EtOAc (3x20 mL) and CH2Cl2 (2x20 mL). The combined organic phases were 
washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification of the crude product by chromatography on silica gel [eluent: CH2Cl2 / MeOH 
(1% NH4OH) 93:7] afforded 131 (0.38 g, 1.63 mmol) in 85% yield as a colourless oil. 
131:Rf = 0.26; []D
24
= + 53.70 (c = 0.64, CHCl3); 
1
H NMR (CDCl3, 400 MHz):  = 7.33-7.18 
(m, 5H, HAr), 3.77 (ddd, J = 7.7, 5.5, 4.6 Hz, 1H, 3-H), 3.10 (pseudo dt, J = 9.2, 5.2 Hz, 1H, 2-
H), 3.02-2.94 (m, 3H, 5-H, CH2Ph), 2.60 (dd, J= 13.5, 9.1 Hz, 1H, CH2Ph-H), 2.52 (br s, 1H, 
NH), 2.09 (pseudo dq, J = 13.1, 8 Hz, 1H, 4-Ha), 1.72-1.63 (m, 1H, 4-Hb), 1.16 (s, 9H, 
CH3x3), 
13
C-NMR (50 MHz):  =139.7 (s; CAr), 128.9 (d; 2C, CHAr), 128.3 (d; 2C, CHAr), 
126.1 (d; CHAr), 75.8 (d; C-3), 66.3 (d; C-2), 44.2 (t; C-5), 39.5 (t; C-CH2Ph), 34.1 (t; C-4), 
28.5 (q; 3C, CH3 ) ppm; MS (EI): m/z = 233.18, calcd. for C15H23NO [M + H]
+
: 234.10; [M + 
Na]
+
: 256.11; IR (CDCl3): v
 
= 2976, 2935, 1602, 1495, 1453, 1390, 1364, 1189, 1091 cm
-1
; 
anal. calcd. for C15H23NO (233.18): C, 77.21; H, 9.93; N, 6.00; found C, 76.50; H, 9.25; N, 
6.72 
(1R,10aS)-1-(tert-butoxy)-2,3,10,10a-tetrahydropyrrolo[1,2-b]isoquinolin-5(1H)-one (132) 
 
1,4-Dioxane (2.1 mL) was added to a mixture of 131 (50 mg, 0.214 mmol), Pd(OAc)2 (24 mg, 
0.11 mmol), Cu(OAc)2 (155.7 mg, 0.86 mmol), and t-BuOK (72.13 mg, 0.64 mmol). The 
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reaction mixture was heated in an oil bath at 110 °C for 24 h under CO atmosphere and then 
was filtered through a small pad of Celite
 ®
. The filtrate was diluted with H2O and sequentially 
extracted with CH2Cl2 (3x10 mL) and EtOAc (2x10 mL). The combined organic phases were 
washed with NH4OH solution (2% H2O solution) as well as brine, dried over Na2SO4, filtered 
and concentrated under reduced pressure. Purification of the crude product by chromatography 
on silica gel [eluent: EtOAc (1% TEA) /petroleum ether 1:1] afforded 132 (25 mg, 0.1 mmol) 
in 45% yield as a brown solid. 
132:Rf = 0.36; m.p. 95-97 
0
C; []D
25
= +118.05  (c = 0.66, CHCl3); 
1
H NMR (CDCl3, 400 
MHz):  = 8.03 (dd, J = 7.6, 1.3 Hz, 1H, HAr ), 7.40 (pseudo dt, J = 1.5, 7.4 Hz, 1H, HAr), 7.32 
(pseudo tt, J = 7.5, 1.0 Hz, 1H, H Ar), 7.19 (dm, J = 7.4 Hz, 1H, H Ar), 3.95 (ddd, J = 9.0, 8.1, 
6.8 Hz, 1H, 1-H), 3.80 (ddd, J = 12.5, 9.9, 2.2 Hz, 1H, 3-Ha), 3.66 (ddd, J = 12.5, 9.9, 7.5 Hz, 
1H, 3-Hb), 3.60 (ddd, J = 14.3, 8.1, 4.1 Hz, 1H,10a-H), 3.10 (dd, J = 15.1, 4.1 Hz, 1H, 10-
Ha), 2.79 (pseudo t, J = 14.3 Hz, 1H, 10-Hb), 2.25 (dddd, J = 12.5, 7.7, 6.8, 2.3 Hz, 1H, 2-
Ha), 1.82 (dq, J = 12.5, 9.9 Hz, 1H, 2-Hb), 1.26 (s, 9H, CH3x3); 
13
C-NMR (CDCl3, 50 MHz): 
 =164.4 (s; CO), 137 (s; CAr), 131.6 (d; CHAr),  130 (s; CAr), 127.5 (d; CHAr), 127.2 (d; 
CHAr), 127 (d; CHAr), 76.9 (t; C-1), 60.4 (d; C-10a), 42.2 (d; C-3), 32.9 (t; C-10), 31.6 (t; C-2), 
28.5 (q; 3C,CH3 ) ppm; IR (CDCl3): v
 
= 2978, 1641, 1467, 1436, 1365, 1191, 1093 cm
-1
; MS 
(EI): m/z = 259.16, calcd. for C16H21NO2 [M + H]
+
: 260.18; [M + Na]
+
: 282.11;  anal. calcd. 
for C16H21NO2 (259.16): C, 74.10; H, 8.16; N, 5.40; found C, 74.23; H, 8.55; N, 5. 05. 
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(1R,10aS)-1-hydroxy-2,3,10,10a-tetrahydropyrrolo[1,2-b]isoquinolin-5(1H)-one (133) 
 
Amide 132 (32 mg, 0.12 mmol) was dissolved in TFA (1.23 mL) at 0 °C and the solution was 
stirred at rt for 1 h. The excess of TFA was co-evaporated with toluene (4 × 3 mL) under 
reduced pressure (each addition of toluene was done at 0 °C) and then the residue was co-
evaporated with MeOH (3 × 3 mL) to remove the last traces of toluene. Purification of the 
crude product by chromatography on silica gel [eluent: CH2Cl2 / MeOH (1% NH4OH) 94:6] 
gave 133 (19.9 mg, 0.1 mmol) in 79 % yield as a white solid.   
133:Rf = 0.33; m.p. 198-200 
0
C; []D
25
=  +88.95 (c = 0.65, CH3OH);
1
H NMR (CD3OD, 400 
MHz):  = 7.90 (br d, J = 7.3, 1H, HAr ), 7.47 (pseudo dt, J = 1.0, 7.5 Hz, 1H, HAr), 7.35 
(pseudo tm, J = 7.6 Hz, 1H, H Ar),7.30 (dm, J = 7.5 Hz, 1H, H Ar), 4.14 (pseudo dt, J = 9.0, 7.2 
Hz, 1H, 1-H), 3.74 (ddd, J = 12.2, 9.5, 2.5 Hz, 1H, 3-Ha), 3.66-3.53 (m, 2H, 3-Hb, 10a-H), 
3.20 (dd, J = 15.4, 4.1 Hz, 1H, 10-Ha), 2.85 (pseudo t, J = 14.4 Hz, 1H, 10-Hb), 2.31 (pseudo 
ddt, J = 12.3, 2.5, 6.9 Hz, 1H, 2-Ha), 1.86 (pseudo dq, J = 12.3, 9.6 Hz, 1H, 2-Hb); 
13
C-NMR 
(CDCl3, 50 MHz):  =165.5 (s; CO), 139.2 (s; CAr), 133.4 (d; CHAr),  130.7 (s; CAr), 128.8 (d; 
CHAr), 128.2 (d; CHAr), 128.1 (d; CHAr), 77.5 (d; C-1), 63.6 (t; C-10a), 43.4 (d; C-3), 33.5 (t; 
C-10), 32.3 (t; C-2) ppm; anal. calcd. for C12H13NO2 (203.09): C, 70.92; H, 6.45; N, 6.89; 
found C, 69.84; H, 6.33; N, 6.40. 
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(1R,2R,9bR)- and (1R,2R,9bS)-1,2-di-tert-butoxy-1,2,3,9b-tetrahydrobenzo[d]pyrrolo[1,2-
b]isoxazole (135 and 136) and 2-(4-(tert-butoxy)-1-phenyl-1H-pyrrol-2-yl)phenol (139) 
 
Bu4NF (220 µL, 0.87 mmol) was added to a solution of nitrone 28 (50 mg, 0.22 mmol) in dry 
DMF (2 mL) and then a solution of the aryne precursor 134 (79 µL, 0.33 mmol) was added. 
The reaction mixture was stirred at room temperature for 2.5 h. After completion of the 
reaction, the DMF was evaporated in a nitrogen stream. The obtained residue was absorbed on 
silica gel and loaded on a column chromatography. Purification by chromatography on silica 
gel (eluent: EtOAc /petroleum ether 2:98) afforded the major adduct 135 (21.9 mg, 0.07 
mmol) in 33 % yield, and the minor adduct 136 (17 mg, 0.06 mmol) in 26% as yellow oils 
along with side product 139 (28.7 mg, 0.09 mmol) as a white solid.  
135: Rf = 0.4; 
1
H NMR (CDCl3, 400 MHz):  = 7.25 (dm, J = 7.4 Hz, 1H, HAr ), 7.17-7.12 (m, 
1H, HAr), 6.90 (pseudo dt, J = 0.9, 7.4 Hz, 1H, H Ar), 6.73 (br d, J = 8.0 Hz, 1H, H Ar), 4.77 (br 
s, 1H, 9b-H), 4.13-4.10 (m, 1H, 1-H), 3.96 (ddd, J = 6.1, 4.9, 3.6 Hz, 1H, 2-H), 3.58 (dd, J = 
11.6, 4.9 Hz, 1H, 3-Ha), 3.16 (ddm, J = 11.6, 6.1  Hz, 1H, 3-Hb), 1.29 (s, 9H, CH3x3), 1.06 (s, 
9H, CH3x3); 
13
C-NMR (CDCl3, 50 MHz):  = 156.1 (s; CAr), 128.3 (d; CHAr), 126.8 (s; CAr),  
123.1 (d; CHAr), 120.6 (d; CHAr), 107.1 (d; CHAr), 81.8 (d; C-1), 74.2 (d; C-2), 73.4 (d; C-9b), 
61.8 (t; C-3), 28.4 (q; 3C, CH3 ), 28.0 (q; 3C, CH3 )ppm; IR (CDCl3): v
 
= 2977, 2831, 1597, 
1480, 1456, 1390, 1365, 1253, 1190, 1099, 1079 cm
-1
; anal. calcd. for C18H27NO3 (305.20): C, 
70.79; H, 8.91; N, 4.59; found C, 69.53; H, 8.76; N, 5.29. 
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136: Rf = 0.28; 
1
H NMR (CDCl3, 400 MHz):  = 7.32 (br d, J = 7.5 Hz, 1H, HAr ), 7.17(pseudo 
tm, J = 7.7 Hz, 1H, HAr), 6.91 (pseudo dt, J = 0.9, 7.4 Hz, 1H, H Ar), 6.76 (br d, J = 8.0 Hz, 
1H, H Ar), 4.87 (br d, J = 6.9 Hz, 1H, 9b-H), 4.24 (pseudo t, J = 7.2 Hz, 1H, 1-H), 3.86-3.78 
(m, 1H, 2-H), 3.49 (dd, J = 14.0, 7.6 Hz, 1H, 3-Ha), 3.23 (dd, J = 14.0, 8.6 Hz, 1H, 3-Hb), 
1.28 (s, 9H, CH3x3), 1.19 (s, 9H, CH3x3); 
13
C-NMR (CDCl3, 50 MHz):  = 157.0 (s; CAr), 
128.2 (d; CHAr), 125.7 (d; CHAr), 125.0 (s; CAr),  120.5 (d; CHAr), 107.0 (d; CHAr), 77.4 (d; C-
1), 72.7 (d; C-2), 68.1 (d; C-9b), 62.3 (t; C-3), 28.2(q; 6C, CH3 ) ppm; IR: 2977, 2935, 1593, 
1474, 1458, 1390, 1365, 1236, 1192, 1119, 1016 cm
-1
; anal. calcd. for C18H27NO3 (305.20): C, 
70.79; H, 8.91; N, 4.59; found C, 70.51; H, 9.12; N, 4.56. 
139: Rf = 0.37; NMR (CDCl3, 400 MHz):  = 7.32-7.24 (m, 2H, HAr ), 7.23-7.17 (m, 1H, HAr), 
7.13-7.00 (m, 4H, HAr), 6.84 (d, J = 3.2 Hz, 1H, 5-H ), 6.55 (dddd, J = 14.6, 9.2, 7.8, 1.4 Hz, 
2H, H Ar), 6.14 (d, J = 3.2 Hz, 1H, 3-H ), 1.23 (s, 9H, CH3x3); 
13
C-NMR (CDCl3, 100 MHz):  
= 140.8 (s; CAr), 139.6 (s; CAr), 130.8 (d, CHAr), 128.9 (d; 2C, CHAr), 128.0 (d; 2C, CHAr), 
126.3 (d; CHAr), 125.3 (d; 2C, CHAr), 122.4 (s; C-5),  119.6 (d; CHAr), 118.3 (d; CHAr), 105.1 
(s, C-3),  28.0 (q; 3C, CH3 ) ppm. 
 
2-[(3R,4R)-3,4-di-tert-butoxypyrrolidin-2-yl]phenol (143). 
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A mixture of isoxazolidine 135 (167 mg, 0.55 mmol) and zinc powder (1.3 g, 21.9 mmol) in 
AcOH:H2O [1:1 (v/v), 16.4 mL) was heated in an oil bath at 70 °C for 2 h. The reaction 
mixture was diluted with MeOH, filtered through cotton wool and then concentrated under 
reduced pressure. The residue was dissolved in CH2Cl2 and the solution was basified to pH = 9 
with a saturated aq. NaHCO3 solution and solid Na2CO3 at 0 °C. The two phases were 
separated. The aqueous phase was sequentially extracted with CH2Cl2 (3x30 mL) and EtOAc 
(2x30 mL). The combined organic phases were washed with brine, dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification of the crude product by 
chromatography on silica gel [eluent: CH2Cl2 / MeOH (1% NH4OH) 98:2] afforded 143 (127 
mg, 0.41 mmol) in 75% yield as a white solid. 
143: Rf = 0.31; 
1
H NMR (CDCl3, 400 MHz):  = 7.15-7.09 (m, 1H, HAr ), 7.00(dd, J = 7.5, 1.6 
Hz, 1H, HAr), 6.80 (dd, J = 8.1, 1.0 Hz, 1H, H Ar), 6.74 (pseudo dt, J = 1.2, 7.4 Hz, 1H, H Ar), 
4.08 (dd, J = 7.8 , 5.4 Hz, 1H, 3-H), 3.98 (ddd, J = 7.4, 5.5, 4.4 Hz, 1H, 4-H), 3.93 (d, J = 7.8 
Hz, 1H, 2-H), 3.29 (dd, J = 10.6, 7.4 Hz, 1H, 5-Ha), 3.00 (dd, J = 10.6, 4.4 Hz, 1H, 5-Hb), 
1.19 (s, 9H, CH3x3), 0.93 (s, 9H, CH3x3); 
13
C-NMR (CDCl3, 50 MHz):  = 158.0 (s; CAr), 
129.6 (d; CHAr), 128.7 (d; CHAr), 123.3 (s; CAr),  118.4 (d; CHAr), 116.7 (d; CHAr), 80.7.4 (d; 
C-3), 76.3 (d; C-4), 66.6 (d; C-2), 51.0 (t; C-3), 28.6 (q; 3C, CH3), 28.5 (q; 3C, CH3)  ppm; IR: 
2977, 2935, 1589, 1489, 1392, 1367, 1257, 1190, 1106, 1068 cm
-1
. 
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